No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3r83A_, 1.0000, 0.00, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
2, d3r7yA_, 0.9959, 0.40, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3, d3r1yA_, 0.9945, 0.47, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
4, d4kd1A_, 0.9943, 0.48, 0.993, 298, 294, CDK2 IN COMPLEX WITH DINACICLIB
5, d3r71A_, 0.9942, 0.48, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
6, d3qx2A_, 0.9942, 0.49, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
7, d3rpoA_, 0.9936, 0.51, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
8, d1pxiA_, 0.9935, 0.51, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
9, d3r8pA_, 0.9933, 0.52, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
10, d1hclA_, 0.9929, 0.54, 1.000, 294, 294, HUMAN CYCLIN-DEPENDENT KINASE 2
11, d1pw2A_, 0.9928, 0.54, 1.000, 294, 294, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
12, d2exmA_, 0.9927, 0.55, 0.993, 298, 294, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
13, d5aneA_, 0.9920, 0.57, 1.000, 294, 294, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
14, d3r7eA_, 0.9918, 0.58, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
15, d3qxoA_, 0.9917, 0.58, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
16, d2b53A_, 0.9917, 0.61, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
17, d1hckA_, 0.9916, 0.59, 1.000, 294, 294, HUMAN CYCLIN-DEPENDENT KINASE 2
18, d3r7vA_, 0.9912, 0.61, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
19, d3qqlA_, 0.9911, 0.65, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L3
20, d3qx4A_, 0.9906, 0.62, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
21, d1pxjA_, 0.9906, 0.62, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
22, d3rm7A_, 0.9905, 0.63, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
23, d3raiA_, 0.9903, 0.63, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
24, d3qwjA_, 0.9903, 0.63, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
25, d3qqfA_, 0.9899, 0.65, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L1
26, d3r1sA_, 0.9895, 0.66, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
27, d2b54A_, 0.9890, 0.69, 0.997, 298, 294, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
28, d3qzhA_, 0.9888, 0.69, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
29, d3pxrA_, 0.9885, 0.71, 1.000, 294, 294, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
30, d2a0cX_, 0.9885, 0.69, 1.000, 294, 294, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
31, d3r6xA_, 0.9884, 0.71, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
32, d3qzfA_, 0.9876, 0.72, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
33, d3r73A_, 0.9874, 0.74, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
34, d3r1qA_, 0.9872, 0.76, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
35, d1ykrA_, 0.9870, 0.74, 0.997, 298, 294, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
36, d2clxA_, 0.9869, 0.64, 0.997, 293, 293, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
37, d3qziA_, 0.9868, 0.77, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
38, d3r8uA_, 0.9862, 0.76, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
39, d3royA_, 0.9860, 0.80, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
40, d3r28A_, 0.9857, 0.79, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
41, d2xmyA_, 0.9850, 0.79, 0.993, 295, 294, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
42, d3rm6A_, 0.9845, 0.76, 1.000, 293, 293, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
43, d1y8yA_, 0.9845, 0.60, 0.997, 292, 292, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
44, d3s00A_, 0.9843, 0.81, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L4-14
45, d2c69A_, 0.9842, 0.61, 0.997, 292, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
46, d3r8lA_, 0.9841, 0.81, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L3-4
47, d3qwkA_, 0.9837, 0.87, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
48, d1pxpA_, 0.9837, 0.83, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
49, d3ql8A_, 0.9836, 0.83, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
50, d2v0dA_, 0.9836, 0.63, 0.997, 292, 292, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
51, d1h0uA_, 0.9827, 0.54, 1.000, 291, 291,  
52, d3lfsA_, 0.9826, 0.39, 1.000, 290, 290, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
53, d2c6kA_, 0.9822, 0.68, 0.997, 292, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
54, d3rk7A_, 0.9818, 0.90, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
55, d3qrtA_, 0.9818, 0.92, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
56, d1pxoA_, 0.9816, 0.90, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
57, d3tiyA_, 0.9806, 0.84, 1.000, 293, 293, CDK2 IN COMPLEX WITH NSC 35676
58, d4fklA_, 0.9804, 0.49, 1.000, 290, 290, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
59, d2vtlA_, 0.9804, 0.49, 1.000, 290, 290, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
60, d3rk9A_, 0.9803, 0.93, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
61, d2c6lA_, 0.9803, 0.63, 1.000, 291, 291, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
62, d3r8vA_, 0.9802, 0.92, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
63, d2r3fA_, 0.9801, 0.51, 1.000, 290, 290, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
64, d2r3rA_, 0.9800, 0.51, 1.000, 290, 290, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
65, d1gz8A_, 0.9799, 0.51, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
66, d1b38A_, 0.9798, 0.52, 1.000, 290, 290, HUMAN CYCLIN-DEPENDENT KINASE 2
67, d3iggA_, 0.9797, 0.52, 1.000, 290, 290, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
68, d3qu0A_, 0.9796, 0.95, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
69, d3lfqA_, 0.9794, 0.39, 1.000, 289, 289, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
70, d1w8cA_, 0.9793, 0.54, 1.000, 290, 290, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
71, d3tizA_, 0.9792, 0.86, 0.997, 293, 293, CDK2 IN COMPLEX WITH NSC 111848
72, d3qzgA_, 0.9791, 0.95, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
73, d3r9hA_, 0.9790, 0.96, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
74, d3qtqA_, 0.9790, 0.96, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
75, d2ds1A_, 0.9790, 0.55, 0.990, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
76, d2vtmA_, 0.9789, 0.55, 1.000, 290, 290, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
77, d4ek5A_, 0.9786, 0.42, 1.000, 289, 289, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
78, d3rk5A_, 0.9785, 0.98, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
79, d1b39A_, 0.9783, 0.58, 1.000, 290, 290, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
80, d2c6iA_, 0.9782, 0.80, 0.997, 292, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
81, d2c5yA_, 0.9779, 0.59, 1.000, 290, 290, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
82, d3qqjA_, 0.9776, 0.99, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L2
83, d3qruA_, 0.9775, 1.01, 1.000, 295, 294, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
84, d2c68A_, 0.9774, 0.61, 0.997, 290, 290, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
85, d2vtrA_, 0.9771, 0.62, 1.000, 290, 290, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
86, d3qqgA_, 0.9767, 1.00, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L2-5
87, d3ns9A_, 0.9766, 0.51, 1.000, 289, 289, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
88, d2r3pA_, 0.9761, 0.53, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
89, d2r3oA_, 0.9761, 0.53, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
90, d2xnbA_, 0.9760, 1.02, 0.993, 296, 294, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
91, d3r9dA_, 0.9756, 1.04, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
92, d2r3hA_, 0.9756, 0.55, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
93, d2r3iA_, 0.9754, 0.56, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
94, d1e1xA_, 0.9752, 0.68, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
95, d3qtwA_, 0.9749, 1.15, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
96, d3rjcA_, 0.9748, 1.07, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L4-12
97, d3qqkA_, 0.9745, 1.07, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L4
98, d3qqhA_, 0.9744, 1.04, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L2-2
99, d2c6oA_, 0.9743, 0.71, 0.997, 290, 290, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
100, d3qtuA_, 0.9742, 1.09, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
101, d3ti1A_, 0.9741, 1.08, 1.000, 294, 294, CDK2 IN COMPLEX WITH SUNITINIB
102, d3rniA_, 0.9740, 1.18, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
103, d3qtxA_, 0.9739, 1.07, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
104, d2c6mA_, 0.9737, 0.74, 0.997, 290, 290, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
105, d1pxlA_, 0.9737, 0.73, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
106, d1pxnA_, 0.9735, 1.07, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
107, d3rpvA_, 0.9733, 1.09, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
108, d1pxkA_, 0.9732, 0.75, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
109, d1e1vA_, 0.9732, 0.74, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
110, d3rkbA_, 0.9731, 1.18, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
111, d1h0vA_, 0.9731, 0.52, 1.000, 288, 288, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
112, d3pxyA_, 0.9729, 1.08, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS648
113, d3unkA_, 0.9728, 1.09, 1.000, 295, 294, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
114, d3qxpA_, 0.9725, 1.18, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
115, d2uzoA_, 0.9725, 0.77, 0.997, 290, 290, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
116, d4ez3A_, 0.9724, 1.14, 1.000, 294, 294, CDK2 IN COMPLEX WITH NSC 134199
117, d4ek4A_, 0.9724, 0.39, 1.000, 287, 287, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
118, d1jsvA_, 0.9718, 0.42, 1.000, 287, 287, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
119, d3qtzA_, 0.9717, 1.12, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
120, d3py0A_, 0.9716, 1.11, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR SU9516
121, d3s0oA_, 0.9713, 0.98, 0.997, 293, 292, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
122, d4fkiA_, 0.9711, 0.46, 1.000, 287, 287, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
123, d4ek3A_, 0.9711, 0.46, 1.000, 287, 287, CRYSTAL STRUCTURE OF APO CDK2
124, p5oo0A_, 0.9708, 0.61, 1.000, 288, 288, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
125, d5mhqA1, 0.9707, 0.61, 0.997, 288, 288, CCT068127 IN COMPLEX WITH CDK2
126, d5jq5A_, 0.9707, 0.48, 1.000, 287, 287, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
127, d2r3gA_, 0.9706, 0.48, 1.000, 287, 287, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
128, d4rj3A_, 0.9705, 0.51, 0.997, 287, 287, CDK2 WITH EGFR INHIBITOR COMPOUND 8
129, d1pxmA_, 0.9699, 0.84, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
130, d4fkgA_, 0.9678, 0.45, 1.000, 286, 286, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
131, d2a4lA_, 0.9678, 0.46, 1.000, 286, 286, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
132, d5anjA_, 0.9675, 0.61, 1.000, 291, 287, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
133, d2r3qA_, 0.9668, 0.50, 1.000, 286, 286, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
134, d3unjA_, 0.9664, 1.22, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
135, d3r8zA_, 0.9663, 0.95, 1.000, 290, 290, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
136, d4erwA_, 0.9662, 1.19, 0.997, 292, 292, CDK2 IN COMPLEX WITH STAUROSPORINE
137, d1oirA_, 0.9658, 0.56, 0.997, 286, 286, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
138, d1h01A_, 0.9657, 0.56, 1.000, 286, 286, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
139, d4fkuA_, 0.9611, 1.32, 0.979, 293, 292, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
140, d1h07A_, 0.9605, 0.61, 1.000, 285, 285, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
141, d1y91A_, 0.9597, 0.76, 0.997, 286, 286, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
142, d3pj8A1, 0.9596, 0.76, 0.993, 287, 286, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
143, d3le6A_, 0.9574, 0.47, 1.000, 283, 283, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
144, d3sqqA_, 0.9572, 1.01, 0.986, 288, 288, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
145, d3lfnA_, 0.9570, 0.72, 1.000, 285, 285, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
146, d3fz1A_, 0.9566, 0.63, 1.000, 284, 284, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
147, d1pf8A_, 0.9561, 1.72, 0.935, 298, 293, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
148, d2vtoA_, 0.9548, 0.57, 1.000, 283, 283, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
149, d1wccA_, 0.9542, 0.59, 1.000, 283, 283, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
150, d5ieyA_, 0.9541, 0.92, 0.997, 286, 286, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
151, d4fkoA_, 0.9527, 1.58, 0.997, 291, 291, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
152, d1buhA_, 0.9524, 1.06, 0.990, 287, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
153, d3wblA_, 0.9517, 0.69, 0.996, 283, 283, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
154, d2vtsA_, 0.9516, 0.57, 1.000, 282, 282, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
155, d4lynA_, 0.9513, 0.70, 0.993, 287, 283, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
156, d3uliA_, 0.9513, 0.99, 0.993, 286, 286, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
157, d4gcjA1, 0.9511, 1.65, 0.938, 298, 292, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
158, d3r7iA_, 0.9507, 0.63, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
159, d5iexA_, 0.9499, 0.96, 0.996, 285, 285, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
160, d1h08A_, 0.9499, 0.74, 1.000, 283, 283, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
161, d3r7uA_, 0.9498, 0.65, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
162, d4fkqA_, 0.9495, 0.77, 0.996, 283, 283, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
163, d2w06A_, 0.9491, 0.66, 1.000, 282, 282, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
164, d1fvtA_, 0.9490, 0.66, 1.000, 282, 282, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
165, d4fkvA_, 0.9488, 0.67, 0.996, 282, 282, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
166, d1h0wA_, 0.9482, 0.87, 1.000, 283, 283, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
167, d1ke8A_, 0.9473, 0.72, 1.000, 282, 282, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
168, d2vtpA_, 0.9472, 0.60, 1.000, 281, 281, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
169, d4fkrA_, 0.9471, 0.73, 0.996, 282, 282, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
170, d2b52A_, 0.9461, 0.86, 0.996, 283, 283, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
171, d5ievA_, 0.9460, 0.95, 0.996, 284, 284, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
172, d5aniA_, 0.9459, 0.52, 1.000, 280, 280, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
173, d1di8A_, 0.9452, 0.88, 1.000, 283, 283, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
174, d5k4jA1, 0.9450, 0.69, 1.000, 281, 281, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
175, d1ke7A_, 0.9447, 0.69, 1.000, 281, 281, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
176, d4ek8A_, 0.9442, 0.59, 1.000, 280, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
177, d3qtsA_, 0.9440, 0.82, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
178, d3rahA_, 0.9438, 0.83, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
179, d3rprA_, 0.9436, 0.83, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
180, d2w1hA_, 0.9435, 0.92, 1.000, 283, 283, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
181, d1ke5A_, 0.9430, 0.75, 1.000, 281, 281, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
182, d3r9nA_, 0.9428, 0.85, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
183, d1ckpA_, 0.9425, 0.53, 1.000, 279, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
184, d3s2pA_, 0.9423, 0.53, 1.000, 279, 279, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
185, d1vyzA_, 0.9421, 0.54, 1.000, 279, 279, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
186, d1ke9A_, 0.9420, 0.78, 1.000, 281, 281, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
187, d2r64A_, 0.9412, 0.58, 1.000, 279, 279, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
188, d4fkpA_, 0.9410, 0.58, 1.000, 279, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
189, d2vtiA_, 0.9409, 0.70, 1.000, 280, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
190, d3r8mA_, 0.9406, 1.26, 0.972, 286, 285, CDK2 IN COMPLEX WITH INHIBITOR L3-3
191, d1ke6A_, 0.9405, 0.72, 1.000, 280, 280, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
192, d4ek6A_, 0.9404, 0.47, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
193, d4fkjA_, 0.9401, 0.48, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
194, d2uznA_, 0.9398, 0.63, 1.000, 279, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
195, d3r9oA_, 0.9382, 1.00, 0.996, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
196, d4fktA_, 0.9379, 0.57, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
197, d1w0xC_, 0.9375, 0.81, 1.000, 280, 280, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
198, d2r3mA_, 0.9374, 0.59, 1.000, 278, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
199, d3ig7A_, 0.9363, 0.63, 1.000, 278, 278, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
200, d2vthA_, 0.9362, 0.64, 1.000, 278, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
201, d2vtaA_, 0.9360, 0.65, 1.000, 278, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
202, d5jq8A_, 0.9359, 0.65, 1.000, 278, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
203, d1h00A_, 0.9356, 0.66, 1.000, 278, 278, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
204, d4fkwA_, 0.9353, 0.88, 0.993, 280, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
205, d3pxfA1, 0.9351, 1.92, 0.942, 298, 292, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
206, d2r3jA_, 0.9349, 0.68, 1.000, 278, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
207, d3qtrA_, 0.9346, 1.12, 0.996, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
208, d4ez7A1, 0.9345, 1.90, 0.924, 298, 291, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
209, d1giiA_, 0.9344, 0.80, 0.989, 279, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
210, d2vu3A_, 0.9339, 1.45, 0.965, 285, 283, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
211, d3sw4A_, 0.9336, 0.84, 1.000, 279, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
212, d3pxzA1, 0.9334, 2.05, 0.956, 298, 293, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
213, d2r3kA_, 0.9332, 0.62, 1.000, 277, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
214, d2vv9A_, 0.9323, 0.88, 0.986, 279, 279, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
215, d5anoA_, 0.9321, 0.66, 1.000, 277, 277, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
216, d3pxqA1, 0.9320, 1.83, 0.934, 294, 290, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
217, d3rzbA_, 0.9305, 1.23, 0.996, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
218, d4acmA_, 0.9300, 0.73, 1.000, 277, 277, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
219, d1aq1A_, 0.9298, 0.74, 1.000, 277, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
220, d2vtjA_, 0.9291, 0.65, 1.000, 276, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
221, d2w17A_, 0.9288, 0.89, 0.982, 278, 278, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
222, d3sw7A_, 0.9284, 0.89, 0.986, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
223, d2fvdA_, 0.9284, 1.48, 0.957, 284, 282, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
224, d2w05A_, 0.9281, 0.69, 0.989, 276, 276, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
225, d3ezvA_, 0.9274, 0.82, 0.993, 277, 277, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
226, d4nj3A_, 0.9273, 0.85, 0.986, 277, 277, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
227, d2btrA_, 0.9273, 0.59, 1.000, 275, 275, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
228, d1h06A_, 0.9272, 0.82, 0.996, 277, 277,  
229, d1v1kA_, 0.9269, 0.83, 0.996, 277, 277, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
230, d3rmfA_, 0.9263, 0.94, 0.986, 278, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
231, d4fksA_, 0.9253, 0.67, 1.000, 275, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
232, d3py1A1, 0.9248, 2.06, 0.925, 298, 292, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
233, d2r3nA_, 0.9242, 0.70, 0.993, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
234, d4bzdA_, 0.9239, 0.92, 0.964, 277, 277, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
235, d3s1hA_, 0.9239, 0.91, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
236, d2r3lA_, 0.9233, 0.73, 1.000, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
237, d2btsA_, 0.9233, 0.63, 0.993, 274, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
238, d3rakA_, 0.9229, 0.94, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
239, d2j9mA_, 0.9228, 0.75, 0.993, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
240, d1gihA_, 0.9227, 0.85, 1.000, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
241, d3rpyA_, 0.9223, 0.95, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
242, d1v0bA_, 0.9221, 1.26, 0.621, 286, 280, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
243, d2b55A_, 0.9219, 0.87, 0.996, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
244, d5andA_, 0.9217, 0.54, 1.000, 273, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
245, d1oitA_, 0.9212, 0.57, 0.996, 273, 273, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
246, d2vtqA_, 0.9211, 0.70, 0.996, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
247, d1g5sA_, 0.9209, 0.81, 0.993, 275, 275, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
248, d1dm2A_, 0.9206, 0.71, 0.993, 274, 274, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
249, d2bheA_, 0.9205, 0.72, 0.993, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
250, d2bhhA_, 0.9202, 0.73, 0.993, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
251, d5ankA_, 0.9199, 0.61, 1.000, 273, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
252, d2vtnA_, 0.9199, 0.73, 0.996, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
253, d3ralA_, 0.9198, 1.02, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
254, d1urwA_, 0.9195, 0.76, 0.978, 274, 274, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
255, d4d1xA_, 0.9184, 0.79, 0.996, 274, 274, CDK2 IN COMPLEX WITH LUCIFERIN
256, d4bghA_, 0.9183, 0.89, 1.000, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
257, d3ezrA_, 0.9182, 0.68, 1.000, 273, 273, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
258, d2duvA_, 0.9177, 0.57, 1.000, 272, 272, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
259, d2vttA_, 0.9117, 0.83, 0.993, 272, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
260, d1gijA_, 0.9105, 0.92, 0.989, 273, 273, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
261, d1r78A_, 0.9103, 0.92, 0.996, 273, 273, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
262, d4yc6E_, 0.9097, 1.58, 0.661, 285, 280, CDK1/CKS1
263, d4yc6C_, 0.9088, 1.59, 0.661, 285, 280, CDK1/CKS1
264, d4yc6A_, 0.9087, 1.59, 0.661, 285, 280, CDK1/CKS1
265, d5fp6A_, 0.9086, 1.07, 0.974, 278, 274, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
266, d1fvvA_, 0.9063, 2.15, 0.944, 298, 287, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
267, d1p2aA_, 0.9056, 0.87, 0.978, 271, 271, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
268, d4yc6G_, 0.9052, 1.67, 0.661, 285, 280, CDK1/CKS1
269, d4fx3A_, 0.9051, 2.16, 0.934, 298, 287, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
270, d1v0pA_, 0.9051, 1.11, 0.626, 277, 273, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
271, d1ob3A_, 0.9047, 1.12, 0.626, 277, 273, STRUCTURE OF P. FALCIPARUM PFPK5
272, d5if1A_, 0.9038, 2.31, 0.941, 298, 288, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
273, d2wxvA1, 0.9029, 2.32, 0.944, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
274, d4fx3C_, 0.9028, 2.34, 0.931, 298, 288, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
275, d3qhwC1, 0.9011, 2.08, 0.951, 295, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
276, d3qhwA1, 0.9007, 2.09, 0.951, 295, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
277, d3qhrC1, 0.9005, 2.09, 0.951, 295, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
278, d3qhrA1, 0.9003, 2.10, 0.951, 295, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
279, d2wihA1, 0.8995, 2.35, 0.944, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
280, d1finA_, 0.8990, 2.25, 0.944, 298, 287, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
281, d5angA_, 0.8989, 0.77, 0.989, 268, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
282, d2cchC2, 0.8986, 2.13, 0.940, 295, 284, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
283, d1vywA1, 0.8986, 2.39, 0.944, 298, 288, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
284, d1pyeA_, 0.8974, 0.57, 1.000, 266, 266, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
285, d4ii5A_, 0.8969, 2.16, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
286, d4ii5C_, 0.8967, 2.16, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
287, d2wpaA1, 0.8962, 2.45, 0.979, 298, 288, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
288, d1jvpP_, 0.8961, 0.85, 1.000, 268, 268, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
289, d4i3zA_, 0.8958, 2.17, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
290, d2i40A_, 0.8954, 2.30, 0.989, 291, 285, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
291, d4i3zC_, 0.8953, 2.18, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
292, d2bpmA2, 0.8953, 2.41, 0.944, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
293, d2uzdA_, 0.8951, 2.17, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
294, d5cyiA1, 0.8950, 2.28, 0.986, 297, 286, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
295, d1h1pA1, 0.8946, 2.17, 0.940, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
296, d3eidA_, 0.8945, 2.45, 0.983, 292, 286, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
297, d5hq0A1, 0.8942, 1.72, 0.606, 289, 279, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
298, d4y72A1, 0.8942, 1.72, 0.606, 289, 279, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
299, d1h1sC1, 0.8941, 2.18, 0.940, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
300, d5cyiC1, 0.8938, 2.21, 0.986, 295, 284, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
301, d4eokA1, 0.8933, 2.28, 0.975, 292, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
302, d2bkzA2, 0.8933, 2.52, 0.941, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
303, d1oiyC1, 0.8933, 2.24, 0.982, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
304, d4eonC1, 0.8930, 2.26, 0.930, 296, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
305, d2iw8A1, 0.8930, 2.26, 0.979, 296, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
306, d2cchA2, 0.8924, 2.22, 0.940, 295, 284, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
307, d4eolA1, 0.8923, 2.22, 0.930, 293, 284, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
308, d4bcoA1, 0.8921, 2.33, 0.983, 297, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
309, d2uzlC_, 0.8921, 2.23, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
310, d2uzeC_, 0.8920, 2.22, 0.940, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
311, d1jstC_, 0.8919, 2.38, 0.983, 297, 286, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
312, d4bcpA1, 0.8917, 2.34, 0.983, 297, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
313, d4bcnA1, 0.8916, 2.34, 0.990, 295, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
314, d3f5xC_, 0.8914, 2.50, 0.979, 298, 288, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
315, d1h1pC1, 0.8914, 2.21, 0.940, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
316, d2uzlA_, 0.8913, 2.24, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
317, d2c6tA_, 0.8913, 2.23, 0.951, 295, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
318, d2c4gC2, 0.8913, 2.55, 0.941, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
319, d3ddpC1, 0.8912, 2.31, 0.955, 297, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
320, d3bhuA1, 0.8912, 2.33, 0.990, 295, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
321, d1h1qC1, 0.8911, 2.25, 0.982, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
322, d1qmzC1, 0.8910, 2.24, 0.951, 295, 284, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
323, d1qmzA1, 0.8909, 2.25, 0.951, 295, 284, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
324, d3bhtA2, 0.8908, 2.34, 0.983, 295, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
325, d2uzeA_, 0.8908, 2.23, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
326, d2iw6C2, 0.8908, 2.17, 0.947, 294, 283, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
327, d1oi9C1, 0.8908, 2.23, 0.982, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
328, d1gy3C_, 0.8907, 2.23, 0.951, 295, 284, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
329, d2c5pC_, 0.8906, 2.31, 0.982, 296, 285,  
330, d1h1rC1, 0.8905, 2.23, 0.940, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
331, d4eoiC1, 0.8904, 2.24, 0.933, 295, 284, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
332, d2cciC2, 0.8904, 2.29, 0.989, 295, 284, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
333, d4eopC1, 0.8903, 2.27, 0.982, 295, 284, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
334, d4cfwC1, 0.8903, 2.28, 0.986, 295, 284, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
335, d2g9xA2, 0.8903, 2.34, 0.990, 297, 286, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
336, d3dogA1, 0.8902, 2.35, 0.990, 296, 286, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
337, d3ddpA1, 0.8902, 2.30, 0.989, 296, 285, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
338, d1okuC_, 0.8902, 2.30, 0.982, 296, 285,  
339, d4eonA1, 0.8901, 2.38, 0.941, 297, 286, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
340, d2c4gA2, 0.8901, 2.33, 0.941, 297, 286, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
341, d1ua2A_, 0.8900, 2.15, 0.440, 286, 282, CRYSTAL STRUCTURE OF HUMAN CDK7
342, d1gy3A_, 0.8900, 2.25, 0.951, 295, 284, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
343, d5d1jA_, 0.8899, 0.73, 0.996, 265, 265, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
344, d2c5vC_, 0.8897, 2.31, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
345, d2c5nA_, 0.8897, 2.34, 0.979, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
346, d3f5xA_, 0.8895, 2.50, 0.983, 297, 287, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
347, d2wxvC1, 0.8894, 2.55, 0.941, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
348, d1h1sA1, 0.8893, 2.27, 0.989, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
349, d3gc0A_, 0.8892, 1.68, 0.567, 278, 275, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
350, d2c5nC_, 0.8892, 2.34, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
351, d5nevA1, 0.8890, 2.26, 0.989, 294, 283, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
352, d4eolC1, 0.8890, 2.29, 0.930, 296, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
353, d2wevC_, 0.8889, 2.32, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
354, d2bkzC2, 0.8888, 2.55, 0.941, 297, 287, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
355, d1oiuA1, 0.8888, 2.33, 0.989, 293, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
356, d1oiqA_, 0.8887, 0.66, 1.000, 264, 264, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
357, d5lmkA1, 0.8886, 2.38, 0.990, 295, 286, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
358, d2iw9A2, 0.8886, 2.33, 0.982, 292, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
359, d4eosC1, 0.8885, 2.27, 0.951, 295, 284, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
360, d1h1qA1, 0.8885, 2.29, 0.989, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
361, d1ol1C_, 0.8884, 2.32, 0.982, 296, 285, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
362, d1oi9A1, 0.8884, 2.29, 0.989, 294, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
363, d1h1rA1, 0.8884, 2.28, 0.989, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
364, d1ol2C_, 0.8883, 2.34, 0.982, 296, 285, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
365, d4eooC1, 0.8881, 2.30, 0.982, 295, 284, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
366, d1okuA_, 0.8880, 2.34, 0.982, 296, 285,  
367, d1oiyA1, 0.8879, 2.30, 0.989, 292, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
368, d2c5vA_, 0.8878, 2.35, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
369, d4cfmA1, 0.8875, 2.31, 0.989, 295, 284, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
370, d2c5oA_, 0.8874, 2.37, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
371, d1fvvC_, 0.8874, 2.55, 0.937, 298, 288, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
372, d3ddqA1, 0.8873, 2.39, 0.990, 295, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
373, d3bhvA1, 0.8873, 2.39, 0.983, 295, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
374, d1urcC_, 0.8873, 2.52, 0.972, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
375, d1oguA1, 0.8873, 2.35, 0.989, 293, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
376, d1ua2D_, 0.8872, 2.27, 0.447, 286, 282, CRYSTAL STRUCTURE OF HUMAN CDK7
377, d2c5oC_, 0.8871, 2.37, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
378, d1fq1B_, 0.8871, 2.49, 0.979, 295, 287, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
379, d2wmbA1, 0.8868, 2.33, 0.989, 295, 284, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
380, d2cciA2, 0.8868, 2.32, 0.989, 295, 284, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
381, d4eojA1, 0.8867, 2.43, 0.976, 293, 286, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
382, d2v22C_, 0.8867, 2.38, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
383, d3my5A1, 0.8865, 2.41, 0.990, 294, 286, CDK2/CYCLINA IN COMPLEX WITH DRB
384, d4cfwA1, 0.8864, 2.40, 0.979, 297, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
385, d4eoiA1, 0.8863, 2.43, 0.979, 293, 286, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
386, d4cfvA1, 0.8863, 2.40, 0.983, 297, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
387, d2iw6A1, 0.8863, 2.29, 0.986, 291, 283, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
388, d2whaC_, 0.8862, 2.38, 0.982, 296, 285,  
389, d2wfyC_, 0.8862, 2.40, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
390, d2uzbA_, 0.8862, 2.33, 0.989, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
391, d4bcnC1, 0.8861, 2.25, 0.982, 293, 282, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
392, d1vywC1, 0.8860, 2.62, 0.979, 298, 288, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
393, d4cfnA1, 0.8858, 2.38, 0.989, 293, 285, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
394, d2c5pA_, 0.8858, 2.37, 0.982, 296, 285,  
395, d1okwC_, 0.8858, 2.29, 0.989, 296, 284, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
396, d2x1nC_, 0.8857, 2.52, 0.979, 296, 286, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
397, d2whaA_, 0.8857, 2.40, 0.982, 296, 285,  
398, d1ua2B_, 0.8857, 2.29, 0.443, 286, 282, CRYSTAL STRUCTURE OF HUMAN CDK7
399, d5nevC1, 0.8856, 2.31, 0.989, 295, 284, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
400, d4eopA1, 0.8856, 2.38, 0.986, 294, 285, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
401, d2x1nA_, 0.8856, 2.41, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
402, d2c5xC_, 0.8856, 2.27, 0.989, 296, 284, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
403, d4eokC1, 0.8854, 2.33, 0.930, 296, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
404, d4cfuA1, 0.8854, 2.42, 0.990, 295, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
405, d4bcmA1, 0.8854, 2.35, 0.989, 292, 284, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
406, d2wpaC1, 0.8854, 2.64, 0.976, 298, 288, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
407, d2c5xA_, 0.8854, 2.38, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
408, d2wevA_, 0.8853, 2.38, 0.979, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
409, d4eorA1, 0.8852, 2.40, 0.986, 292, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
410, d4eooA1, 0.8852, 2.39, 0.982, 292, 285, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
411, d4eomA1, 0.8852, 2.39, 0.972, 294, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
412, d1okvC_, 0.8852, 2.30, 0.989, 296, 284, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
413, d2uzbC_, 0.8851, 2.30, 0.951, 292, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
414, d2wihC1, 0.8850, 2.59, 0.941, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
415, d1urcA_, 0.8850, 2.56, 0.979, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
416, d5if1C_, 0.8847, 2.49, 0.944, 296, 286, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
417, d3tnwA1, 0.8847, 2.43, 0.990, 294, 286, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
418, d2uueC_, 0.8846, 2.41, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
419, d2c5tC_, 0.8846, 2.53, 0.979, 296, 286,  
420, d1ua2C_, 0.8846, 2.17, 0.423, 286, 281, CRYSTAL STRUCTURE OF HUMAN CDK7
421, d4eosA1, 0.8845, 2.40, 0.986, 293, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
422, d1h28A1, 0.8843, 2.33, 0.951, 295, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
423, d2wipA1, 0.8841, 2.36, 0.943, 293, 283, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
424, d2whbA_, 0.8840, 2.43, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
425, d1pkdA1, 0.8840, 2.37, 0.989, 295, 284, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
426, d4bcmC1, 0.8838, 2.29, 0.986, 293, 282, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
427, d1h26A1, 0.8837, 2.37, 0.989, 295, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
428, d2v22A_, 0.8836, 2.42, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
429, d4eoqA1, 0.8835, 2.41, 0.989, 293, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
430, d1h28C1, 0.8835, 2.35, 0.951, 295, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
431, d2uueA_, 0.8832, 2.44, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
432, d4cfnC1, 0.8827, 2.29, 0.986, 293, 282, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
433, d2c5tA_, 0.8827, 2.45, 0.982, 296, 285,  
434, d1f5qA_, 0.8826, 2.46, 0.951, 296, 288, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
435, d1ol2A_, 0.8822, 2.59, 0.976, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
436, d1e9hC1, 0.8822, 2.36, 0.989, 295, 284, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
437, d5uq2A_, 0.8821, 2.51, 0.979, 296, 285, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
438, d5lqfA1, 0.8819, 1.64, 0.613, 284, 274, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
439, d2whbC_, 0.8817, 2.45, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
440, d2c6tC_, 0.8813, 2.35, 0.951, 295, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
441, d1ol1A_, 0.8813, 2.60, 0.976, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
442, d2bpmC2, 0.8809, 2.65, 0.941, 298, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
443, d1okwA_, 0.8809, 2.46, 0.982, 296, 285, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
444, d2i40C_, 0.8807, 2.46, 0.979, 296, 285, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
445, d3gbzA_, 0.8806, 1.65, 0.566, 274, 272, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
446, d2wfyA_, 0.8803, 2.43, 0.982, 295, 284, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
447, d5fp5A_, 0.8802, 0.93, 0.989, 264, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
448, d1e9hA_, 0.8801, 2.41, 0.989, 295, 284, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
449, d2uzdC_, 0.8800, 2.40, 0.989, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
450, d1h27A1, 0.8800, 2.41, 0.989, 295, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
451, d1p5eA1, 0.8796, 2.45, 0.989, 295, 284, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
452, d2wmaA1, 0.8795, 2.38, 0.951, 295, 284, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
453, d1finC_, 0.8790, 2.53, 0.930, 298, 287, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
454, d1pkdC1, 0.8769, 2.43, 0.989, 295, 284, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
455, d5lqfD1, 0.8766, 1.68, 0.615, 282, 273, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
456, d3tnwC_, 0.8756, 2.30, 0.979, 291, 280, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
457, d4bckA1, 0.8752, 2.54, 0.986, 296, 285, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
458, d1jstA_, 0.8752, 2.59, 0.983, 297, 286, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
459, d2wipC1, 0.8751, 2.47, 0.940, 291, 281, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
460, d1p5eC1, 0.8751, 2.46, 0.951, 295, 284, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
461, d4yc3A1, 0.8749, 2.09, 0.644, 294, 278, CDK1/CYCLINB1/CKS2 APO
462, d1okvA_, 0.8742, 2.63, 0.975, 295, 285, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
463, d1h25A1, 0.8724, 2.40, 0.989, 292, 281, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
464, d2cjmC_, 0.8716, 2.45, 0.982, 294, 283, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
465, d1h24A1, 0.8691, 2.45, 0.989, 292, 281, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
466, d4or5A_, 0.8690, 2.70, 0.404, 319, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
467, d3eidC_, 0.8688, 2.72, 0.979, 290, 285, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
468, d1v0bB_, 0.8687, 1.00, 0.628, 261, 261, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
469, d5l2wA1, 0.8674, 2.38, 0.982, 296, 278, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
470, d5a14A_, 0.8674, 2.57, 0.950, 284, 282, HUMAN CDK2 WITH TYPE II INHIBITOR
471, d4or5F_, 0.8672, 2.73, 0.407, 324, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
472, d4bcqC1, 0.8671, 2.41, 0.986, 291, 280, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
473, d1f5qC_, 0.8657, 2.28, 0.957, 288, 279, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
474, d4bckC1, 0.8654, 2.43, 0.986, 291, 280, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
475, d2w99B_, 0.8654, 2.24, 0.458, 291, 277, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
476, d4bcgA_, 0.8643, 2.58, 0.403, 312, 283, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
477, d4bchA_, 0.8642, 2.58, 0.406, 308, 283, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
478, d4ogrI_, 0.8638, 2.70, 0.407, 318, 285, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
479, d3mi9A_, 0.8629, 2.79, 0.404, 328, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
480, d3my1A_, 0.8628, 2.58, 0.403, 314, 283, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
481, d1unlB_, 0.8628, 2.37, 0.552, 292, 277, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
482, d3miaA_, 0.8627, 2.74, 0.387, 324, 284, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
483, d4ogrA_, 0.8620, 2.76, 0.407, 314, 285, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
484, d2w9zB_, 0.8615, 2.18, 0.464, 287, 274, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
485, d2jgzA_, 0.8613, 2.31, 0.938, 288, 276, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
486, d4d1zA_, 0.8612, 0.91, 0.969, 258, 258, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
487, d1blxA_, 0.8612, 2.52, 0.461, 305, 282, P19INK4D/CDK6 COMPLEX
488, d1h24C1, 0.8609, 2.51, 0.950, 292, 281, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
489, d3g33A_, 0.8606, 2.22, 0.465, 291, 275, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
490, d1h27C1, 0.8601, 2.45, 0.989, 290, 279, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
491, d4bcfA_, 0.8598, 2.62, 0.415, 307, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
492, d4j71A_, 0.8596, 2.55, 0.332, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
493, d4cxaA_, 0.8594, 2.72, 0.412, 329, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
494, d4bcjA_, 0.8594, 2.62, 0.404, 309, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
495, d2cjmA_, 0.8592, 2.43, 0.986, 285, 278, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
496, d1w98A2, 0.8592, 2.51, 0.950, 296, 278, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
497, d4imyE_, 0.8588, 2.72, 0.408, 313, 284, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
498, d4j1rC_, 0.8585, 2.57, 0.329, 344, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
499, d4j1rA_, 0.8585, 2.57, 0.329, 343, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
500, d4j1rD_, 0.8583, 2.57, 0.329, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
501, d3nizA1, 0.8577, 2.63, 0.583, 284, 278, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
502, d3g33C_, 0.8577, 2.32, 0.462, 291, 275, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
503, d4ogrE_, 0.8574, 2.64, 0.399, 310, 281, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
504, d5hlnB_, 0.8569, 2.57, 0.319, 346, 279, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
505, d1v0oA_, 0.8569, 1.98, 0.601, 276, 271, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
506, d3lq5A_, 0.8563, 2.62, 0.399, 307, 281, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
507, d4imyA_, 0.8557, 2.79, 0.394, 314, 284, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
508, d4bciA_, 0.8555, 2.62, 0.406, 308, 281, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
509, d4j71B_, 0.8550, 2.63, 0.329, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
510, d2o5kA1, 0.8547, 2.56, 0.325, 350, 280, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
511, d3zrkB_, 0.8545, 2.65, 0.329, 348, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
512, d3i4bB_, 0.8544, 2.59, 0.332, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
513, d5f94A_, 0.8543, 2.69, 0.335, 346, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
514, d3sayB_, 0.8543, 2.66, 0.332, 347, 280, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
515, d1v0pB_, 0.8543, 1.11, 0.628, 258, 258, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
516, d4pteB_, 0.8539, 2.72, 0.331, 347, 281, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
517, d3zrmB_, 0.8539, 2.66, 0.329, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
518, d3zrlB_, 0.8538, 2.66, 0.329, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
519, d5f94B_, 0.8537, 2.70, 0.331, 349, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
520, d4ptcA_, 0.8537, 2.69, 0.335, 342, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
521, d3gc8A_, 0.8537, 2.52, 0.357, 347, 280, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
522, d1ob3B_, 0.8535, 1.13, 0.628, 258, 258, STRUCTURE OF P. FALCIPARUM PFPK5
523, d4krcA_, 0.8533, 2.70, 0.556, 297, 279, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
524, d3i4bA_, 0.8533, 2.69, 0.335, 359, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
525, d3sd0B_, 0.8530, 2.72, 0.335, 349, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
526, d5hlnA_, 0.8524, 2.69, 0.332, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
527, d4ptcB_, 0.8524, 2.73, 0.335, 347, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
528, d4bcqA1, 0.8523, 2.55, 0.986, 289, 278, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
529, d3sayA_, 0.8523, 2.57, 0.335, 347, 278, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
530, d4j1rB_, 0.8521, 2.57, 0.331, 346, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
531, d4nm0A1, 0.8517, 2.75, 0.331, 355, 281, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
532, d1v0oB_, 0.8516, 1.92, 0.599, 274, 269, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
533, d1j1bB_, 0.8516, 2.70, 0.335, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
534, d1j1bA_, 0.8514, 2.73, 0.331, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
535, d5acbC_, 0.8508, 2.90, 0.425, 324, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
536, d4pteA_, 0.8508, 2.67, 0.337, 341, 279, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
537, d3zrkA_, 0.8508, 2.65, 0.330, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
538, d3m1sB_, 0.8506, 2.68, 0.336, 349, 280, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
539, d3f88A_, 0.8506, 2.58, 0.335, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
540, d3f88B_, 0.8505, 2.61, 0.331, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
541, d4krdA_, 0.8504, 2.65, 0.560, 294, 277, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
542, d3tn8A_, 0.8504, 2.63, 0.407, 304, 280, CDK9/CYCLIN T IN COMPLEX WITH CAN508
543, d4nstC_, 0.8503, 2.86, 0.412, 317, 284, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
544, d1h8fB_, 0.8503, 2.74, 0.331, 350, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
545, d1j1cB_, 0.8502, 2.72, 0.335, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
546, d1h8fA_, 0.8501, 2.74, 0.331, 352, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
547, d4nstA_, 0.8499, 2.86, 0.408, 322, 284, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
548, d1j1cA_, 0.8498, 2.74, 0.331, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
549, d1gngB_, 0.8498, 2.67, 0.336, 355, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
550, d3zrmA_, 0.8496, 2.66, 0.330, 344, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
551, d4imyC_, 0.8495, 2.74, 0.409, 310, 281, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
552, d1q41B_, 0.8495, 2.75, 0.331, 343, 281, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
553, d3sd0A_, 0.8493, 2.77, 0.331, 350, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
554, d1uv5A_, 0.8492, 2.73, 0.335, 348, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
555, d3gb2A_, 0.8491, 2.59, 0.336, 340, 277, GSK3BETA INHIBITOR COMPLEX
556, d3zrlA_, 0.8488, 2.68, 0.330, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
557, d2pk9A_, 0.8486, 2.35, 0.553, 287, 273, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
558, d3gc8B_, 0.8485, 2.58, 0.336, 346, 280, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
559, d1o9uA_, 0.8483, 2.76, 0.339, 349, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
560, d4achB_, 0.8480, 2.77, 0.331, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
561, d4acgA_, 0.8480, 2.78, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
562, d4nm7A1, 0.8476, 2.89, 0.331, 354, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
563, d4acdA_, 0.8471, 2.79, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
564, d4acgB_, 0.8468, 2.79, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
565, d4nm5A1, 0.8467, 2.87, 0.331, 360, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
566, d2jldB_, 0.8466, 2.73, 0.336, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
567, d2ow3A_, 0.8465, 2.76, 0.336, 346, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
568, d4achA_, 0.8464, 2.78, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
569, d3m1sA_, 0.8464, 2.73, 0.341, 348, 279, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
570, d5efqC_, 0.8461, 2.94, 0.419, 325, 284, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
571, d2ow3B_, 0.8460, 2.79, 0.332, 351, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
572, d4afjB_, 0.8459, 2.60, 0.333, 346, 276, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
573, d4afjA_, 0.8459, 2.59, 0.333, 342, 276, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
574, d4un0C_, 0.8458, 2.87, 0.413, 308, 283, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
575, d3pupB_, 0.8458, 2.78, 0.343, 347, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
576, d4accA_, 0.8457, 2.78, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
577, d2jldA_, 0.8457, 2.76, 0.339, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
578, d5acbD_, 0.8456, 2.97, 0.428, 319, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
579, d3pupA_, 0.8455, 2.66, 0.341, 346, 279, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
580, d5efqA_, 0.8454, 2.96, 0.419, 321, 284, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
581, d1q5kA_, 0.8452, 2.72, 0.335, 345, 278, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
582, d4acdB_, 0.8449, 2.80, 0.338, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
583, d1r0eB_, 0.8443, 2.82, 0.335, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
584, d4i5hA_, 0.8442, 2.38, 0.356, 335, 275, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
585, d3f7zB1, 0.8442, 2.62, 0.330, 338, 276, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
586, d1gngA_, 0.8442, 2.67, 0.333, 348, 279, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
587, d1r0eA_, 0.8439, 2.82, 0.335, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
588, d4qp8B_, 0.8438, 2.29, 0.341, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
589, d4accB_, 0.8438, 2.82, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
590, d4au8B_, 0.8436, 2.41, 0.599, 277, 272, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
591, d4nifE_, 0.8435, 2.51, 0.361, 348, 277, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
592, d4iz5D_, 0.8434, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
593, d4iz5B_, 0.8434, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
594, d4iz5A_, 0.8433, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
595, d4iz5C_, 0.8432, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
596, d4bbmA1, 0.8431, 2.69, 0.394, 306, 279, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
597, d4nifB_, 0.8430, 2.52, 0.357, 349, 277, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
598, d4qp9A_, 0.8429, 2.28, 0.341, 335, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
599, d4qp7A_, 0.8429, 2.32, 0.341, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
600, p4fmqA_, 0.8429, 2.56, 0.359, 350, 276, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
601, d2fysA_, 0.8429, 2.51, 0.361, 348, 277, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
602, d5f95A_, 0.8426, 2.58, 0.343, 345, 277, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
603, d4qp4A_, 0.8426, 2.31, 0.341, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
604, d5hlpA_, 0.8425, 2.66, 0.341, 337, 276, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
605, d4cjyC_, 0.8417, 2.87, 0.401, 303, 282,  
606, d1pyxA_, 0.8416, 2.70, 0.339, 343, 277, GSK-3 BETA COMPLEXED WITH AMP-PNP
607, p4h3qA_, 0.8414, 2.61, 0.361, 352, 277, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
608, d3fwqB_, 0.8407, 2.63, 0.310, 334, 277, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
609, d2gphA_, 0.8404, 2.55, 0.366, 345, 276, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
610, d1unlA_, 0.8404, 2.67, 0.585, 292, 277, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
611, d2rkpA_, 0.8402, 2.67, 0.310, 334, 277,  
612, d3qyiA_, 0.8399, 2.69, 0.363, 346, 278,  
613, d5cqwA_, 0.8395, 2.59, 0.310, 331, 274, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
614, d4bxaA_, 0.8395, 2.59, 0.310, 331, 274,  
615, p3u9cA_, 0.8395, 2.54, 0.315, 331, 273, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
616, d3blrA_, 0.8395, 2.66, 0.404, 300, 277, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
617, d3h30B_, 0.8394, 2.73, 0.310, 333, 277, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
618, p3u9cB_, 0.8392, 2.54, 0.315, 331, 273, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
619, d4md7H_, 0.8390, 2.54, 0.315, 330, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
620, d5nqcA_, 0.8389, 2.73, 0.310, 331, 277, CK2ALPHA IN COMPLEX WITH NMR154
621, p5v61A_, 0.8385, 2.41, 0.357, 348, 272, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
622, d3q9xB_, 0.8385, 2.54, 0.315, 330, 273, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
623, d3juhA_, 0.8385, 2.69, 0.318, 334, 277, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
624, d5h8bA_, 0.8384, 2.58, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
625, d1pyxB_, 0.8384, 2.67, 0.342, 338, 275, GSK-3 BETA COMPLEXED WITH AMP-PNP
626, d5cqwB_, 0.8382, 2.60, 0.310, 331, 274, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
627, d4md7E_, 0.8382, 2.55, 0.315, 332, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
628, d3q3bA_, 0.8382, 2.75, 0.343, 344, 277, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
629, p2h96B_, 0.8381, 2.44, 0.337, 357, 273, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
630, d3ngaB_, 0.8380, 2.60, 0.310, 331, 274, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
631, d4md7F_, 0.8379, 2.55, 0.315, 332, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
632, d4bxaB_, 0.8379, 2.61, 0.310, 331, 274,  
633, p3zu7A_, 0.8378, 2.67, 0.371, 344, 278, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
634, d5h8eA_, 0.8377, 2.59, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
635, d5k5nA_, 0.8376, 2.54, 0.338, 331, 272, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
636, d4md7G_, 0.8376, 2.57, 0.315, 332, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
637, d3rpsA_, 0.8376, 2.50, 0.315, 334, 273, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
638, d1ymiA_, 0.8376, 2.70, 0.318, 334, 277,  
639, d1q3wB_, 0.8376, 2.72, 0.337, 341, 276, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
640, d3od6X_, 0.8375, 2.37, 0.359, 344, 270, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
641, d3ngaA_, 0.8375, 2.61, 0.310, 331, 274, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
642, d3bw5A_, 0.8375, 2.70, 0.318, 334, 277,  
643, d4kwpA_, 0.8374, 2.64, 0.310, 329, 274, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
644, d3q9zA_, 0.8374, 2.62, 0.310, 332, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
645, p3be9A_, 0.8374, 2.61, 0.310, 327, 274, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
646, d3ofmA_, 0.8373, 2.60, 0.321, 325, 274, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
647, d1q3wA_, 0.8373, 2.79, 0.343, 344, 277, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
648, p5v62A_, 0.8372, 2.55, 0.359, 349, 273, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
649, d5kwhA_, 0.8372, 2.62, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
650, d4ubaA_, 0.8371, 2.52, 0.308, 333, 273, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
651, d5kwhB_, 0.8370, 2.62, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
652, d5m56A_, 0.8369, 2.61, 0.321, 331, 274, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
653, d3q9zB_, 0.8369, 2.54, 0.315, 332, 273, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
654, p5ooiA_, 0.8366, 2.62, 0.318, 329, 274, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
655, p4gubA_, 0.8366, 2.52, 0.311, 329, 273, CASEIN KINASE II BOUND TO INHIBITOR
656, d3o2mB_, 0.8366, 2.43, 0.337, 358, 273, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
657, d3du8A_, 0.8366, 2.69, 0.338, 336, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
658, d3q9xA_, 0.8365, 2.63, 0.310, 330, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
659, d3qa0B_, 0.8364, 2.57, 0.315, 330, 273, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
660, p5omyA_, 0.8363, 2.53, 0.315, 332, 273, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
661, p4md8F_, 0.8363, 2.68, 0.309, 332, 275, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
662, p4md8E_, 0.8363, 2.70, 0.309, 332, 275, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
663, d4fbxA_, 0.8363, 2.52, 0.315, 333, 273, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
664, d3h30A_, 0.8363, 2.75, 0.310, 333, 277, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
665, d3u87A_, 0.8362, 2.61, 0.310, 329, 274, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
666, d3q04A_, 0.8362, 2.55, 0.311, 328, 273, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
667, d3juhB_, 0.8362, 2.73, 0.318, 334, 277, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
668, d5t1hA_, 0.8361, 2.61, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
669, d5h8eB_, 0.8361, 2.63, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
670, p4md8G_, 0.8360, 2.61, 0.307, 332, 274, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
671, p4ib5A_, 0.8360, 2.64, 0.318, 331, 274, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
672, d4bxbA_, 0.8360, 2.53, 0.311, 328, 273,  
673, d5cquA_, 0.8359, 2.53, 0.311, 328, 273, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
674, d4au8A1, 0.8358, 2.15, 0.581, 274, 267, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
675, d3qa0A_, 0.8358, 2.64, 0.310, 330, 274, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
676, d5h8bB_, 0.8357, 2.64, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
677, d5cu2A_, 0.8357, 2.61, 0.314, 328, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
678, d4qnyA_, 0.8357, 2.58, 0.307, 333, 277, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
679, p4nh1A_, 0.8357, 2.64, 0.307, 330, 274, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
680, d3u87B_, 0.8357, 2.69, 0.313, 329, 275, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
681, d3q3bB_, 0.8357, 2.73, 0.337, 341, 276, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
682, p2pvmA_, 0.8357, 2.64, 0.310, 327, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
683, p2pvkA_, 0.8357, 2.64, 0.310, 327, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
684, d5n1vB_, 0.8356, 2.63, 0.310, 331, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
685, d4rlkA_, 0.8356, 2.62, 0.314, 327, 274, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
686, p3o17B_, 0.8356, 2.44, 0.342, 357, 272, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
687, d3rp0A_, 0.8355, 2.65, 0.307, 329, 274,  
688, p4nh1B_, 0.8354, 2.69, 0.313, 332, 275, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
689, p4md8H_, 0.8354, 2.70, 0.313, 331, 275, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
690, d3rp0D_, 0.8354, 2.66, 0.307, 329, 274,  
691, d3q9wA_, 0.8354, 2.67, 0.318, 328, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
692, d1ds5A_, 0.8354, 2.69, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
693, d5cu0A_, 0.8353, 2.54, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
694, d3wowA_, 0.8353, 2.60, 0.307, 334, 274, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
695, d3c13A_, 0.8353, 2.59, 0.319, 328, 273, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
696, p2pvjA_, 0.8353, 2.65, 0.310, 326, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
697, d1jamA_, 0.8353, 2.70, 0.316, 327, 275, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
698, d1ds5C_, 0.8353, 2.68, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
699, p5owlB_, 0.8352, 2.63, 0.310, 332, 274, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
700, d5ku8B_, 0.8352, 2.65, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
701, d3rp0B_, 0.8352, 2.61, 0.310, 329, 274,  
702, d1i09B_, 0.8352, 2.75, 0.337, 341, 276, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
703, d3pzhA_, 0.8351, 2.68, 0.316, 327, 275, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
704, d1lpuA_, 0.8351, 2.69, 0.316, 327, 275, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
705, d4qteA_, 0.8350, 2.50, 0.359, 348, 273, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
706, d3rp0C_, 0.8350, 2.62, 0.310, 329, 274,  
707, d3pvgA_, 0.8349, 2.69, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
708, d3fl5A_, 0.8349, 2.63, 0.314, 324, 274, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
709, p2pvhA_, 0.8349, 2.70, 0.313, 327, 275, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
710, d5n1vA_, 0.8348, 2.63, 0.310, 331, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
711, d3kxjA_, 0.8348, 2.69, 0.316, 326, 275,  
712, p2pvnA_, 0.8348, 2.70, 0.313, 327, 275, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
713, d1ds5D_, 0.8348, 2.70, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
714, d5t1hB_, 0.8347, 2.66, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
715, p4lfiA_, 0.8347, 2.73, 0.287, 370, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
716, d5cx9A_, 0.8346, 2.64, 0.314, 328, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
717, d5ctpB_, 0.8346, 2.65, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
718, p4md9F_, 0.8346, 2.61, 0.310, 327, 274, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
719, p4lfiB_, 0.8346, 2.73, 0.287, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
720, d1q99A_, 0.8346, 2.78, 0.300, 354, 277, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
721, d1ds5B_, 0.8346, 2.70, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
722, p5n9lA_, 0.8345, 2.67, 0.310, 329, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
723, p5lw1B_, 0.8345, 2.68, 0.341, 355, 279, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
724, d3w55A_, 0.8345, 2.30, 0.344, 335, 270, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
725, d3du8B_, 0.8345, 2.72, 0.345, 339, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
726, d2e14A_, 0.8345, 2.30, 0.344, 335, 270,  
727, p4md9E_, 0.8344, 2.72, 0.309, 329, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
728, d3bqcA_, 0.8344, 2.61, 0.319, 328, 273, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
729, d2zjwA_, 0.8344, 2.60, 0.314, 332, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
730, d2jd5A_, 0.8344, 2.66, 0.305, 353, 275, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
731, d5ct0A_, 0.8343, 2.55, 0.311, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
732, d5v60A_, 0.8342, 2.47, 0.364, 347, 272, PHOSPHO-ERK2 BOUND TO AMP-PCP
733, d5moeA_, 0.8342, 2.53, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
734, d5mmrA_, 0.8342, 2.55, 0.311, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
735, d3kxgA_, 0.8342, 2.71, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
736, d3f7zA1, 0.8342, 2.62, 0.330, 338, 273, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
737, d5cu0B_, 0.8341, 2.57, 0.311, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
738, p4md9K_, 0.8341, 2.71, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
739, d1q8zA_, 0.8341, 2.79, 0.303, 354, 277, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
740, d5clpB_, 0.8340, 2.63, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
741, p4ib5C_, 0.8340, 2.72, 0.313, 332, 275, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
742, d1lr4A_, 0.8340, 2.71, 0.316, 327, 275, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
743, d5nhjA_, 0.8339, 2.50, 0.355, 345, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
744, p5lw1E_, 0.8339, 2.83, 0.352, 355, 281, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
745, d4qnyB_, 0.8339, 2.61, 0.310, 339, 277, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
746, p4md9P_, 0.8339, 2.72, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
747, p4md9G_, 0.8339, 2.62, 0.310, 329, 274, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
748, d3o0gA_, 0.8339, 2.68, 0.589, 289, 275, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
749, p2pvlA_, 0.8339, 2.67, 0.310, 327, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
750, d1zohA_, 0.8339, 2.71, 0.316, 326, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
751, d5hlpB_, 0.8338, 2.65, 0.341, 335, 273, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
752, p3nieA_, 0.8338, 2.66, 0.384, 369, 276, CRYSTAL STRUCTURE OF PF11_0147
753, p4md9H_, 0.8337, 2.73, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
754, d4anmA1, 0.8337, 2.72, 0.316, 327, 275, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
755, d3at2A_, 0.8337, 2.64, 0.307, 334, 274, CRYSTAL STRUCTURE OF CK2ALPHA
756, d5mmfA_, 0.8336, 2.57, 0.311, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
757, d4dgmA_, 0.8336, 2.72, 0.316, 326, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
758, d5modA_, 0.8335, 2.57, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
759, p4md9M_, 0.8335, 2.73, 0.309, 331, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
760, d3wilA_, 0.8335, 2.55, 0.311, 331, 273, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
761, d3r0tA_, 0.8335, 2.65, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
762, d3o2mA_, 0.8334, 2.46, 0.337, 358, 273, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
763, p5lw1H_, 0.8333, 2.65, 0.356, 355, 278, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
764, d5buiA_, 0.8333, 2.23, 0.353, 338, 269, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
765, d4izaA_, 0.8333, 2.57, 0.364, 346, 275, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
766, d3rpsB_, 0.8333, 2.49, 0.312, 334, 272, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
767, d5m4uA_, 0.8332, 2.59, 0.322, 332, 273, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
768, d5ku8A_, 0.8332, 2.64, 0.311, 328, 273, CRYSTAL STRUCTURE OF CK2
769, d3warA_, 0.8332, 2.65, 0.307, 334, 274, CRYSTAL STRUCTURE OF HUMAN CK2A
770, d3owlA_, 0.8332, 2.74, 0.313, 330, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
771, d3kxmA_, 0.8332, 2.73, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
772, d1zoeA_, 0.8332, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
773, d1di9A_, 0.8332, 2.68, 0.357, 348, 277, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
774, d5csvA_, 0.8331, 2.62, 0.319, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
775, d5cspA_, 0.8331, 2.61, 0.319, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
776, p4md9L_, 0.8331, 2.76, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
777, d1m2qA_, 0.8331, 2.76, 0.316, 327, 275, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
778, d1dayA_, 0.8331, 2.64, 0.314, 327, 274, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
779, p6g97A_, 0.8330, 2.48, 0.360, 344, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
780, d4cxaC_, 0.8330, 2.91, 0.419, 330, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
781, d3pe2A_, 0.8330, 2.65, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
782, d1om1A_, 0.8330, 2.72, 0.316, 325, 275, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
783, d1m2pA_, 0.8330, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
784, d4dgnA_, 0.8329, 2.72, 0.316, 325, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
785, d3kxnA_, 0.8329, 2.72, 0.316, 327, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
786, d3at3A_, 0.8329, 2.58, 0.311, 332, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
787, d1j91B_, 0.8329, 2.81, 0.315, 327, 276, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
788, d1dawA_, 0.8329, 2.72, 0.316, 327, 275, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
789, d4rllA_, 0.8328, 2.66, 0.314, 329, 274, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
790, d1xo2B_, 0.8328, 2.42, 0.469, 289, 271, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
791, d1jwhB_, 0.8328, 2.76, 0.313, 335, 275, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
792, p5otzA_, 0.8327, 2.67, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
793, d5mpjA_, 0.8327, 2.61, 0.311, 326, 273, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
794, d3wikA_, 0.8327, 2.64, 0.307, 334, 274, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
795, d3owkA_, 0.8327, 2.75, 0.313, 330, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
796, d5mohA_, 0.8326, 2.57, 0.316, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
797, d3owjA_, 0.8326, 2.76, 0.313, 328, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
798, d1lp4A_, 0.8326, 2.72, 0.316, 327, 275, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
799, d5u6iA_, 0.8325, 2.49, 0.357, 339, 272, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
800, d5mp8A_, 0.8324, 2.56, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
801, p4mwhA_, 0.8324, 2.75, 0.287, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
802, d4dgoA_, 0.8324, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
803, d3pe1A_, 0.8324, 2.66, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
804, d3at4A_, 0.8324, 2.59, 0.311, 331, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
805, d5nhhA_, 0.8323, 2.53, 0.359, 348, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
806, d5motA_, 0.8323, 2.64, 0.319, 328, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
807, p4fi1A_, 0.8323, 2.75, 0.287, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
808, d3q9yA_, 0.8323, 2.69, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
809, d5mo7A_, 0.8322, 2.59, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
810, d2pvrA_, 0.8322, 2.67, 0.314, 328, 274, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
811, p3nieB_, 0.8321, 2.69, 0.384, 367, 276, CRYSTAL STRUCTURE OF PF11_0147
812, d1pjkA_, 0.8321, 2.65, 0.314, 331, 274, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
813, d4ptgA_, 0.8320, 2.68, 0.352, 333, 273, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
814, d2qc6A_, 0.8320, 2.73, 0.316, 326, 275, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
815, d2oxxA_, 0.8320, 2.75, 0.316, 325, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
816, d1wbwA_, 0.8320, 2.68, 0.361, 351, 277, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
817, d5mo5A_, 0.8319, 2.55, 0.312, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
818, d4mygA_, 0.8319, 2.68, 0.380, 335, 274, MAPK13 ACTIVE FORM
819, d3blqA_, 0.8319, 2.68, 0.411, 295, 275, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
820, d1na7A_, 0.8319, 2.64, 0.314, 326, 274, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
821, d1f0qA_, 0.8319, 2.74, 0.316, 329, 275, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
822, d4ubaB_, 0.8318, 2.65, 0.310, 333, 274, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
823, d3mb6A_, 0.8318, 2.66, 0.319, 329, 273, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
824, d3gc9A_, 0.8318, 2.26, 0.361, 335, 269, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
825, d1q41A_, 0.8317, 2.73, 0.343, 339, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
826, p5os8A_, 0.8316, 2.68, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
827, d4grbA_, 0.8316, 2.56, 0.309, 327, 272, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
828, d3zduA_, 0.8316, 2.69, 0.349, 297, 275, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
829, d5nhoA_, 0.8315, 2.53, 0.355, 343, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
830, d5cu6A_, 0.8315, 2.72, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA
831, d3kxhA_, 0.8315, 2.74, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
832, d3axwA_, 0.8314, 2.68, 0.310, 329, 274, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
833, d1zogA_, 0.8314, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
834, d3fwqA_, 0.8313, 2.80, 0.310, 334, 277, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
835, p5owlA_, 0.8312, 2.74, 0.310, 331, 274, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
836, d5k5nB_, 0.8312, 2.48, 0.338, 334, 269, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
837, d5cu2B_, 0.8312, 2.58, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
838, d4kinB_, 0.8312, 2.41, 0.375, 341, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
839, d2oxdA_, 0.8312, 2.75, 0.316, 325, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
840, d1h4lA_, 0.8312, 2.36, 0.569, 278, 267, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
841, p5n9nA_, 0.8311, 2.68, 0.314, 329, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
842, d5cvhA_, 0.8311, 2.63, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA
843, p5oulA_, 0.8310, 2.72, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
844, p5otyA_, 0.8310, 2.71, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
845, d5cshA_, 0.8310, 2.59, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
846, d4kipB_, 0.8310, 2.34, 0.378, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
847, d5mo6B_, 0.8309, 2.58, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
848, d3gc9B_, 0.8309, 2.34, 0.343, 339, 271, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
849, d5mo8A_, 0.8308, 2.61, 0.311, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
850, d5mmfB_, 0.8308, 2.58, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
851, d5b0xA_, 0.8308, 2.68, 0.310, 329, 274, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
852, d5mmrB_, 0.8307, 2.57, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
853, p5n9kA_, 0.8306, 2.68, 0.314, 329, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
854, d5mpjB_, 0.8306, 2.59, 0.312, 324, 272, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
855, d5cu4A_, 0.8306, 2.67, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
856, d2zoqB_, 0.8306, 2.35, 0.370, 351, 270, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
857, d1q99B_, 0.8306, 2.69, 0.296, 364, 277, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
858, d5mo7B_, 0.8305, 2.57, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
859, d5mo5B_, 0.8305, 2.59, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
860, d5cx9B_, 0.8305, 2.59, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
861, d1q5kB_, 0.8305, 2.79, 0.338, 344, 275, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
862, p6ehuB_, 0.8304, 2.77, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
863, d5mo6A_, 0.8304, 2.57, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
864, p4jqeA_, 0.8304, 2.80, 0.287, 369, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
865, p3zuvC_, 0.8303, 2.69, 0.380, 357, 274, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
866, p2h96A_, 0.8303, 2.59, 0.355, 358, 273, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
867, d5moeB_, 0.8302, 2.54, 0.310, 323, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
868, d5l2sA_, 0.8302, 1.62, 0.512, 263, 258, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
869, d3pwdA_, 0.8302, 2.77, 0.316, 327, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
870, d3mb7A_, 0.8302, 2.80, 0.313, 330, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
871, d1w82A_, 0.8302, 2.73, 0.359, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
872, d5movA_, 0.8301, 2.60, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
873, d5cvfA_, 0.8301, 2.61, 0.320, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
874, d3u4uA_, 0.8301, 2.56, 0.309, 327, 272, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
875, p3e3bX_, 0.8301, 2.77, 0.320, 334, 275, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
876, d1wboA_, 0.8301, 2.71, 0.361, 351, 277, FRAGMENT BASED P38 INHIBITORS
877, d1j91A_, 0.8301, 2.78, 0.316, 327, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
878, d5m4cA_, 0.8300, 2.73, 0.313, 329, 275, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
879, d5ctpA_, 0.8300, 2.59, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
880, p3zuvA_, 0.8300, 2.71, 0.376, 357, 274, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
881, d3w8lB_, 0.8300, 2.66, 0.311, 326, 273, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
882, d1q8zB_, 0.8300, 2.84, 0.306, 364, 278, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
883, d5ct0B_, 0.8299, 2.59, 0.312, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
884, p4looA_, 0.8299, 2.80, 0.371, 349, 280, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
885, d4aaaA1, 0.8299, 2.28, 0.405, 290, 269, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
886, d1howA_, 0.8299, 2.84, 0.314, 346, 277, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
887, d4ewqA_, 0.8298, 2.64, 0.355, 346, 276, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
888, d1q4lA_, 0.8298, 2.73, 0.343, 342, 274, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
889, d4iq6B_, 0.8296, 2.71, 0.344, 332, 273, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
890, p3o17A_, 0.8296, 2.52, 0.342, 357, 272, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
891, d3mvlB_, 0.8296, 2.35, 0.374, 339, 270, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
892, d3d7zA_, 0.8295, 2.68, 0.373, 348, 276, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
893, d1ouyA_, 0.8294, 2.73, 0.357, 350, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
894, p4ib5B_, 0.8293, 2.75, 0.307, 329, 274, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
895, p4f9bA_, 0.8293, 2.32, 0.267, 318, 270, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
896, d3nszA_, 0.8293, 2.66, 0.311, 327, 273, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
897, p2g01B_, 0.8293, 2.62, 0.341, 356, 273, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
898, d1jsuA_, 0.8293, 2.87, 0.879, 285, 272, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
899, p6gihA_, 0.8292, 2.62, 0.311, 324, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
900, d5cvhB_, 0.8292, 2.62, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA
901, d5mo8B_, 0.8291, 2.61, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
902, d5m56B_, 0.8291, 2.77, 0.320, 328, 275, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
903, d5ke0A_, 0.8291, 2.59, 0.355, 340, 273, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
904, d4mygB_, 0.8291, 2.59, 0.377, 335, 273, MAPK13 ACTIVE FORM
905, d2b9iA_, 0.8291, 2.63, 0.378, 338, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
906, d4kiqA_, 0.8290, 2.31, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
907, d2pmiC_, 0.8290, 2.46, 0.561, 285, 269, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
908, d5modB_, 0.8289, 2.62, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
909, d4qtbA_, 0.8288, 2.59, 0.371, 351, 272, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
910, d3dt1A2, 0.8288, 2.73, 0.372, 352, 277, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
911, d3blhA1, 0.8287, 2.65, 0.418, 291, 273, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
912, d5mowA1, 0.8286, 2.61, 0.312, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
913, d4fv6A_, 0.8285, 2.22, 0.356, 332, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
914, d4dglD_, 0.8285, 2.73, 0.310, 328, 274, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
915, d2zb0A_, 0.8285, 2.69, 0.362, 349, 276, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
916, d2oxyA_, 0.8284, 2.77, 0.316, 327, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
917, d1q3dB_, 0.8284, 2.78, 0.342, 339, 275, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
918, p5xyyA_, 0.8283, 2.73, 0.361, 350, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
919, d3mvlA_, 0.8283, 2.37, 0.378, 339, 270, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
920, d3fmhA_, 0.8283, 2.65, 0.367, 347, 275, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
921, d2b9hA_, 0.8283, 2.57, 0.358, 337, 274, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
922, d1q97B_, 0.8283, 2.86, 0.295, 361, 278, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
923, d1q97A_, 0.8283, 2.70, 0.303, 351, 274, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
924, d1h4lB_, 0.8283, 2.40, 0.569, 278, 267, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
925, d3w8lA_, 0.8281, 2.70, 0.314, 326, 274, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
926, d2jd5B_, 0.8281, 2.86, 0.295, 360, 278, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
927, p2g01A_, 0.8281, 2.55, 0.353, 355, 272, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
928, d4aguC_, 0.8280, 2.21, 0.387, 278, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
929, d1oukA_, 0.8280, 2.72, 0.357, 348, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
930, d4aguA_, 0.8279, 2.24, 0.383, 277, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
931, d2zoqA_, 0.8279, 2.47, 0.369, 351, 271, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
932, d1wbsA_, 0.8279, 2.80, 0.359, 351, 276, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
933, d2erkA_, 0.8278, 2.71, 0.380, 351, 274, PHOSPHORYLATED MAP KINASE ERK2
934, d4fv7A_, 0.8277, 2.56, 0.353, 342, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
935, d5m4fA_, 0.8276, 2.76, 0.313, 330, 275, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
936, d4kiqC_, 0.8276, 2.32, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
937, d4aguB_, 0.8276, 2.23, 0.376, 276, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
938, d3c9wA2, 0.8276, 2.32, 0.364, 335, 269, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
939, d2b9jA_, 0.8276, 2.57, 0.358, 337, 274, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
940, p4h3pA_, 0.8275, 2.56, 0.366, 342, 273, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
941, d5mowB_, 0.8274, 2.64, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
942, d4kipA_, 0.8274, 2.34, 0.375, 337, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
943, d2oxyB_, 0.8274, 2.79, 0.316, 327, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
944, d5h8gA_, 0.8273, 2.49, 0.307, 324, 270, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
945, d5k4iA_, 0.8272, 2.32, 0.353, 336, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
946, d1m2rA_, 0.8271, 2.81, 0.316, 327, 275, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
947, d5m4iA_, 0.8269, 2.77, 0.310, 331, 274, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
948, d4qtbB_, 0.8269, 2.68, 0.366, 348, 273, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
949, p6ehuA_, 0.8267, 2.81, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
950, d1q8yA_, 0.8267, 2.73, 0.303, 351, 274, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
951, d3c9wB2, 0.8266, 2.37, 0.368, 335, 269, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
952, p2no3B_, 0.8266, 2.58, 0.338, 357, 272, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
953, d1q3dA_, 0.8266, 2.83, 0.342, 339, 275, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
954, p2no3A_, 0.8265, 2.59, 0.338, 357, 272, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
955, d5cu3B_, 0.8264, 2.63, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
956, d3nnwA_, 0.8263, 2.80, 0.359, 349, 276, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
957, d5cu3A_, 0.8262, 2.65, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
958, d5nhpA_, 0.8261, 2.66, 0.370, 338, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
959, d4ub7A_, 0.8261, 2.64, 0.309, 334, 272, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
960, p2gmxA_, 0.8261, 2.65, 0.355, 357, 273, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
961, d2b9fA_, 0.8261, 2.68, 0.382, 337, 275, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
962, d1r3cA_, 0.8261, 2.79, 0.361, 349, 277, THE STRUCTURE OF P38ALPHA C162S MUTANT
963, d5nhlA_, 0.8260, 2.63, 0.366, 345, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
964, d5nhvA_, 0.8259, 2.63, 0.352, 345, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
965, d5cs6A_, 0.8259, 2.73, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
966, p4ux9D_, 0.8259, 2.35, 0.332, 344, 268, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
967, d4kiqB_, 0.8259, 2.34, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
968, d4ic7A_, 0.8256, 2.62, 0.372, 355, 274, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
969, d1bl6A_, 0.8256, 2.80, 0.365, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
970, d5mz3A_, 0.8253, 2.90, 0.357, 350, 277, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
971, d3s3iA_, 0.8252, 2.79, 0.372, 349, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
972, d3flyA_, 0.8252, 2.64, 0.369, 347, 274, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
973, p3vuiA_, 0.8251, 2.50, 0.339, 355, 271, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
974, d1jwhA_, 0.8250, 2.72, 0.307, 336, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
975, d5bvdA_, 0.8249, 2.12, 0.348, 330, 264, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
976, d1w84A_, 0.8249, 2.75, 0.362, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
977, d1unhA_, 0.8249, 2.37, 0.566, 276, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
978, d3py3A1, 0.8248, 2.55, 0.364, 352, 272, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
979, d2r7iB_, 0.8248, 2.54, 0.313, 322, 268, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
980, p3n9xB_, 0.8247, 2.71, 0.396, 362, 275, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
981, d2qkrA1, 0.8247, 2.38, 0.586, 269, 263, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
982, d5hd7A_, 0.8246, 2.73, 0.363, 347, 273, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
983, d5bveA_, 0.8246, 2.12, 0.348, 330, 264, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
984, p6g93A_, 0.8245, 2.60, 0.349, 343, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
985, d1wbtA_, 0.8245, 2.89, 0.361, 351, 277, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
986, d1q4lB_, 0.8245, 2.72, 0.338, 337, 272, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
987, d4kinA_, 0.8244, 2.42, 0.378, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
988, d5mp8B_, 0.8243, 2.60, 0.311, 323, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
989, p3vugA_, 0.8243, 2.64, 0.338, 356, 272, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
990, d3mptA_, 0.8242, 2.70, 0.367, 347, 275, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
991, d3flzA_, 0.8242, 2.71, 0.367, 347, 275, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
992, p3vuhA_, 0.8241, 2.66, 0.338, 355, 272, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
993, p3vukA_, 0.8240, 2.51, 0.339, 355, 271, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
994, d3nnvA_, 0.8240, 2.82, 0.359, 348, 276, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
995, d3i60A_, 0.8240, 2.24, 0.350, 335, 266, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
996, d3fklA_, 0.8239, 2.68, 0.372, 344, 274, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
997, p2gmxB_, 0.8239, 2.64, 0.355, 357, 273, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
998, d5cshB_, 0.8238, 2.56, 0.316, 323, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
999, d4kinD_, 0.8236, 2.35, 0.373, 339, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1000, d3nnuA_, 0.8236, 2.85, 0.359, 348, 276, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1001, d4fv8A_, 0.8235, 2.25, 0.350, 333, 266, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1002, p3vudA_, 0.8235, 2.52, 0.339, 355, 271, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1003, d2r7iD_, 0.8235, 2.57, 0.313, 322, 268, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1004, p6g9aA_, 0.8234, 2.62, 0.353, 341, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1005, d5xvuB_, 0.8234, 2.69, 0.308, 321, 273, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1006, d3ds6D_, 0.8234, 2.88, 0.363, 349, 278, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1007, d1bl7A_, 0.8234, 2.82, 0.365, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1008, d3ocgA_, 0.8233, 2.30, 0.371, 336, 267, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
1009, d3nuxA_, 0.8233, 1.68, 0.486, 261, 257, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1010, d3e92A_, 0.8232, 2.83, 0.373, 348, 276, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1011, d4iz7C_, 0.8231, 2.58, 0.370, 340, 273, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1012, d1g3nE_, 0.8230, 2.68, 0.448, 293, 270, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1013, d3mvmA_, 0.8229, 2.31, 0.372, 335, 266, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1014, d1m7qA_, 0.8229, 2.76, 0.359, 348, 276, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1015, d1unhB_, 0.8227, 2.40, 0.566, 276, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1016, d5bujA_, 0.8224, 2.21, 0.351, 331, 265, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1017, d3iphA_, 0.8222, 2.64, 0.366, 345, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1018, d2zb1A_, 0.8218, 2.77, 0.358, 345, 274, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1019, d1g3nA_, 0.8218, 2.69, 0.448, 293, 270, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1020, d5cvgA_, 0.8217, 2.65, 0.314, 326, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1021, d2lgcA1, 0.8217, 2.92, 0.366, 353, 279, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1022, d4kiqD_, 0.8216, 2.44, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1023, d1ungA_, 0.8216, 2.75, 0.582, 288, 273, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1024, d5hd4A_, 0.8215, 2.74, 0.355, 347, 273, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1025, d1zz2A_, 0.8215, 2.42, 0.375, 337, 269, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
1026, d4ic7D_, 0.8214, 2.66, 0.372, 353, 274, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1027, d5xvuA_, 0.8213, 2.72, 0.308, 321, 273, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1028, d1bmkA_, 0.8213, 2.87, 0.361, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1029, d3e3pA_, 0.8211, 2.73, 0.364, 337, 272, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1030, d2yixA_, 0.8211, 2.86, 0.357, 351, 277, TRIAZOLOPYRIDINE INHIBITORS OF P38
1031, d5m44A_, 0.8210, 2.73, 0.312, 329, 272, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1032, d5l2iA_, 0.8210, 1.67, 0.516, 260, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
1033, d1zzlA_, 0.8210, 2.85, 0.357, 351, 277, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1034, p3n9xA_, 0.8208, 2.71, 0.394, 374, 274, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1035, d3kq7A_, 0.8208, 2.92, 0.362, 348, 276, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1036, d2r7iA_, 0.8208, 2.61, 0.310, 322, 268, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1037, d4aa4A_, 0.8207, 2.59, 0.379, 347, 272, P38ALPHA MAP KINASE BOUND TO CMPD 22
1038, d1w83A_, 0.8207, 2.95, 0.357, 351, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1039, d5xvuC_, 0.8206, 2.73, 0.308, 321, 273, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1040, d4y46A_, 0.8206, 2.90, 0.360, 340, 278, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1041, d3flwA_, 0.8206, 2.71, 0.369, 345, 274, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1042, d2ozaB_, 0.8206, 2.48, 0.354, 340, 271, STRUCTURE OF P38ALPHA COMPLEX
1043, p5nzzE_, 0.8204, 2.49, 0.351, 343, 268, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1044, d4aa5A_, 0.8204, 2.51, 0.378, 340, 270, P38ALPHA MAP KINASE BOUND TO CMPD 33
1045, d3flsA_, 0.8203, 2.53, 0.359, 343, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1046, d4qyyA_, 0.8202, 2.76, 0.355, 337, 273, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
1047, d5larA_, 0.8201, 2.90, 0.359, 350, 276, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
1048, d1q8yB_, 0.8201, 2.85, 0.295, 357, 275, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1049, d1w7hA_, 0.8200, 2.80, 0.353, 351, 275, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1050, p3v3vA_, 0.8199, 2.55, 0.341, 351, 270, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
1051, d2zdtA_, 0.8199, 2.71, 0.345, 342, 275, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1052, p6gdqA_, 0.8198, 2.67, 0.349, 339, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1053, p4lopD_, 0.8198, 2.83, 0.365, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1054, d3nwwA_, 0.8198, 2.49, 0.374, 339, 270, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1055, d3gfeA_, 0.8198, 2.87, 0.372, 352, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1056, d2zazA_, 0.8198, 2.68, 0.355, 345, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1057, d1h25C1, 0.8198, 2.46, 0.981, 277, 266, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1058, d4kinC_, 0.8197, 2.52, 0.370, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1059, d4aacA_, 0.8197, 2.52, 0.378, 350, 270, P38ALPHA MAP KINASE BOUND TO CMPD 29
1060, p3teiA_, 0.8194, 2.53, 0.370, 339, 270, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1061, d5clpA_, 0.8192, 2.66, 0.316, 322, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1062, d4fv9A_, 0.8192, 2.27, 0.355, 331, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1063, d5bueA_, 0.8191, 2.26, 0.351, 329, 265, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1064, d4y5hA_, 0.8191, 2.91, 0.360, 349, 278, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1065, d4awiA_, 0.8191, 2.73, 0.342, 352, 275, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1066, d5l2tA_, 0.8190, 1.71, 0.504, 261, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1067, d3hllA_, 0.8189, 2.43, 0.375, 337, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
1068, d3gp0A1, 0.8189, 2.47, 0.336, 332, 268, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1069, p5nzzF_, 0.8188, 2.47, 0.352, 341, 267, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1070, d4qtdA_, 0.8187, 2.82, 0.339, 355, 277, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1071, p4jr7A_, 0.8184, 2.78, 0.281, 367, 270, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1072, d2r7iC_, 0.8184, 2.60, 0.311, 321, 267, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1073, d1wbnA_, 0.8184, 3.01, 0.361, 351, 277, FRAGMENT BASED P38 INHIBITORS
1074, d2rg6A_, 0.8183, 2.38, 0.372, 335, 266, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1075, d2g9xC2, 0.8183, 2.30, 0.985, 273, 262, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
1076, d1wbvA_, 0.8183, 2.93, 0.362, 351, 276, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1077, p5etaB_, 0.8182, 2.32, 0.366, 335, 265, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1078, d1p38A_, 0.8182, 2.93, 0.362, 351, 276, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1079, d4eojC1, 0.8181, 2.56, 0.918, 278, 267, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
1080, d3cgfA_, 0.8181, 2.75, 0.364, 346, 275, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1081, d2f49A_, 0.8181, 2.75, 0.361, 335, 274, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1082, d3rinA_, 0.8180, 2.88, 0.372, 349, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1083, d4qp1B_, 0.8179, 2.75, 0.364, 343, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1084, d3u8wA_, 0.8177, 2.97, 0.371, 349, 278, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1085, d3bx5A_, 0.8177, 2.52, 0.378, 338, 270, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1086, d1lewA_, 0.8177, 2.53, 0.370, 341, 270, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1087, p4ux9A_, 0.8174, 2.52, 0.342, 343, 269, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1088, d4kkhA_, 0.8174, 2.91, 0.354, 351, 277, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1089, d3e3pB_, 0.8174, 2.82, 0.355, 337, 273, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1090, d2rg5A_, 0.8174, 2.31, 0.377, 333, 265, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1091, d1lezA_, 0.8174, 2.66, 0.368, 343, 272, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1092, d3flqA_, 0.8173, 2.68, 0.360, 345, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1093, p4ux9C_, 0.8172, 2.62, 0.337, 333, 270, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1094, d3nnxA_, 0.8172, 2.50, 0.366, 336, 268, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1095, d3hl7A_, 0.8171, 2.43, 0.375, 336, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1096, d4kkeA_, 0.8170, 2.97, 0.360, 354, 278, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1097, d4w4wA_, 0.8169, 2.95, 0.353, 349, 278, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1098, d2f9gA_, 0.8169, 2.48, 0.364, 332, 269, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
1099, d5nguA_, 0.8168, 2.69, 0.360, 339, 272, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1100, d5bvfA_, 0.8165, 2.09, 0.352, 327, 261, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1101, d5f95B_, 0.8164, 2.67, 0.336, 338, 268, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1102, d4ptgB_, 0.8163, 2.64, 0.337, 332, 267, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1103, d3fmjA_, 0.8163, 2.64, 0.365, 344, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1104, d3bv2A_, 0.8163, 2.55, 0.362, 337, 268, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1105, d5etcA_, 0.8162, 2.84, 0.360, 355, 275, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1106, d3mvmB_, 0.8162, 2.35, 0.377, 332, 265, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1107, d1wzyA_, 0.8162, 2.70, 0.348, 350, 273, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
1108, d3rocA_, 0.8161, 2.47, 0.372, 337, 269, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1109, d3e93A_, 0.8161, 2.88, 0.361, 346, 274, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1110, d2balA_, 0.8160, 2.44, 0.377, 337, 268, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1111, d1jnkA_, 0.8160, 2.79, 0.364, 346, 275, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1112, d4ez5A_, 0.8159, 1.65, 0.488, 258, 254, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1113, d1a9uA_, 0.8159, 2.92, 0.342, 351, 275, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1114, d4iz7A_, 0.8158, 2.82, 0.359, 344, 273, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1115, p4lopB_, 0.8157, 2.85, 0.357, 350, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1116, d3o8uA_, 0.8157, 2.32, 0.360, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1117, d3bv3A_, 0.8157, 2.67, 0.363, 338, 270, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1118, d3kf7A_, 0.8154, 2.48, 0.375, 337, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1119, d4xj0A_, 0.8153, 2.80, 0.364, 345, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1120, d4fv3A_, 0.8153, 2.80, 0.360, 346, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
1121, d3itzA1, 0.8153, 2.90, 0.359, 353, 276, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1122, d3fknA_, 0.8153, 2.77, 0.355, 346, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1123, d3fmkA_, 0.8152, 2.73, 0.370, 346, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1124, d4qp8A_, 0.8151, 2.58, 0.346, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
1125, d3cgoA_, 0.8150, 2.81, 0.364, 332, 275, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1126, d2onlB1, 0.8150, 2.53, 0.372, 339, 269, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1127, d4o2zA1, 0.8149, 2.66, 0.332, 357, 271, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1128, d2pmiA_, 0.8149, 2.45, 0.561, 284, 264, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1129, d2p33A_, 0.8149, 2.80, 0.364, 332, 275, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1130, d4kkgA_, 0.8148, 2.91, 0.350, 353, 277, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1131, d4fv4A_, 0.8148, 2.21, 0.347, 329, 262, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1132, d3hv4B_, 0.8148, 2.68, 0.367, 338, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1133, d2ojgA_, 0.8146, 2.81, 0.370, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1134, d1oveA_, 0.8145, 2.91, 0.338, 349, 275, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1135, d4dglC_, 0.8144, 2.95, 0.309, 334, 275, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1136, d3ds6A_, 0.8144, 2.70, 0.352, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1137, d4o6eA_, 0.8143, 2.50, 0.366, 328, 268, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
1138, d3eljA_, 0.8142, 2.74, 0.336, 347, 274, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1139, p6g9hA_, 0.8141, 2.81, 0.360, 343, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1140, d5etiA1, 0.8141, 2.93, 0.349, 352, 275, STRUCTURE OF DEAD KINASE MAPK14
1141, d4qp1A_, 0.8141, 2.79, 0.364, 342, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1142, d2okrA_, 0.8140, 2.55, 0.372, 339, 269, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1143, d4qp7B_, 0.8139, 2.54, 0.347, 335, 271, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
1144, d4qpaB_, 0.8138, 2.81, 0.364, 345, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1145, d3e7oA_, 0.8138, 3.05, 0.344, 342, 276, CRYSTAL STRUCTURE OF JNK2
1146, d4ehvA_, 0.8136, 2.63, 0.368, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1147, d1oz1A_, 0.8135, 2.75, 0.364, 344, 272, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1148, d2ojjA_, 0.8133, 2.86, 0.352, 344, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1149, p6g91A_, 0.8132, 2.76, 0.349, 344, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1150, d5byyA_, 0.8132, 2.94, 0.374, 338, 273, ERK5 IN COMPLEX WITH SMALL MOLECULE
1151, d3ctqA_, 0.8132, 2.55, 0.366, 336, 268, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1152, d2fysB_, 0.8132, 2.65, 0.348, 338, 273, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
1153, p4lopA_, 0.8131, 2.91, 0.365, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1154, d4l7fA1, 0.8130, 2.44, 0.352, 343, 267, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1155, d2pkjA_, 0.8130, 2.33, 0.371, 332, 264,  
1156, d3fmmA_, 0.8129, 2.80, 0.355, 346, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1157, d4qp4B_, 0.8126, 2.60, 0.346, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1158, d2onlA1, 0.8126, 2.52, 0.373, 338, 268, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1159, p5nzzG_, 0.8125, 2.60, 0.362, 342, 268, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1160, d4xrlA_, 0.8125, 2.74, 0.368, 337, 272, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1161, d4qtaA_, 0.8125, 2.54, 0.364, 335, 269, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1162, p4loqD_, 0.8125, 2.90, 0.354, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1163, d3i5zA_, 0.8125, 2.35, 0.351, 331, 265, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1164, d2i6lA_, 0.8124, 2.71, 0.331, 292, 269, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1165, d1zyjA_, 0.8124, 2.29, 0.369, 331, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1166, p4h3pD_, 0.8123, 2.60, 0.372, 338, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1167, d4fv2A_, 0.8123, 2.82, 0.364, 344, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
1168, d3hv5B_, 0.8122, 2.72, 0.367, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1169, d3d83A_, 0.8122, 3.01, 0.364, 347, 275, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1170, d1yqjA2, 0.8122, 2.87, 0.339, 351, 274, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1171, d4w4yA_, 0.8121, 3.16, 0.354, 350, 280, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1172, d4fa2A_, 0.8120, 2.55, 0.361, 339, 269, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1173, d3mh0A_, 0.8120, 2.35, 0.371, 332, 264, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1174, d3ttiA_, 0.8119, 2.82, 0.364, 341, 275, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1175, d1ywrA_, 0.8119, 2.55, 0.379, 338, 269, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1176, p6g8xA_, 0.8118, 2.75, 0.347, 338, 271, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1177, d4fuxA_, 0.8118, 2.78, 0.353, 342, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
1178, d3g90X_, 0.8118, 2.74, 0.352, 345, 273, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1179, p3lhjA_, 0.8117, 2.83, 0.370, 341, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1180, d3flnC_, 0.8117, 2.66, 0.374, 343, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1181, d3erkA_, 0.8117, 2.81, 0.359, 350, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
1182, d2ojiA_, 0.8117, 2.85, 0.366, 344, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1183, d2ghmA_, 0.8117, 2.47, 0.369, 336, 268, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1184, p4loqB_, 0.8114, 2.93, 0.357, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1185, d4fv1A_, 0.8114, 2.83, 0.364, 342, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
1186, d3g9nA_, 0.8114, 2.81, 0.365, 346, 274, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1187, d2o0uA_, 0.8114, 2.85, 0.356, 331, 275, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1188, d4w4vA_, 0.8113, 3.18, 0.354, 342, 280, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1189, d4w4xA_, 0.8112, 3.15, 0.354, 342, 280, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1190, d2zduA_, 0.8111, 2.58, 0.358, 330, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1191, d3gcuB_, 0.8110, 2.69, 0.364, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1192, d1pmnA_, 0.8110, 2.80, 0.358, 344, 274, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1193, d4eh2A_, 0.8108, 2.43, 0.372, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1194, d3oxiA_, 0.8108, 2.33, 0.356, 322, 264, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1195, p4ux9B_, 0.8107, 2.49, 0.338, 327, 266, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1196, d3hv4A_, 0.8107, 2.78, 0.367, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1197, d5cs6B_, 0.8106, 2.53, 0.318, 316, 264, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1198, d4ka3A_, 0.8106, 2.54, 0.369, 340, 268, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1199, d5lcjA_, 0.8105, 2.80, 0.360, 345, 272, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1200, d2fa2A_, 0.8105, 2.85, 0.380, 333, 274, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1201, d4f9yA_, 0.8104, 2.63, 0.381, 339, 270, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1202, d1tvoA_, 0.8103, 2.88, 0.363, 350, 273, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1203, p6ge0A_, 0.8102, 2.78, 0.358, 343, 271, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1204, p6g9mA_, 0.8102, 2.87, 0.360, 341, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1205, d4b99A_, 0.8101, 2.90, 0.379, 335, 272, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
1206, p6g9dA_, 0.8100, 2.82, 0.360, 345, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1207, d2wajA_, 0.8100, 2.88, 0.364, 348, 275, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1208, d4fv5A_, 0.8097, 2.33, 0.345, 330, 264, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1209, d3ptgA_, 0.8097, 2.41, 0.365, 340, 266, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1210, d3p78A_, 0.8094, 2.40, 0.360, 332, 264, P38 INHIBITOR-BOUND
1211, d5ci6B_, 0.8092, 2.61, 0.361, 350, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1212, p4loqA_, 0.8092, 2.95, 0.354, 352, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1213, d4erkA_, 0.8092, 2.84, 0.366, 350, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
1214, d2gfsA_, 0.8090, 2.77, 0.354, 344, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1215, d4zzoA_, 0.8089, 2.63, 0.368, 339, 269, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1216, p4whzA_, 0.8088, 2.86, 0.356, 342, 275, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1217, d3l1sA_, 0.8088, 2.64, 0.340, 336, 265, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1218, d3fkoA_, 0.8088, 2.76, 0.358, 343, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1219, d4zthA_, 0.8087, 2.56, 0.362, 339, 268, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1220, d3o71A_, 0.8087, 2.93, 0.353, 340, 275, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
1221, d4auaA_, 0.8085, 1.74, 0.474, 256, 253, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
1222, d1cm8B_, 0.8085, 2.67, 0.342, 327, 266, PHOSPHORYLATED MAP KINASE P38-GAMMA
1223, d1cm8A_, 0.8085, 2.67, 0.342, 327, 266, PHOSPHORYLATED MAP KINASE P38-GAMMA
1224, d4s33A_, 0.8084, 2.89, 0.366, 347, 273, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
1225, d3p7cA_, 0.8084, 2.43, 0.356, 332, 264, P38 INHIBITOR-BOUND
1226, d3p5kA_, 0.8084, 2.42, 0.360, 332, 264, P38 INHIBITOR-BOUND
1227, d2gtnA_, 0.8084, 2.63, 0.358, 337, 268, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1228, d4xp2A_, 0.8083, 2.83, 0.364, 337, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1229, d4f9wA_, 0.8081, 2.52, 0.373, 336, 268, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1230, p3vulA_, 0.8081, 2.40, 0.332, 344, 265, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1231, d3p79A_, 0.8081, 2.43, 0.360, 332, 264, P38 INHIBITOR-BOUND
1232, d2f49B_, 0.8081, 2.86, 0.358, 337, 274, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1233, d3gc7A_, 0.8080, 3.01, 0.332, 349, 274, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1234, d2okrD_, 0.8080, 2.56, 0.367, 339, 267, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1235, d5nhfA_, 0.8079, 2.85, 0.349, 339, 272, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1236, d4un0D_, 0.8079, 2.82, 0.431, 276, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
1237, d3gcvA_, 0.8079, 2.70, 0.360, 338, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1238, d4bbmB1, 0.8078, 2.59, 0.415, 288, 265, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1239, d3l1sB_, 0.8078, 2.73, 0.346, 330, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1240, d3hp2A_, 0.8078, 2.68, 0.364, 341, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1241, p6cpwA_, 0.8076, 2.75, 0.353, 328, 269, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
1242, d4bgqA_, 0.8076, 2.40, 0.375, 276, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1243, d1golA_, 0.8076, 2.91, 0.366, 357, 273, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
1244, d4zznA_, 0.8075, 2.85, 0.364, 338, 272, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
1245, d3queA_, 0.8075, 2.77, 0.359, 343, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1246, d4s34A_, 0.8074, 2.88, 0.374, 343, 273, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
1247, d4n4sA_, 0.8073, 2.84, 0.354, 342, 274, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1248, d1pmvA_, 0.8073, 2.90, 0.364, 347, 275, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1249, d5umoA_, 0.8072, 2.90, 0.370, 347, 273, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
1250, d2i0hA_, 0.8072, 3.02, 0.328, 349, 274, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1251, p6g9nA_, 0.8071, 2.90, 0.360, 344, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1252, d4qp3B_, 0.8071, 2.56, 0.355, 331, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1253, d3fmlA_, 0.8071, 2.76, 0.359, 342, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1254, d3qudA_, 0.8070, 2.85, 0.362, 345, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1255, d3ds6C_, 0.8070, 3.03, 0.361, 349, 277, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1256, d1yw2A_, 0.8069, 2.74, 0.356, 341, 270, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1257, d3p7bA_, 0.8068, 2.44, 0.360, 332, 264, P38 INHIBITOR-BOUND
1258, d5lckA_, 0.8067, 2.82, 0.362, 345, 271, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1259, d3p4kA_, 0.8067, 2.56, 0.371, 338, 267, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1260, d3kvxA_, 0.8066, 2.49, 0.351, 327, 265, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1261, d3gcuA_, 0.8066, 2.86, 0.370, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1262, d2fa2B_, 0.8066, 2.90, 0.330, 332, 273, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1263, d1erkA_, 0.8066, 2.93, 0.363, 357, 273, STRUCTURE OF SIGNAL-REGULATED KINASE
1264, d3o8tA_, 0.8063, 2.45, 0.360, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1265, d5byzA_, 0.8062, 2.86, 0.387, 348, 271, ERK5 IN COMPLEX WITH SMALL MOLECULE
1266, d4xp3A_, 0.8061, 2.68, 0.364, 339, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1267, d3newA_, 0.8061, 2.49, 0.383, 334, 266, P38-ALPHA COMPLEXED WITH COMPOUND 10
1268, d3amyA_, 0.8061, 2.61, 0.308, 318, 266, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1269, d4qp3A_, 0.8060, 2.66, 0.367, 339, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1270, d3pzeA_, 0.8060, 2.74, 0.339, 347, 271, JNK1 IN COMPLEX WITH INHIBITOR
1271, d3uvpA_, 0.8059, 2.55, 0.366, 334, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1272, d3ds6B_, 0.8059, 2.87, 0.372, 343, 274, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1273, p6g92A_, 0.8058, 2.89, 0.368, 343, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1274, d4zzmA_, 0.8058, 2.85, 0.347, 344, 271, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1275, d2z7lA_, 0.8058, 2.81, 0.367, 329, 270, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
1276, d4s32A_, 0.8057, 2.94, 0.359, 346, 273, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
1277, d3hv5A_, 0.8055, 2.88, 0.370, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1278, d5tbeA_, 0.8054, 2.37, 0.361, 332, 263, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1279, d3fmnA_, 0.8054, 2.68, 0.369, 341, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1280, d4l8mA_, 0.8053, 2.71, 0.364, 339, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1281, d4g6nA_, 0.8053, 2.87, 0.360, 341, 272, CRYSTAL STRUCTURE OF THE ERK2
1282, d2eufB_, 0.8053, 2.47, 0.506, 282, 261, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1283, p4lopC_, 0.8052, 2.81, 0.371, 341, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1284, d4g6oA_, 0.8052, 2.84, 0.359, 339, 270, CRYSTAL STRUCTURE OF THE ERK2
1285, d5uojA_, 0.8051, 2.87, 0.365, 343, 271, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1286, d4eomC1, 0.8051, 2.43, 0.965, 271, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
1287, d4eh3A_, 0.8051, 2.70, 0.362, 339, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1288, d4s2zA_, 0.8050, 2.92, 0.374, 346, 273, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
1289, d4eh7A_, 0.8050, 2.55, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1290, d3qywA_, 0.8050, 2.68, 0.368, 340, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1291, d4s31A_, 0.8049, 2.95, 0.359, 347, 273, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
1292, d3fv8A_, 0.8049, 2.45, 0.358, 331, 265, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1293, d3fskA_, 0.8049, 2.86, 0.368, 342, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1294, d1r39A_, 0.8049, 2.98, 0.363, 345, 273, THE STRUCTURE OF P38ALPHA
1295, d4xneA_, 0.8047, 2.88, 0.360, 344, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1296, d3odzX_, 0.8047, 2.50, 0.373, 335, 263, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1297, d3mgyA_, 0.8047, 2.35, 0.360, 329, 261, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1298, d3lffA_, 0.8045, 2.64, 0.365, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1299, d1wfcA_, 0.8045, 2.89, 0.365, 340, 271, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1300, p6gdmA_, 0.8044, 2.89, 0.365, 341, 271, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1301, d2xrwA1, 0.8044, 2.33, 0.340, 346, 262, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1302, d1oguC1, 0.8044, 2.34, 0.981, 269, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1303, d4iq6A_, 0.8043, 2.74, 0.347, 324, 265, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1304, d4eh8A_, 0.8043, 2.49, 0.366, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1305, p3vumA_, 0.8043, 2.45, 0.332, 347, 265, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1306, d2pv5A_, 0.8042, 2.35, 0.364, 329, 261,  
1307, d3uvqA_, 0.8040, 2.42, 0.375, 333, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1308, p6g9jA_, 0.8038, 2.85, 0.356, 347, 270, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1309, d3v6sA_, 0.8037, 2.74, 0.365, 349, 271, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1310, d3bhuC1, 0.8037, 2.36, 0.981, 269, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1311, d4qp6B_, 0.8036, 2.61, 0.366, 334, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1312, d3v6rA_, 0.8035, 2.75, 0.365, 349, 271, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1313, d4qpaA_, 0.8034, 2.64, 0.366, 331, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1314, d3r63A_, 0.8033, 2.96, 0.359, 347, 273, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
1315, d4izaC_, 0.8031, 2.67, 0.364, 335, 269, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1316, d4gt3A_, 0.8031, 2.92, 0.371, 347, 272, ATP-BOUND FORM OF THE ERK2 KINASE
1317, d3fl4A_, 0.8030, 2.75, 0.362, 339, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1318, d4eoqC1, 0.8029, 2.46, 0.981, 271, 260, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
1319, d4eh6A_, 0.8029, 2.47, 0.364, 335, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1320, d2gtmA_, 0.8029, 2.83, 0.361, 341, 269, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1321, d4qp6A_, 0.8027, 2.68, 0.363, 339, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1322, d4qp2B_, 0.8026, 2.65, 0.381, 329, 265, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1323, d4h36A_, 0.8025, 3.22, 0.361, 353, 277, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1324, d4tyhB_, 0.8024, 2.50, 0.357, 335, 266, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1325, d3bhtC1, 0.8023, 2.38, 0.981, 269, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1326, p5nzzH_, 0.8021, 2.55, 0.365, 335, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1327, d3c5uA_, 0.8020, 2.65, 0.369, 338, 268, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1328, d4eorC1, 0.8019, 2.36, 0.938, 269, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1329, d4bcoC1, 0.8019, 2.34, 0.981, 268, 257, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1330, d1i09A_, 0.8019, 2.72, 0.347, 338, 265, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1331, d4xp0A_, 0.8018, 2.83, 0.367, 336, 270, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1332, d3hrbA_, 0.8018, 2.89, 0.368, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1333, d2ghlA_, 0.8017, 2.54, 0.372, 334, 266, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1334, d1ungB_, 0.8017, 2.37, 0.564, 268, 257, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1335, d4yr8C_, 0.8016, 2.34, 0.335, 318, 260, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1336, p4h3bC_, 0.8016, 3.06, 0.360, 351, 275, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1337, p4h3bA_, 0.8016, 3.06, 0.360, 351, 275, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1338, d3obgA_, 0.8015, 2.49, 0.371, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1339, d3fi4A_, 0.8015, 2.63, 0.380, 339, 266, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1340, d4qp2A_, 0.8014, 2.68, 0.363, 336, 267, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1341, d2w96B_, 0.8012, 2.24, 0.478, 267, 255, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1342, d4xozA_, 0.8010, 2.90, 0.375, 341, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1343, d4xj0B_, 0.8010, 2.75, 0.360, 338, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1344, d3zyaA1, 0.8010, 2.64, 0.369, 341, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1345, d4r3cA_, 0.8009, 2.57, 0.376, 335, 266, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1346, p5ax3A_, 0.8006, 2.51, 0.356, 329, 264, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1347, d1pmeA_, 0.8006, 2.81, 0.361, 333, 269, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
1348, d4zsjA_, 0.8005, 2.91, 0.376, 344, 271, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1349, d4eh4A_, 0.8005, 2.68, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1350, d3uvrA_, 0.8005, 2.67, 0.361, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1351, d3nupA_, 0.8005, 1.56, 0.492, 252, 248, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1352, d4s30A_, 0.8003, 2.93, 0.346, 342, 272, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
1353, d3bhvC1, 0.8003, 2.41, 0.981, 269, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
1354, d4ditA_, 0.8002, 2.17, 0.335, 328, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1355, d3o8pA_, 0.8002, 2.80, 0.362, 336, 268, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1356, d3p7aA_, 0.8000, 2.55, 0.360, 332, 264, P38 INHIBITOR-BOUND
1357, d5n66A_, 0.7999, 2.53, 0.364, 332, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1358, d5mtxA_, 0.7999, 2.54, 0.367, 331, 264, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1359, d3ttjA_, 0.7999, 2.84, 0.358, 333, 271, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1360, d3o0gB_, 0.7999, 2.13, 0.557, 264, 253, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1361, d3mpaA_, 0.7999, 2.39, 0.359, 331, 262, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1362, d4cfuC1, 0.7998, 2.42, 0.981, 269, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1363, d2f2cB_, 0.7998, 2.43, 0.479, 280, 259, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
1364, d4yr8A_, 0.7997, 2.50, 0.350, 320, 263, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1365, d3v6rB_, 0.7994, 3.00, 0.349, 346, 272, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1366, d3qyzA_, 0.7994, 2.78, 0.361, 339, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1367, d2pk9C_, 0.7993, 2.20, 0.567, 266, 254, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1368, d3hp5A_, 0.7992, 2.47, 0.365, 330, 263, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1369, d3hecA_, 0.7991, 2.44, 0.352, 329, 261, P38 IN COMPLEX WITH IMATINIB
1370, d3cg2A_, 0.7991, 2.25, 0.375, 327, 259,  
1371, p5o7iA_, 0.7990, 2.84, 0.379, 340, 269, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
1372, d4zsgA_, 0.7989, 2.93, 0.376, 347, 271, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1373, d4xrjA_, 0.7987, 2.95, 0.360, 344, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1374, d4x21A_, 0.7984, 2.67, 0.356, 336, 267, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1375, d3npcA_, 0.7983, 3.27, 0.330, 357, 276, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1376, d4cjyD_, 0.7982, 2.76, 0.430, 272, 265,  
1377, d3mw1A_, 0.7981, 2.95, 0.358, 342, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1378, d3fsfA_, 0.7980, 2.77, 0.360, 340, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1379, p2xs0A_, 0.7979, 2.68, 0.345, 346, 267, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1380, d2iw9C2, 0.7978, 2.34, 0.977, 267, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
1381, d4dljA_, 0.7975, 2.60, 0.374, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1382, d1pmuA_, 0.7974, 2.82, 0.358, 342, 271, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1383, d4fv0A_, 0.7971, 2.92, 0.365, 341, 271, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
1384, d3pg1A_, 0.7970, 2.81, 0.325, 341, 268, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1385, d4bcpC1, 0.7968, 2.25, 0.965, 266, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1386, d5awmA_, 0.7967, 2.92, 0.335, 345, 269, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1387, d4x21B_, 0.7964, 2.59, 0.361, 336, 266, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1388, d3hegA_, 0.7963, 2.68, 0.362, 333, 265, P38 IN COMPLEX WITH SORAFENIB
1389, d3gi3A_, 0.7963, 2.53, 0.359, 330, 262, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1390, d5ci6A_, 0.7962, 2.64, 0.355, 335, 265, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1391, d4gvaA_, 0.7959, 3.00, 0.325, 345, 271, ADP-BOUND FORM OF THE ERK2 KINASE
1392, d3hv3A_, 0.7956, 2.65, 0.366, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1393, d3oefX_, 0.7955, 2.82, 0.361, 334, 266, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1394, d2r9sB_, 0.7953, 2.39, 0.352, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1395, d2r9sA_, 0.7953, 2.40, 0.360, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1396, d4z9lA_, 0.7952, 2.85, 0.359, 333, 270, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1397, d3oz6B_, 0.7952, 2.84, 0.373, 341, 268, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1398, d4ynoA_, 0.7951, 2.93, 0.342, 342, 269, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1399, d4gsbA_, 0.7951, 2.92, 0.361, 343, 269, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
1400, p5xyxA_, 0.7950, 2.67, 0.364, 337, 264, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1401, d4fuyA_, 0.7950, 2.90, 0.369, 329, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
1402, d3gcqA_, 0.7950, 2.66, 0.366, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1403, d3an0A_, 0.7950, 2.66, 0.246, 291, 264,  
1404, d4yr8E_, 0.7948, 2.63, 0.345, 317, 264, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1405, d4n0sA_, 0.7948, 3.03, 0.365, 348, 271, COMPLEX OF ERK2 WITH CAFFEIC ACID
1406, d3vn9A_, 0.7948, 2.66, 0.246, 291, 264, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
1407, d3mh1A_, 0.7948, 2.77, 0.367, 337, 267, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1408, d3l8xA_, 0.7948, 2.24, 0.370, 326, 257, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1409, d1ukiA_, 0.7948, 2.62, 0.340, 328, 265, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1410, d4zslA_, 0.7947, 2.96, 0.378, 341, 270, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1411, d4lmnA1, 0.7947, 2.36, 0.270, 291, 259, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
1412, d4eh9A_, 0.7947, 2.68, 0.367, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1413, d2pv8A_, 0.7947, 2.77, 0.367, 337, 267,  
1414, d1kv1A_, 0.7947, 2.53, 0.369, 331, 263, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1415, d3s4qA_, 0.7944, 2.25, 0.377, 326, 257, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1416, p4loqC_, 0.7942, 2.91, 0.349, 337, 269, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1417, d3ha8A_, 0.7941, 3.10, 0.337, 342, 270, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1418, d4ic8B_, 0.7940, 3.03, 0.338, 336, 272, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1419, d3v6sB_, 0.7940, 2.58, 0.358, 340, 265, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1420, p5o90A_, 0.7939, 2.50, 0.384, 330, 263, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1421, d3mblA_, 0.7939, 2.35, 0.270, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
1422, d3pp1A1, 0.7937, 2.34, 0.270, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
1423, d3e8nA1, 0.7936, 2.30, 0.271, 290, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
1424, d2qd9A_, 0.7935, 2.49, 0.378, 330, 262, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1425, d3objA_, 0.7934, 2.66, 0.360, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1426, d2wmbC1, 0.7933, 2.33, 0.980, 265, 254, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1427, d1h26C1, 0.7933, 2.38, 0.980, 266, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1428, d3da6A_, 0.7930, 2.79, 0.366, 328, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1429, d4arkA1, 0.7929, 2.40, 0.270, 290, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
1430, d4cfmC1, 0.7927, 2.36, 0.988, 265, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1431, d3sa0A_, 0.7927, 3.02, 0.373, 354, 271, COMPLEX OF ERK2 WITH NORATHYRIOL
1432, d2ok1A_, 0.7926, 2.77, 0.357, 333, 266, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1433, d3eqgA_, 0.7925, 2.40, 0.270, 314, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
1434, d3tg1A_, 0.7924, 2.68, 0.370, 334, 265, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1435, d3eqhA_, 0.7920, 2.40, 0.270, 314, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
1436, d4u7zA1, 0.7919, 2.32, 0.271, 290, 258, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
1437, d3lfbA_, 0.7919, 2.66, 0.354, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1438, d2ptoA_, 0.7918, 2.50, 0.368, 330, 261,  
1439, d3k3iA_, 0.7917, 2.65, 0.371, 332, 264, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1440, d3npcB_, 0.7916, 3.28, 0.331, 356, 275, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1441, d3hvcA_, 0.7915, 2.36, 0.371, 327, 259, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1442, d2p5aA_, 0.7915, 2.36, 0.371, 327, 259,  
1443, d2o2uA_, 0.7913, 2.65, 0.366, 319, 265, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1444, d3dogC1, 0.7911, 2.36, 0.945, 266, 255, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
1445, d3mh2A_, 0.7910, 2.51, 0.368, 330, 261, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1446, d2puuA_, 0.7910, 2.55, 0.359, 330, 262, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1447, d4dliA_, 0.7909, 2.73, 0.371, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1448, d2iw8C2, 0.7909, 2.26, 0.929, 264, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
1449, d2ptjA_, 0.7908, 2.71, 0.364, 334, 264,  
1450, d4zxtA_, 0.7907, 3.06, 0.365, 348, 271, COMPLEX OF ERK2 WITH CATECHOL
1451, d4xoyA_, 0.7906, 2.77, 0.381, 326, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1452, d3fc1X_, 0.7906, 2.74, 0.364, 330, 264, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1453, d3eqfA_, 0.7905, 2.52, 0.269, 314, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
1454, d4u40A_, 0.7903, 2.45, 0.265, 295, 260, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1455, d4a9yA_, 0.7902, 2.79, 0.374, 334, 265, P38ALPHA MAP KINASE BOUND TO CMPD 8
1456, d3oc1A_, 0.7902, 2.57, 0.366, 330, 262, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1457, d3mh3A_, 0.7902, 2.73, 0.364, 334, 264, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1458, d2bakA_, 0.7902, 2.79, 0.374, 334, 265, P38ALPHA MAP KINASE BOUND TO MPAQ
1459, p6f5eB_, 0.7901, 2.90, 0.336, 346, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1460, d5o8uA_, 0.7901, 2.68, 0.365, 331, 263, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1461, d5lmkC1, 0.7901, 2.34, 0.984, 264, 253, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
1462, p5lenB_, 0.7901, 2.90, 0.336, 346, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1463, d3uibA_, 0.7898, 2.36, 0.322, 309, 258, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1464, d5mtyA_, 0.7897, 2.49, 0.363, 328, 259, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1465, d3e7oB_, 0.7895, 2.51, 0.333, 326, 261, CRYSTAL STRUCTURE OF JNK2
1466, d4u81A1, 0.7894, 2.47, 0.271, 288, 258, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
1467, d1ianA_, 0.7894, 2.44, 0.377, 328, 260, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1468, d3v04A1, 0.7891, 2.35, 0.268, 288, 257, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1469, d2p55A2, 0.7890, 2.46, 0.271, 288, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1470, d3oz6A_, 0.7887, 3.14, 0.368, 343, 269, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1471, d3dv3A_, 0.7886, 2.28, 0.270, 288, 256, MEK1 WITH PF-04622664 BOUND
1472, d2excX_, 0.7885, 2.64, 0.364, 335, 264, INHIBITOR COMPLEX OF JNK3
1473, d3hv6A_, 0.7884, 2.62, 0.363, 331, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1474, d1oiuC1, 0.7884, 2.35, 0.976, 264, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1475, d3eqdA_, 0.7883, 2.52, 0.269, 315, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
1476, d5tcoA_, 0.7882, 2.52, 0.363, 327, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1477, d3eqbA1, 0.7882, 2.27, 0.273, 288, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1478, d4u79A_, 0.7880, 2.84, 0.371, 337, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1479, d1s9jA1, 0.7880, 2.37, 0.268, 288, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1480, d3eqiA_, 0.7878, 2.54, 0.269, 315, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
1481, d5bx0A_, 0.7876, 2.53, 0.269, 315, 260, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
1482, d3v01A1, 0.7874, 2.29, 0.273, 288, 256, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1483, d3pg3A_, 0.7873, 2.87, 0.361, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1484, d3hv7A_, 0.7873, 2.63, 0.366, 330, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1485, d4n4sB_, 0.7872, 2.94, 0.331, 337, 269, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1486, d3g9lX_, 0.7872, 2.81, 0.357, 336, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1487, d3my5C1, 0.7871, 2.43, 0.980, 265, 254, CDK2/CYCLINA IN COMPLEX WITH DRB
1488, d3ddqC1, 0.7869, 2.41, 0.976, 265, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
1489, d3eqcA_, 0.7868, 2.37, 0.268, 312, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
1490, d5n68A_, 0.7867, 2.53, 0.377, 328, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1491, d3vvhC1, 0.7865, 2.58, 0.269, 282, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1492, d3zlsA_, 0.7863, 2.48, 0.266, 315, 259, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
1493, d2w9fB_, 0.7862, 2.10, 0.474, 261, 249, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1494, d4u80A_, 0.7860, 2.53, 0.267, 286, 258, MEK 1 KINASE BOUND TO G799
1495, d1s9iA_, 0.7860, 2.43, 0.280, 303, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1496, d3oy1A_, 0.7858, 2.60, 0.366, 329, 262, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1497, d3iw6A_, 0.7858, 2.95, 0.371, 337, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1498, d5n65A_, 0.7856, 2.85, 0.370, 333, 265, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1499, d5ekoA_, 0.7855, 3.05, 0.353, 341, 269, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1500, d3zsiA_, 0.7854, 2.66, 0.368, 326, 261, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1501, d3vvhA1, 0.7854, 2.40, 0.270, 286, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1502, d3vvhB1, 0.7852, 2.61, 0.269, 289, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1503, d1ukhA_, 0.7852, 2.56, 0.341, 321, 261, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1504, d1jowB_, 0.7850, 2.54, 0.480, 277, 256, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1505, d3rtpA_, 0.7848, 2.65, 0.363, 331, 262, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1506, d5o8vA_, 0.7847, 2.46, 0.372, 328, 258, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1507, d3iw7A_, 0.7847, 2.92, 0.368, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1508, d4yr8F_, 0.7845, 2.31, 0.352, 300, 253, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1509, d3k3jA_, 0.7836, 2.65, 0.372, 329, 261, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1510, d4mneE_, 0.7835, 2.51, 0.266, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1511, p4h39A_, 0.7834, 3.07, 0.358, 340, 268, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1512, d2baqA_, 0.7832, 2.76, 0.378, 329, 262, P38ALPHA BOUND TO RO3201195
1513, d4eymA_, 0.7828, 3.02, 0.352, 340, 267, MAPK13 COMPLEX WITH INHIBITOR
1514, d3zshA_, 0.7828, 2.86, 0.370, 331, 265, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1515, d3hubA_, 0.7826, 2.87, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1516, d4mneH_, 0.7823, 2.45, 0.267, 275, 258, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1517, d4cfvC1, 0.7823, 2.40, 0.980, 263, 252, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1518, d3zlxA_, 0.7822, 2.44, 0.268, 312, 257, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
1519, d3zlwA_, 0.7821, 2.56, 0.264, 312, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
1520, d5n63A_, 0.7819, 2.40, 0.371, 325, 256, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1521, d4eh5A_, 0.7819, 2.49, 0.376, 329, 258, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1522, d3hucA_, 0.7819, 3.07, 0.367, 337, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1523, d2weiA1, 0.7818, 2.38, 0.287, 269, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
1524, d1kv2A_, 0.7816, 2.46, 0.377, 325, 257, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1525, d5d7aB_, 0.7814, 2.28, 0.256, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1526, d5n67A_, 0.7812, 2.53, 0.376, 327, 258, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1527, d2b1pA_, 0.7810, 2.72, 0.365, 331, 263, INHIBITOR COMPLEX OF JNK3
1528, d4mneD_, 0.7809, 2.48, 0.271, 285, 258, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1529, d4u40B_, 0.7805, 2.83, 0.248, 299, 262, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1530, d4mneA_, 0.7805, 2.54, 0.266, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1531, d3lfeA_, 0.7805, 2.86, 0.367, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1532, p2y4iC_, 0.7803, 2.41, 0.270, 313, 256, KSR2-MEK1 HETERODIMER
1533, d3lfaA_, 0.7801, 2.83, 0.365, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1534, d2wmaC1, 0.7801, 2.46, 0.976, 264, 253, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1535, d1s9iB_, 0.7799, 2.46, 0.278, 291, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1536, d2yiwA_, 0.7798, 2.50, 0.374, 325, 257, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1537, d3l8sA_, 0.7796, 2.91, 0.367, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1538, d3slsA1, 0.7795, 2.32, 0.260, 289, 254, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1539, d3zlyA_, 0.7794, 2.57, 0.268, 310, 257, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
1540, d5cwzB_, 0.7793, 2.28, 0.241, 284, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1541, d5d7aC_, 0.7789, 2.32, 0.260, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1542, d5d7aA_, 0.7789, 2.37, 0.259, 289, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1543, d2fslX_, 0.7789, 2.79, 0.372, 332, 261, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1544, d2ewaA_, 0.7788, 2.65, 0.373, 330, 260, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1545, d4e6cA_, 0.7787, 2.83, 0.378, 330, 262, P38A-PERIFOSINE COMPLEX
1546, d4e5aX_, 0.7786, 2.69, 0.377, 332, 260, THE W197A MUTANT OF P38A MAP KINASE
1547, d5n64A_, 0.7783, 2.64, 0.375, 329, 259, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1548, d4u45A_, 0.7783, 2.51, 0.268, 289, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1549, d4u44A_, 0.7783, 2.44, 0.270, 286, 256, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1550, d3iw5A_, 0.7782, 3.08, 0.367, 336, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1551, d5cwzA_, 0.7778, 2.29, 0.245, 284, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1552, d4zk5A_, 0.7778, 2.49, 0.261, 286, 257, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1553, d4eyjA_, 0.7776, 3.02, 0.371, 338, 267, MAPK13 COMPLEX WITH INHIBITOR
1554, d3zm4A_, 0.7776, 2.56, 0.270, 309, 256, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
1555, d4aa0A_, 0.7775, 2.78, 0.379, 328, 261, P38ALPHA MAP KINASE BOUND TO CMPD 2
1556, d5hzeA_, 0.7773, 2.64, 0.260, 305, 258, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
1557, d3slsB1, 0.7773, 2.45, 0.263, 291, 255, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1558, d4u43A_, 0.7769, 2.38, 0.239, 287, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1559, d4obpA_, 0.7769, 2.51, 0.261, 285, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1560, d4fzaB1, 0.7769, 2.85, 0.263, 280, 259, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1561, d3lfcA_, 0.7769, 2.88, 0.365, 334, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1562, d3fi2A_, 0.7768, 2.64, 0.356, 326, 261, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1563, d3ma6B_, 0.7765, 2.37, 0.312, 266, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
1564, d4u44B_, 0.7763, 2.96, 0.244, 296, 262, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1565, d4geoA_, 0.7762, 2.64, 0.362, 326, 257, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1566, d3is5F1, 0.7758, 2.15, 0.301, 259, 249, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1567, d2i6lB_, 0.7758, 2.87, 0.312, 269, 260, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1568, d3fi3A_, 0.7750, 2.60, 0.351, 328, 259, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1569, d3iw8A_, 0.7748, 2.98, 0.364, 334, 264, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1570, d2bajA2, 0.7748, 3.12, 0.370, 334, 265, P38ALPHA BOUND TO PYRAZOLOUREA
1571, d5j95A_, 0.7747, 2.37, 0.268, 284, 254, MAP4K4 IN COMPLEX WITH INHIBITOR
1572, p5w5qB_, 0.7744, 2.97, 0.252, 297, 262, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
1573, d5ajqA_, 0.7744, 2.74, 0.317, 280, 259, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
1574, d3gcsA_, 0.7744, 2.87, 0.370, 331, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1575, d5ng3A_, 0.7740, 3.08, 0.222, 283, 261, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1576, d5eknA_, 0.7739, 2.99, 0.348, 336, 264, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1577, d4zp5A_, 0.7737, 2.39, 0.264, 284, 254, MAP4K4 IN COMPLEX WITH INHIBITOR
1578, d2yisA_, 0.7736, 2.59, 0.374, 325, 257, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1579, d5di1A_, 0.7732, 2.40, 0.264, 285, 254, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1580, d5ax9C_, 0.7726, 2.36, 0.257, 282, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1581, d4l46A_, 0.7723, 2.53, 0.290, 317, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
1582, d4l3lA_, 0.7721, 2.53, 0.294, 291, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1583, d3zs5A1, 0.7721, 3.17, 0.361, 339, 266, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1584, d3zsgA_, 0.7716, 3.16, 0.361, 337, 266, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1585, d2x7fB_, 0.7713, 2.44, 0.268, 288, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1586, d3odyX_, 0.7712, 2.63, 0.382, 321, 254, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
1587, d4l44A_, 0.7711, 2.59, 0.298, 321, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
1588, d3zh8A_, 0.7711, 2.47, 0.294, 318, 252, A NOVEL SMALL MOLECULE APKC INHIBITOR
1589, d4l3jA_, 0.7709, 2.55, 0.298, 291, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
1590, d4u42A_, 0.7708, 2.33, 0.254, 282, 252, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
1591, d4zk5B_, 0.7706, 2.90, 0.247, 294, 259, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1592, d4ic8A_, 0.7703, 2.99, 0.332, 325, 262, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1593, d3d0eB_, 0.7703, 2.60, 0.289, 322, 253, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1594, d3d0eA_, 0.7703, 2.60, 0.289, 322, 253, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1595, d3zh8B_, 0.7701, 2.49, 0.294, 317, 252, A NOVEL SMALL MOLECULE APKC INHIBITOR
1596, d4e8aA_, 0.7700, 2.83, 0.372, 327, 258, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1597, d4rvtB_, 0.7699, 3.13, 0.236, 297, 263, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1598, d1o6lA_, 0.7699, 2.58, 0.289, 316, 253, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1599, d1o6kA_, 0.7699, 2.57, 0.289, 317, 253, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1600, d5ax9A_, 0.7697, 2.34, 0.250, 282, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1601, d2f7xE_, 0.7697, 2.70, 0.276, 336, 254, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1602, d5ng3D_, 0.7696, 3.01, 0.221, 278, 258, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1603, d3wf7A_, 0.7696, 2.77, 0.293, 288, 256, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
1604, d2oh0E_, 0.7696, 2.57, 0.277, 336, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1605, d1rejA_, 0.7694, 2.63, 0.277, 333, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1606, d2uzvA_, 0.7693, 2.73, 0.276, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1607, d3zh8C_, 0.7692, 2.45, 0.299, 312, 251, A NOVEL SMALL MOLECULE APKC INHIBITOR
1608, d3we4A_, 0.7692, 2.58, 0.294, 286, 255, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
1609, d2f7eE_, 0.7692, 2.58, 0.277, 336, 253, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1610, d2ojfE_, 0.7691, 2.71, 0.276, 336, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1611, d1re8A_, 0.7690, 2.62, 0.277, 337, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1612, d4o0vA1, 0.7689, 2.94, 0.263, 289, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1613, d4nw5A1, 0.7689, 2.53, 0.290, 296, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1614, d3amaA_, 0.7689, 2.65, 0.285, 342, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1615, d3dfaA1, 0.7688, 2.41, 0.303, 262, 251, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
1616, d2uzuE_, 0.7687, 2.58, 0.273, 336, 253, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1617, d2gfcA_, 0.7687, 2.62, 0.277, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1618, d4njdA1, 0.7686, 2.83, 0.264, 289, 254, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1619, d3e88B_, 0.7686, 2.62, 0.289, 319, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1620, d3e88A_, 0.7686, 2.62, 0.289, 319, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1621, d2uw7A_, 0.7686, 2.78, 0.272, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1622, d1jbpE_, 0.7686, 2.62, 0.277, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1623, d4e5bA_, 0.7685, 2.76, 0.374, 324, 257, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1624, d2gnjA_, 0.7685, 2.64, 0.289, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1625, d1rekA_, 0.7685, 2.77, 0.276, 336, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1626, d4nw6A1, 0.7683, 2.59, 0.289, 296, 253, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1627, d2q0nA_, 0.7683, 2.76, 0.260, 293, 254, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1628, d2jdrA_, 0.7683, 2.63, 0.289, 316, 253, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1629, d2uvxA_, 0.7682, 2.64, 0.273, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1630, d1q24A_, 0.7682, 2.66, 0.273, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1631, d1q61A_, 0.7681, 2.79, 0.276, 335, 254, PKA TRIPLE MUTANT MODEL OF PKB
1632, d3aglB_, 0.7680, 2.64, 0.281, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1633, d2gniA_, 0.7680, 2.63, 0.292, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1634, d2gcdB_, 0.7680, 2.75, 0.285, 308, 256, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1635, d3gcpA_, 0.7679, 3.15, 0.366, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1636, d2npqA_, 0.7679, 2.79, 0.368, 326, 258, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1637, d1q62A_, 0.7679, 2.66, 0.273, 336, 253, PKA DOUBLE MUTANT MODEL OF PKB
1638, d2gnfA_, 0.7678, 2.64, 0.292, 339, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1639, d4e6aA_, 0.7677, 2.77, 0.370, 324, 257, P38A-PIA23 COMPLEX
1640, d2fsmX_, 0.7677, 2.77, 0.370, 326, 257, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1641, d4yxrA_, 0.7676, 2.66, 0.277, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1642, d1ydrE_, 0.7676, 2.64, 0.277, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1643, d4rvtA_, 0.7675, 2.38, 0.274, 281, 252, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1644, d3coiA1, 0.7675, 3.32, 0.384, 342, 271, CRYSTAL STRUCTURE OF P38DELTA KINASE
1645, d2jdtA_, 0.7675, 2.65, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1646, d2gnhA_, 0.7675, 2.65, 0.292, 338, 253, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1647, d1fmoE_, 0.7675, 2.63, 0.273, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1648, d1apmE_, 0.7675, 2.64, 0.277, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1649, d3qamE_, 0.7674, 2.65, 0.273, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1650, d2gnlA_, 0.7674, 2.82, 0.287, 338, 254, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1651, d1jluE_, 0.7674, 2.65, 0.277, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1652, d1bkxA_, 0.7674, 2.60, 0.269, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1653, d5ml5A_, 0.7673, 2.92, 0.369, 326, 260, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1654, d5li1A1, 0.7673, 2.52, 0.303, 329, 251, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1655, d4o0xA1, 0.7673, 2.86, 0.264, 289, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1656, d3oogA_, 0.7673, 2.64, 0.281, 333, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1657, d2jdvA_, 0.7673, 2.80, 0.272, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1658, d2f7zE_, 0.7673, 2.62, 0.277, 336, 253, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1659, d2c1aA_, 0.7672, 2.65, 0.277, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1660, d5j95B_, 0.7670, 3.09, 0.257, 300, 261, MAP4K4 IN COMPLEX WITH INHIBITOR
1661, d5di1B_, 0.7670, 3.08, 0.257, 300, 261, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1662, d2erzE_, 0.7670, 2.66, 0.277, 334, 253, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1663, d3e8dB_, 0.7669, 2.66, 0.289, 317, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1664, d1ydsE_, 0.7669, 2.65, 0.277, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1665, d3e8dA_, 0.7668, 2.66, 0.289, 315, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1666, d2vo7A_, 0.7668, 2.66, 0.277, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1667, d2c1bA_, 0.7668, 2.67, 0.277, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1668, d3thbA_, 0.7667, 2.58, 0.258, 287, 252, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1669, d3pooA_, 0.7667, 2.68, 0.281, 331, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1670, d3dneA_, 0.7667, 2.67, 0.277, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1671, d2gngA_, 0.7667, 2.64, 0.289, 338, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1672, d5d7vB1, 0.7666, 2.64, 0.257, 262, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1673, d3ambA_, 0.7665, 2.67, 0.285, 340, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1674, d1atpE_, 0.7665, 2.66, 0.277, 334, 253, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1675, d4zp5B_, 0.7664, 3.09, 0.257, 300, 261, MAP4K4 IN COMPLEX WITH INHIBITOR
1676, p3lfdA_, 0.7664, 3.02, 0.356, 331, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1677, d3e8eA_, 0.7664, 2.67, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1678, d2fstX_, 0.7664, 2.73, 0.375, 324, 256, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1679, d5i0bA_, 0.7663, 2.82, 0.264, 288, 254, STRUCTURE OF PAK4
1680, d3e8cF_, 0.7663, 2.66, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1681, d3e8cC_, 0.7663, 2.66, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1682, d3e8cA_, 0.7663, 2.66, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1683, d2x39A_, 0.7663, 2.64, 0.289, 316, 253, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1684, d3fjqE_, 0.7662, 2.67, 0.277, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1685, d3e8cD_, 0.7662, 2.66, 0.277, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1686, d3oxtA_, 0.7661, 2.86, 0.280, 335, 254, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1687, d3idbA_, 0.7661, 2.68, 0.277, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1688, d3e8cE_, 0.7661, 2.66, 0.277, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1689, d3e8cB_, 0.7661, 2.66, 0.277, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1690, d3e8eP_, 0.7660, 2.66, 0.273, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1691, d3e8eB_, 0.7660, 2.66, 0.273, 337, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1692, d2uw4A_, 0.7660, 2.62, 0.274, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1693, d2uw3A_, 0.7660, 2.77, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1694, d2uw8A_, 0.7659, 2.64, 0.274, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1695, d3cquA_, 0.7658, 2.53, 0.283, 318, 251, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1696, d3agmA_, 0.7658, 2.81, 0.280, 337, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1697, d2uztA_, 0.7658, 2.76, 0.276, 336, 254, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1698, d3nx8A_, 0.7657, 2.65, 0.281, 333, 253, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1699, d1svgA_, 0.7657, 2.82, 0.276, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1700, d3e8eI_, 0.7656, 2.66, 0.273, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1701, d2uzwE_, 0.7655, 2.76, 0.276, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1702, d1xh9A_, 0.7655, 2.84, 0.280, 336, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1703, d3fhiA_, 0.7654, 2.70, 0.277, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1704, d2gu8A_, 0.7654, 2.69, 0.277, 335, 253, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1705, d1u7eA_, 0.7654, 2.70, 0.277, 338, 253,  
1706, d1q8uA_, 0.7654, 2.67, 0.277, 341, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1707, d1q8tA_, 0.7654, 2.67, 0.277, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1708, d5ta6A_, 0.7653, 2.71, 0.257, 294, 253, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1709, d3e87B_, 0.7653, 2.67, 0.289, 321, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1710, d3e87A_, 0.7653, 2.67, 0.289, 321, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1711, d2vo0A_, 0.7653, 2.83, 0.272, 340, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1712, d1cdkB_, 0.7653, 2.68, 0.277, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1713, d4u45B_, 0.7652, 3.08, 0.246, 295, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1714, d3w2sA_, 0.7652, 2.56, 0.206, 307, 252, EGFR KINASE DOMAIN WITH COMPOUND4
1715, d2fsoX_, 0.7652, 2.73, 0.371, 325, 256, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1716, d1xh6A_, 0.7652, 2.70, 0.277, 331, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1717, d1xh5A_, 0.7652, 2.82, 0.276, 335, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1718, d3dndA_, 0.7651, 2.67, 0.277, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1719, d2uvyA_, 0.7651, 2.78, 0.273, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1720, d1vebA_, 0.7651, 2.81, 0.276, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1721, d4o22A1, 0.7650, 2.77, 0.277, 333, 253, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1722, d2vo6A_, 0.7650, 2.80, 0.273, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1723, d1sveA_, 0.7650, 2.68, 0.277, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1724, d5d7vC1, 0.7649, 2.66, 0.257, 262, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1725, d4u41A_, 0.7649, 2.33, 0.260, 275, 250, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
1726, d2vnyA_, 0.7649, 2.80, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1727, d1ydtE_, 0.7649, 2.68, 0.277, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1728, d3mvjA_, 0.7648, 2.69, 0.281, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1729, d2x7fC_, 0.7648, 2.44, 0.270, 285, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1730, d2vnwA_, 0.7648, 2.79, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1731, d5d7vD1, 0.7647, 2.67, 0.257, 262, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1732, d4o0yA1, 0.7647, 2.99, 0.263, 289, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1733, d4l67A_, 0.7647, 2.90, 0.260, 289, 254, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1734, d4a4oA_, 0.7647, 2.52, 0.259, 290, 251, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1735, d2uw5A_, 0.7647, 2.79, 0.273, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1736, d2i0eB_, 0.7647, 2.57, 0.249, 300, 253, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1737, d2jdsA_, 0.7646, 2.65, 0.278, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1738, d3mvhA_, 0.7645, 2.75, 0.281, 311, 253, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1739, d3e8eL_, 0.7645, 2.67, 0.273, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1740, d3e8eE_, 0.7645, 2.67, 0.273, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1741, d2vo3A_, 0.7645, 2.79, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1742, d4a4lA_, 0.7644, 2.53, 0.259, 290, 251, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1743, d3kb7A_, 0.7644, 2.62, 0.258, 289, 252, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1744, d2cpkE_, 0.7644, 2.65, 0.278, 333, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
1745, d2yacA_, 0.7643, 2.53, 0.259, 290, 251, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1746, d2uvzA_, 0.7643, 2.66, 0.274, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1747, d1rdqE_, 0.7643, 2.70, 0.273, 340, 253, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1748, d4oboB_, 0.7642, 3.13, 0.249, 297, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
1749, d4u41B_, 0.7641, 3.03, 0.246, 297, 260, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
1750, d2uw9A_, 0.7641, 2.72, 0.281, 316, 253, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1751, d1svhA_, 0.7641, 2.84, 0.276, 335, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1752, d1l3rE_, 0.7641, 2.66, 0.278, 338, 252, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1753, d4u3yB_, 0.7640, 3.19, 0.252, 300, 262, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
1754, d4obqB_, 0.7640, 2.88, 0.245, 293, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
1755, d4o21A_, 0.7640, 2.65, 0.278, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1756, d3qalE_, 0.7640, 2.70, 0.273, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1757, d3p0mA_, 0.7640, 2.69, 0.281, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1758, d2uw6A_, 0.7640, 2.80, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1759, d2uw0A_, 0.7640, 2.80, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1760, d4l43A_, 0.7639, 2.42, 0.295, 316, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
1761, d3mv5A_, 0.7639, 2.69, 0.289, 315, 253, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1762, d4j52A_, 0.7638, 2.63, 0.258, 293, 252, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1763, d3ow3A_, 0.7638, 2.71, 0.277, 334, 253, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1764, d1u5qB_, 0.7638, 2.81, 0.285, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1765, d2owbA_, 0.7637, 2.62, 0.258, 294, 252, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1766, d4l42A_, 0.7636, 2.48, 0.298, 299, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
1767, d2rkuA_, 0.7635, 2.74, 0.257, 294, 253, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1768, d1cdkA_, 0.7635, 2.70, 0.277, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1769, d1smhA_, 0.7634, 2.84, 0.276, 348, 254, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1770, d4oboA_, 0.7632, 2.36, 0.260, 275, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
1771, d3ocbA_, 0.7630, 2.63, 0.283, 315, 251, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1772, d3fc2A_, 0.7630, 2.54, 0.259, 293, 251, PLK1 IN COMPLEX WITH BI6727
1773, d2qurA_, 0.7630, 2.71, 0.277, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1774, d4j53A_, 0.7629, 2.63, 0.258, 293, 252, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1775, d5h2uB1, 0.7627, 2.65, 0.258, 261, 252, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1776, d4x6rA_, 0.7627, 2.67, 0.278, 347, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1777, d1u5rB_, 0.7627, 2.75, 0.282, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1778, d1bi8C_, 0.7627, 2.69, 0.456, 264, 252, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1779, d1bi8A_, 0.7627, 2.69, 0.456, 264, 252, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1780, d3mvjE_, 0.7624, 2.68, 0.273, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1781, d1xh8A_, 0.7624, 2.65, 0.278, 337, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1782, d4l45A_, 0.7623, 2.43, 0.299, 317, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
1783, d3aglA_, 0.7623, 2.68, 0.273, 338, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1784, d2qcsA_, 0.7623, 2.69, 0.278, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
1785, d1bx6A_, 0.7623, 2.70, 0.273, 337, 253, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1786, d4zjiD_, 0.7622, 2.68, 0.307, 280, 254, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1787, d3ggfA_, 0.7622, 2.51, 0.274, 275, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
1788, d3l9lA_, 0.7621, 2.77, 0.277, 338, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1789, d2gcdA_, 0.7621, 2.72, 0.286, 308, 255, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1790, d1xhaA_, 0.7621, 2.85, 0.276, 348, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1791, d1xh7A_, 0.7620, 2.83, 0.277, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1792, d5ng3B_, 0.7619, 2.95, 0.224, 275, 255, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1793, d4nusA_, 0.7619, 2.91, 0.294, 301, 255, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1794, d1stcE_, 0.7619, 2.82, 0.276, 334, 254, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1795, d1bi7A_, 0.7619, 2.71, 0.446, 269, 251, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
1796, d5h2uD1, 0.7618, 2.66, 0.258, 261, 252, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1797, d4b6lA_, 0.7618, 2.85, 0.283, 281, 254, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1798, d2cdzA_, 0.7618, 2.80, 0.266, 289, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1799, d3tnpF_, 0.7617, 2.67, 0.274, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1800, d3tnpC_, 0.7617, 2.67, 0.274, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1801, d3ocbB_, 0.7617, 2.63, 0.283, 319, 251, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1802, d3dy7A_, 0.7617, 2.29, 0.275, 260, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1803, d2jedA_, 0.7617, 2.78, 0.280, 324, 254, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1804, d5ta8A_, 0.7616, 2.70, 0.258, 294, 252, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1805, d3iw4B_, 0.7614, 2.66, 0.261, 325, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1806, d5h2uC1, 0.7612, 2.67, 0.258, 261, 252, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1807, d3dxnA_, 0.7612, 2.49, 0.324, 258, 247, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
1808, d4x6qC_, 0.7611, 2.67, 0.274, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1809, d4jdiA_, 0.7611, 2.91, 0.260, 289, 254, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1810, d1xh4A_, 0.7611, 2.84, 0.277, 334, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1811, d2x7fA_, 0.7610, 2.35, 0.269, 276, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1812, d4usdA_, 0.7609, 2.26, 0.324, 268, 247, HUMAN STK10 (LOK) WITH SB-633825
1813, d3iw4A_, 0.7609, 2.67, 0.261, 330, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1814, d3w32A_, 0.7608, 3.20, 0.195, 317, 261, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
1815, d4yhfB_, 0.7607, 2.77, 0.199, 269, 251, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
1816, d3l9lB_, 0.7606, 2.80, 0.277, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1817, d3idcA_, 0.7606, 2.73, 0.277, 341, 253, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1818, d3qklA_, 0.7605, 2.81, 0.289, 317, 253, SPIROCHROMANE AKT INHIBITORS
1819, d3l9mA_, 0.7605, 2.79, 0.277, 338, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1820, d3iw4C_, 0.7605, 2.66, 0.261, 332, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1821, d2hy81_, 0.7605, 2.88, 0.298, 293, 255, PAK1 COMPLEX WITH ST2001
1822, d5d7vA1, 0.7603, 2.69, 0.257, 262, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1823, d3a8xA1, 0.7602, 2.61, 0.290, 331, 252, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1824, d4j7bA_, 0.7601, 2.54, 0.264, 284, 250, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1825, d4gv1A1, 0.7601, 2.84, 0.289, 328, 253, PKB ALPHA IN COMPLEX WITH AZD5363
1826, d3is5B1, 0.7600, 2.15, 0.299, 255, 244, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1827, d2jdoA_, 0.7600, 2.59, 0.283, 314, 251, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1828, d2j0iA_, 0.7600, 2.88, 0.265, 289, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1829, d3bwjA_, 0.7596, 2.74, 0.278, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
1830, d4u43B_, 0.7595, 3.09, 0.239, 302, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1831, d4otdA_, 0.7595, 2.69, 0.294, 334, 252, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1832, d4o0tA_, 0.7595, 2.96, 0.298, 292, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1833, d3ma6A_, 0.7595, 2.62, 0.300, 267, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
1834, d3ow4A_, 0.7594, 2.69, 0.283, 317, 251, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1835, d3cqwA_, 0.7594, 2.73, 0.290, 318, 252, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1836, d4ks7A_, 0.7593, 3.00, 0.283, 286, 254, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1837, d3l9mB_, 0.7592, 2.69, 0.282, 336, 252, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1838, d5vedA_, 0.7591, 2.92, 0.268, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1839, d4y95C1, 0.7591, 2.84, 0.190, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1840, d4y95B1, 0.7591, 2.84, 0.190, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1841, d1u5qA_, 0.7591, 2.75, 0.286, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1842, d3tnqB_, 0.7589, 2.90, 0.277, 331, 253, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1843, d2i0eA_, 0.7589, 2.60, 0.254, 326, 252, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1844, d4obpB_, 0.7587, 2.94, 0.246, 290, 256, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1845, d4crsA1, 0.7587, 2.55, 0.292, 329, 250, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1846, p3hdmA_, 0.7586, 2.64, 0.274, 285, 252, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
1847, d5h2uA1, 0.7585, 2.69, 0.258, 261, 252, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1848, d5ax9B_, 0.7583, 2.44, 0.261, 274, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1849, d4zy5B_, 0.7583, 2.84, 0.302, 287, 258, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1850, d5p9fA_, 0.7582, 2.86, 0.198, 266, 253, BTK IN COMPLEX WITH GDC-0834
1851, d5d9kA_, 0.7582, 2.45, 0.292, 280, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1852, d5bmsA1, 0.7582, 2.89, 0.261, 289, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1853, d2ou7A_, 0.7582, 2.78, 0.257, 292, 253, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1854, d4y95A1, 0.7581, 2.85, 0.194, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1855, d4fihA_, 0.7581, 2.97, 0.260, 291, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1856, d4y95D_, 0.7579, 2.85, 0.194, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1857, d4utdA_, 0.7579, 2.69, 0.304, 266, 250, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
1858, d4u3zB_, 0.7578, 3.07, 0.241, 294, 257, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
1859, d4fijA_, 0.7578, 2.95, 0.260, 291, 254, CATALYTIC DOMAIN OF HUMAN PAK4
1860, d5j87D_, 0.7577, 2.76, 0.199, 263, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1861, d4eklA_, 0.7577, 2.73, 0.283, 329, 251, AKT1 WITH GDC0068
1862, d4zjiC_, 0.7575, 2.67, 0.306, 281, 252, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1863, d4tthB_, 0.7574, 2.42, 0.514, 256, 245, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
1864, d5vefA_, 0.7572, 2.98, 0.260, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1865, d4rx5A1, 0.7572, 2.69, 0.199, 264, 251, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
1866, d4ra5B_, 0.7572, 2.88, 0.281, 310, 253, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1867, d3ocsA1, 0.7572, 2.79, 0.198, 262, 252, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
1868, d4wbbB_, 0.7571, 2.92, 0.277, 334, 253, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1869, d4p41B_, 0.7571, 2.43, 0.514, 256, 245,  
1870, d4hctA_, 0.7571, 2.70, 0.227, 265, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
1871, d3ag9B_, 0.7571, 2.92, 0.280, 317, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1872, d2xh5A_, 0.7571, 2.85, 0.281, 316, 253, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1873, d1u5rA_, 0.7571, 2.80, 0.286, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1874, d5veeA_, 0.7570, 2.94, 0.268, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1875, d5f9eB_, 0.7570, 2.95, 0.287, 293, 254, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1876, d4jdjA_, 0.7570, 2.92, 0.261, 288, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1877, d4appA1, 0.7570, 2.89, 0.261, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1878, d3qkmA_, 0.7570, 2.87, 0.289, 329, 253, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1879, d2jedB1, 0.7569, 2.86, 0.280, 315, 254, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1880, d4otfA1, 0.7568, 2.79, 0.198, 261, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1881, d4figA_, 0.7567, 2.92, 0.256, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
1882, d5f9eA1, 0.7566, 2.99, 0.287, 331, 254, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1883, d3dkcA1, 0.7566, 2.92, 0.224, 310, 254, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
1884, d5bpyA1, 0.7565, 2.75, 0.199, 262, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1885, d4usdB_, 0.7565, 2.30, 0.329, 267, 246, HUMAN STK10 (LOK) WITH SB-633825
1886, d3pozA_, 0.7565, 2.79, 0.210, 293, 252, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
1887, d3ow4B_, 0.7565, 2.75, 0.283, 317, 251, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1888, d4jdkA_, 0.7564, 2.92, 0.261, 288, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1889, d3w33A_, 0.7564, 2.62, 0.212, 297, 250, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
1890, d3qkkA_, 0.7564, 2.70, 0.287, 326, 251, SPIROCHROMANE AKT INHIBITORS
1891, d3d5uA_, 0.7564, 2.81, 0.277, 288, 253, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1892, d4zy4B_, 0.7563, 2.88, 0.302, 292, 258, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1893, d4u3zA_, 0.7563, 2.94, 0.220, 282, 255, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
1894, d4yomB1, 0.7562, 2.76, 0.273, 320, 253, STRUCTURE OF SAD KINASE
1895, d4q9zB_, 0.7562, 2.98, 0.287, 308, 254, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1896, d4j7bD_, 0.7562, 2.56, 0.265, 281, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1897, d4figB_, 0.7562, 2.92, 0.260, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
1898, d4aotA1, 0.7562, 2.54, 0.327, 276, 248, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
1899, d4lg4B_, 0.7561, 2.74, 0.276, 284, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
1900, d3is5A1, 0.7561, 2.16, 0.292, 254, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1901, d3gubA1, 0.7561, 2.58, 0.275, 276, 247, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1902, d1vzoA_, 0.7561, 2.78, 0.267, 319, 251, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
1903, d5vgoA1, 0.7560, 2.70, 0.199, 264, 251, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
1904, d5dh3B_, 0.7560, 2.88, 0.294, 283, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1905, d4jdhA_, 0.7560, 2.99, 0.260, 289, 254, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1906, d3krwA2, 0.7560, 3.02, 0.267, 349, 255, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1907, d1xkkA_, 0.7560, 2.80, 0.214, 289, 252, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
1908, d3orxC_, 0.7559, 2.68, 0.271, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1909, d3orxB_, 0.7559, 2.68, 0.275, 280, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1910, d3orxA_, 0.7559, 2.68, 0.271, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1911, d3krxA2, 0.7559, 3.03, 0.267, 349, 255, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
1912, d4zjiA_, 0.7558, 2.81, 0.285, 278, 253, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1913, d4ra5A1, 0.7558, 2.94, 0.280, 331, 254, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1914, d4aw1A_, 0.7558, 2.78, 0.287, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1915, d3orxD_, 0.7558, 2.69, 0.271, 282, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1916, d5kupA1, 0.7557, 2.70, 0.199, 264, 251, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
1917, d5d9kB_, 0.7557, 2.55, 0.292, 280, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1918, d4otgA_, 0.7556, 2.72, 0.290, 322, 252, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1919, d4otrA_, 0.7555, 2.86, 0.194, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
1920, d5dbxB_, 0.7554, 2.45, 0.278, 282, 245, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
1921, d4zjjA_, 0.7554, 2.87, 0.283, 280, 254, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1922, d4ks8A_, 0.7554, 2.89, 0.287, 286, 251, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1923, d4otqA_, 0.7553, 2.85, 0.194, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
1924, d3wf8A_, 0.7553, 2.94, 0.306, 287, 255, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
1925, d5j87B_, 0.7551, 2.76, 0.203, 274, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1926, d4yhfA_, 0.7551, 2.74, 0.200, 268, 250, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
1927, d4hjoA_, 0.7551, 2.79, 0.210, 278, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
1928, d4hcuA_, 0.7551, 2.71, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1929, d5h0gA3, 0.7550, 3.02, 0.244, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
1930, d5p9gA_, 0.7549, 2.87, 0.198, 265, 252, STRUCTURE OF BTK WITH RN486
1931, d4ypdA1, 0.7549, 2.58, 0.271, 276, 247, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1932, d4q9zA1, 0.7549, 2.85, 0.281, 330, 253, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1933, d5p9mA_, 0.7548, 2.81, 0.193, 271, 254, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
1934, d5h0eA3, 0.7548, 3.02, 0.244, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
1935, d4yo4A1, 0.7548, 2.66, 0.270, 276, 248, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1936, d4jboA_, 0.7548, 2.63, 0.293, 266, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
1937, d3wf9A_, 0.7548, 2.89, 0.307, 287, 254, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
1938, d3gu6A1, 0.7548, 2.66, 0.274, 276, 248, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
1939, d5da3A1, 0.7547, 2.81, 0.257, 261, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1940, d5ajqB_, 0.7547, 2.41, 0.320, 267, 247, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
1941, d3wf6A_, 0.7547, 2.72, 0.309, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
1942, d3dfcB1, 0.7547, 2.65, 0.270, 276, 248, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
1943, d2rgpA_, 0.7547, 2.83, 0.215, 284, 251, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
1944, d4zjiB_, 0.7545, 2.84, 0.285, 276, 253, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1945, d3gu7A1, 0.7545, 2.67, 0.270, 276, 248, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
1946, d5h09A3, 0.7544, 3.02, 0.244, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
1947, d4u8zA_, 0.7544, 2.81, 0.274, 289, 252, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1948, d3h9oA_, 0.7544, 2.57, 0.273, 275, 249, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1949, d3gu8A1, 0.7544, 2.67, 0.270, 276, 248, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
1950, d3rwqA_, 0.7543, 2.72, 0.275, 283, 251, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1951, d3gu4A1, 0.7543, 2.67, 0.270, 276, 248, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
1952, d4apcB1, 0.7542, 2.92, 0.246, 291, 252, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1953, d3q53A_, 0.7542, 2.91, 0.298, 291, 255, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1954, d5h0hA3, 0.7541, 3.02, 0.244, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
1955, d3rwpA_, 0.7541, 2.59, 0.269, 277, 249, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1956, d3l9nA_, 0.7541, 2.88, 0.277, 332, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1957, d3dgkA1, 0.7541, 2.66, 0.270, 276, 248, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
1958, d5h0bA3, 0.7540, 3.03, 0.244, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
1959, d5fd2A_, 0.7540, 2.44, 0.207, 264, 246, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
1960, d5ng3C_, 0.7539, 2.94, 0.226, 272, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1961, d5dt3A_, 0.7539, 2.70, 0.297, 263, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
1962, d4rfyA_, 0.7539, 2.80, 0.195, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
1963, d3iopA_, 0.7539, 2.58, 0.273, 275, 249, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
1964, d5orzA_, 0.7538, 2.66, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1965, d3gu5A1, 0.7537, 2.69, 0.274, 276, 248, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1966, d2pe0A_, 0.7537, 2.56, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
1967, d1uu7A_, 0.7537, 2.72, 0.275, 280, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1968, d4zseA_, 0.7536, 2.76, 0.208, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1969, d4u3yA_, 0.7536, 3.15, 0.231, 295, 260, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
1970, d4ixpA_, 0.7536, 2.54, 0.309, 334, 249, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
1971, d5os5A_, 0.7535, 2.66, 0.302, 267, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1972, d5os4A_, 0.7535, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1973, d3sc1A_, 0.7535, 2.75, 0.287, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1974, d3bhyA1, 0.7535, 2.48, 0.256, 267, 246, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
1975, d1jkkA_, 0.7535, 2.69, 0.278, 277, 248, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
1976, d5orpA_, 0.7534, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1977, d5hg5A_, 0.7533, 3.02, 0.213, 302, 254, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
1978, d4rg0A_, 0.7533, 2.89, 0.194, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
1979, d1okzA_, 0.7533, 2.73, 0.291, 276, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1980, d5orxA_, 0.7532, 2.66, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1981, d5orvA_, 0.7532, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1982, d4w8eA_, 0.7532, 2.86, 0.278, 290, 252, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1983, d3a8xB1, 0.7532, 2.71, 0.302, 325, 252, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1984, d2xchA_, 0.7532, 2.74, 0.275, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1985, d2pe2A_, 0.7532, 2.65, 0.284, 275, 250, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
1986, d5osdA_, 0.7531, 2.67, 0.302, 266, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1987, d5orrA_, 0.7531, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1988, d4ot6A_, 0.7531, 2.78, 0.195, 265, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1989, d5p9hA_, 0.7530, 2.83, 0.199, 264, 251, BTK1 COCRYSTALLIZED WITH RN983
1990, d5os1A_, 0.7530, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1991, d5orwA_, 0.7530, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1992, d5ho7A_, 0.7530, 2.59, 0.265, 280, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1993, d5hkmA_, 0.7530, 2.57, 0.281, 272, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1994, d3nuuA_, 0.7530, 2.54, 0.282, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
1995, d3is5C1, 0.7530, 2.23, 0.300, 254, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1996, d2w4jA_, 0.7530, 2.67, 0.270, 276, 248, X-RAY STRUCTURE OF A DAP-KINASE 2-277
1997, d5osfA_, 0.7529, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1998, d5oseA_, 0.7529, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1999, d5os0A_, 0.7529, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2000, d5oryA_, 0.7529, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2001, d5cnnB_, 0.7529, 2.71, 0.216, 304, 250, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
2002, d3ggfB_, 0.7529, 2.55, 0.275, 270, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2003, d2z7rA_, 0.7529, 2.11, 0.320, 265, 241, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
2004, d1jklA_, 0.7529, 2.72, 0.270, 280, 248, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2005, d3ionA_, 0.7528, 2.54, 0.278, 274, 248, PDK1 IN COMPLEX WITH COMPOUND 8H
2006, d1phkA_, 0.7528, 2.70, 0.293, 277, 249, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2007, d5ho8A_, 0.7527, 2.54, 0.274, 278, 248, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2008, d1okyA_, 0.7527, 2.74, 0.271, 281, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2009, d1ig1A_, 0.7527, 2.71, 0.278, 280, 248, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2010, d4hcvA_, 0.7526, 2.78, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
2011, d4z3vA_, 0.7525, 2.87, 0.198, 271, 252, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
2012, d1z5mA_, 0.7525, 2.60, 0.269, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2013, d1jksA_, 0.7525, 2.72, 0.274, 280, 248, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2014, d5os6A_, 0.7524, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2015, d5os3A_, 0.7524, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2016, d5oroA_, 0.7524, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2017, d5j87A_, 0.7524, 2.78, 0.199, 263, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2018, d4pf4A1, 0.7524, 2.68, 0.274, 277, 248, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2019, d4eqmD_, 0.7524, 2.24, 0.240, 268, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2020, d3a7fA_, 0.7524, 2.85, 0.274, 283, 252, HUMAN MST3 KINASE
2021, d4aotB1, 0.7523, 2.68, 0.320, 277, 250, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2022, d3plsA_, 0.7523, 2.95, 0.229, 298, 253, RON IN COMPLEX WITH LIGAND AMP-PNP
2023, d5vloB_, 0.7522, 2.89, 0.311, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2024, d5ornA_, 0.7522, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2025, d5dnrA_, 0.7522, 2.66, 0.302, 264, 248, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2026, d4eqmF_, 0.7522, 2.23, 0.240, 268, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2027, d3d5wA_, 0.7522, 2.81, 0.271, 284, 251, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2028, d5cwzC_, 0.7521, 2.24, 0.258, 271, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2029, d4b9dB1, 0.7521, 2.93, 0.247, 291, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2030, d2r7bA_, 0.7521, 2.63, 0.277, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2031, d5he0A2, 0.7520, 3.11, 0.267, 346, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
2032, d4obqA_, 0.7520, 2.35, 0.280, 275, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2033, d3nunA_, 0.7520, 2.54, 0.270, 278, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2034, d5dr2A1, 0.7519, 2.72, 0.293, 263, 249, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2035, d5dn3A_, 0.7519, 2.66, 0.302, 264, 248, AURORA A IN COMPLEX WITH ATP AND AA35.
2036, d3orzB_, 0.7519, 2.82, 0.287, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2037, d3nusA_, 0.7519, 2.55, 0.282, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2038, d2xikA_, 0.7519, 2.79, 0.287, 288, 251, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
2039, d5orsA_, 0.7518, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2040, d4eqmE_, 0.7518, 2.23, 0.240, 268, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2041, d3wf5A_, 0.7518, 2.75, 0.313, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2042, d3qcqA_, 0.7518, 2.54, 0.274, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2043, d3orzD_, 0.7518, 2.82, 0.287, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2044, d3o7lB_, 0.7518, 2.73, 0.268, 326, 250, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2045, d5hg8A_, 0.7517, 3.02, 0.213, 300, 254, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
2046, d2srcA3, 0.7517, 2.82, 0.247, 284, 251, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
2047, d1zrzA_, 0.7517, 2.71, 0.292, 310, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2048, d4rfzA_, 0.7516, 2.82, 0.195, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
2049, d3eh9A1, 0.7516, 2.68, 0.271, 274, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2050, d2biyA_, 0.7516, 2.90, 0.285, 287, 253, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
2051, d1uvrA_, 0.7516, 2.78, 0.283, 284, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
2052, d1uu3A_, 0.7516, 2.68, 0.280, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2053, d5dbxA_, 0.7515, 2.55, 0.272, 284, 246, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
2054, d5ar5A_, 0.7515, 2.79, 0.202, 284, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2055, d4ot5A_, 0.7515, 2.83, 0.195, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
2056, d3mj2A_, 0.7515, 2.68, 0.229, 259, 249, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
2057, d3f5uA1, 0.7515, 2.66, 0.267, 275, 247, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2058, d2xckA_, 0.7515, 2.72, 0.260, 275, 250, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2059, d5d9lA_, 0.7514, 2.62, 0.300, 299, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2060, d1ql6A_, 0.7514, 2.65, 0.294, 281, 248, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2061, d5p9jA_, 0.7513, 2.89, 0.198, 263, 252, BTK1 COCRYSTALLIZED WITH IBRUTINIB
2062, d4nwmA_, 0.7513, 2.87, 0.199, 261, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2063, d2pe1A_, 0.7513, 2.63, 0.269, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2064, d1uu8A_, 0.7513, 2.67, 0.280, 277, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2065, d1h1wA_, 0.7513, 2.80, 0.283, 284, 251, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
2066, d5p9kA_, 0.7512, 2.89, 0.198, 271, 252, CRYSTAL STRUCTURE OF BTK WITH CNX 774
2067, d5o21A_, 0.7512, 2.65, 0.246, 272, 248, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2068, d5av3A_, 0.7512, 2.66, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2069, d5ar2B_, 0.7512, 2.96, 0.211, 285, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2070, d4qmyA_, 0.7512, 3.01, 0.277, 287, 253, MST3 IN COMPLEX WITH STAUROSPORINE
2071, d3nuyA_, 0.7512, 2.57, 0.278, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2072, d5o21B_, 0.7511, 2.74, 0.245, 273, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2073, d5av0A_, 0.7511, 2.66, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2074, d4eqmA_, 0.7511, 2.38, 0.250, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2075, d3nrmA_, 0.7511, 2.66, 0.306, 263, 248, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2076, d3ehaA1, 0.7511, 2.68, 0.271, 275, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2077, d6babA_, 0.7510, 2.82, 0.308, 290, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2078, d4eqmB_, 0.7510, 2.39, 0.250, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2079, d3orzC_, 0.7510, 2.77, 0.288, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2080, d3f5gA1, 0.7510, 2.58, 0.272, 275, 246, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2081, d6aywB_, 0.7509, 2.91, 0.299, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2082, d5hngA_, 0.7509, 2.61, 0.265, 280, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2083, d4zjjB_, 0.7509, 2.80, 0.286, 277, 252, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2084, d4qmoA_, 0.7509, 2.86, 0.274, 288, 252, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
2085, d4jajA_, 0.7509, 2.71, 0.302, 265, 248, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2086, d3qcsA_, 0.7509, 2.55, 0.274, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2087, d3orzA_, 0.7509, 2.78, 0.288, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2088, d5lvnA_, 0.7508, 2.86, 0.283, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2089, d5dh3A_, 0.7508, 2.98, 0.294, 287, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2090, d4zseB_, 0.7508, 2.77, 0.208, 313, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2091, d3qcxA_, 0.7508, 2.57, 0.270, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2092, d5jrsA1, 0.7507, 2.63, 0.202, 257, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
2093, d5j87C_, 0.7507, 2.86, 0.199, 261, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2094, d4qmxA_, 0.7507, 2.89, 0.275, 287, 251, MST3 IN COMPLEX WITH SARACATINIB
2095, d4eqmC_, 0.7507, 2.39, 0.250, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2096, d5h9bA_, 0.7506, 2.67, 0.320, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2097, d4ra4A_, 0.7506, 2.74, 0.263, 317, 251, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2098, d2x4zA1, 0.7506, 2.98, 0.265, 289, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2099, d1q8wA_, 0.7506, 2.79, 0.275, 334, 251, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2100, d5ortA_, 0.7505, 2.71, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2101, d5av1A_, 0.7505, 2.67, 0.271, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2102, d4qmsA_, 0.7504, 2.94, 0.278, 283, 252, MST3 IN COMPLEX WITH DASATINIB
2103, d3rcjA_, 0.7504, 2.82, 0.287, 281, 251, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2104, d4w8dA_, 0.7503, 2.75, 0.272, 289, 250, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2105, d5fg8A_, 0.7502, 2.67, 0.320, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2106, d5ackA_, 0.7502, 2.88, 0.283, 286, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2107, d3belA_, 0.7502, 2.68, 0.218, 280, 248, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
2108, d2oi4X_, 0.7502, 2.53, 0.263, 275, 247, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2109, d5av2A_, 0.7501, 2.67, 0.271, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2110, d5auyA_, 0.7501, 2.66, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2111, d4qmmA_, 0.7501, 2.89, 0.274, 288, 252, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2112, d1yrpB_, 0.7501, 2.49, 0.269, 275, 245, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2113, d1yrpA_, 0.7501, 2.49, 0.269, 275, 245, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2114, d1ol7A_, 0.7501, 2.73, 0.306, 261, 248, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2115, d4zlzA_, 0.7500, 2.86, 0.199, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
2116, d4nwmB_, 0.7500, 2.79, 0.200, 261, 250, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2117, d3uo5A_, 0.7500, 2.85, 0.304, 267, 250, AURORA A IN COMPLEX WITH YL1-038-31
2118, d3kexA_, 0.7500, 2.89, 0.194, 292, 253, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
2119, d2o64A_, 0.7500, 2.59, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2120, d4o0sA_, 0.7499, 2.77, 0.305, 265, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2121, p4d28C_, 0.7499, 2.84, 0.317, 279, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2122, d4cegA_, 0.7498, 2.74, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2123, d2h8hA3, 0.7498, 2.87, 0.239, 280, 251, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
2124, d2bujA1, 0.7498, 2.69, 0.238, 283, 248, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2125, d1uu9A_, 0.7498, 2.70, 0.280, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2126, d4i24B_, 0.7497, 2.80, 0.212, 304, 250, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
2127, d3lm0A1, 0.7497, 2.68, 0.225, 271, 249, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2128, d3ckxA_, 0.7497, 2.86, 0.279, 276, 251, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2129, d4deeA_, 0.7496, 2.80, 0.301, 271, 249, AURORA A IN COMPLEX WITH ADP
2130, d1szmA_, 0.7496, 2.83, 0.279, 317, 251, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2131, d1kswA3, 0.7496, 2.97, 0.246, 284, 252, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
2132, d5he1A2, 0.7495, 3.15, 0.271, 342, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
2133, d4dawA_, 0.7495, 2.87, 0.304, 293, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2134, d5nttA1, 0.7494, 2.99, 0.291, 268, 254, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
2135, d3orxG_, 0.7494, 2.64, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2136, d2xuuA_, 0.7494, 2.83, 0.268, 301, 250, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2137, d5lvlA_, 0.7493, 2.88, 0.283, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2138, d4mblA_, 0.7493, 2.56, 0.263, 274, 247, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2139, d4jx7A_, 0.7493, 2.57, 0.267, 274, 247, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2140, d4jx3A_, 0.7493, 2.55, 0.267, 274, 247, CRYSTAL STRUCTURE OF PIM1 KINASE
2141, d6babD_, 0.7492, 2.85, 0.312, 291, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2142, d5v82A_, 0.7492, 2.56, 0.267, 273, 247, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2143, d5objA_, 0.7492, 2.76, 0.304, 260, 247, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2144, d5d41B_, 0.7492, 2.81, 0.208, 302, 250, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
2145, d4xx9A_, 0.7492, 2.88, 0.283, 288, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2146, d3vc4A_, 0.7492, 2.62, 0.263, 274, 247, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2147, d3orxH_, 0.7492, 2.65, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2148, d3db6A_, 0.7492, 2.80, 0.278, 287, 252, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2149, d2bzhB_, 0.7492, 2.54, 0.263, 275, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2150, d6b16B_, 0.7491, 2.73, 0.306, 281, 252, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2151, d5p9iA_, 0.7491, 2.91, 0.198, 271, 252, BTK1 SOAKED WITH IBRUTINIB-REV
2152, d5he2A2, 0.7491, 3.14, 0.267, 353, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
2153, d4rqvA_, 0.7491, 2.88, 0.283, 288, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2154, d3orxE_, 0.7491, 2.65, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2155, d5auxA_, 0.7490, 2.64, 0.276, 275, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2156, d4rqkA_, 0.7490, 2.87, 0.283, 285, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2157, d4k11A3, 0.7490, 2.90, 0.239, 282, 251, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
2158, d3r04A_, 0.7490, 2.52, 0.264, 271, 246, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2159, d3a8wB1, 0.7490, 2.65, 0.288, 324, 250, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2160, d5gtyH_, 0.7489, 2.78, 0.217, 300, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2161, d5auvA_, 0.7489, 2.72, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2162, d4wrsA_, 0.7489, 2.52, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2163, d4qmpA_, 0.7489, 2.90, 0.274, 289, 252, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2164, d4k0yA_, 0.7489, 2.56, 0.267, 274, 247, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2165, d3a8wA1, 0.7489, 2.65, 0.296, 323, 250, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2166, d2fumB_, 0.7489, 2.36, 0.262, 262, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2167, d5os2A_, 0.7488, 2.60, 0.306, 261, 245, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2168, d4zseC_, 0.7488, 2.69, 0.210, 301, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2169, d4apcA1, 0.7488, 2.87, 0.257, 289, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2170, d3qd3A_, 0.7488, 2.59, 0.270, 278, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2171, d3pp0B_, 0.7488, 2.88, 0.213, 296, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2172, d2xj0A_, 0.7488, 2.61, 0.267, 274, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2173, d5lvoA_, 0.7487, 2.88, 0.283, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2174, d3orxF_, 0.7487, 2.65, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2175, d3jpvA_, 0.7487, 2.51, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2176, d3hrfA_, 0.7487, 2.91, 0.283, 284, 251, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2177, d5ar8B_, 0.7486, 2.65, 0.229, 274, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
2178, d3uohB_, 0.7486, 2.45, 0.311, 264, 244, AURORA A IN COMPLEX WITH RPM1722
2179, d3uohA_, 0.7486, 2.45, 0.311, 264, 244, AURORA A IN COMPLEX WITH RPM1722
2180, d3r00A_, 0.7486, 2.62, 0.263, 274, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2181, d1qcfA3, 0.7485, 2.90, 0.243, 281, 251, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
2182, d5dgzA_, 0.7484, 2.51, 0.264, 273, 246, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2183, d5deyB_, 0.7484, 2.78, 0.306, 281, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2184, d4zseD_, 0.7484, 2.84, 0.220, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2185, d4a06A_, 0.7484, 2.88, 0.287, 282, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2186, d3vbqA_, 0.7484, 2.54, 0.264, 271, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2187, d2gs7A_, 0.7484, 2.70, 0.222, 281, 248, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2188, d5u9dA_, 0.7483, 2.92, 0.198, 271, 252, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
2189, d5ipjA_, 0.7483, 2.53, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2190, d4qnaA_, 0.7483, 2.93, 0.275, 284, 251, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2191, d4b4lA_, 0.7483, 2.85, 0.268, 299, 250, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2192, d3qcyA_, 0.7483, 2.58, 0.283, 275, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2193, d3pvwA2, 0.7483, 3.09, 0.267, 343, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
2194, d4bn1A_, 0.7482, 2.55, 0.298, 261, 245, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2195, d4alvA_, 0.7482, 2.61, 0.263, 274, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2196, d3r01A_, 0.7482, 2.62, 0.263, 274, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2197, d3c4eD_, 0.7482, 2.54, 0.264, 273, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2198, d5kgdA_, 0.7481, 2.52, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2199, d4mbiA_, 0.7481, 2.59, 0.263, 274, 247, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2200, d4deaA_, 0.7481, 2.84, 0.304, 266, 250, AURORA A IN COMPLEX WITH YL1-038-18
2201, d4ct2A_, 0.7481, 2.84, 0.292, 277, 250, HUMAN PDK1-PKCZETA KINASE CHIMERA
2202, d3vbtA_, 0.7481, 2.54, 0.264, 267, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2203, d5j7bB_, 0.7480, 2.79, 0.230, 281, 252, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2204, d4wt6A_, 0.7480, 2.53, 0.264, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2205, d3c0gA_, 0.7480, 3.12, 0.290, 309, 252, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2206, d1yxxA_, 0.7480, 2.62, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2207, d5diaA_, 0.7479, 2.54, 0.264, 273, 246, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2208, d3vbvA_, 0.7479, 2.55, 0.264, 268, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2209, d1xqzA_, 0.7479, 2.68, 0.270, 277, 248, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2210, d6aywA_, 0.7478, 2.93, 0.299, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2211, d5o23B1, 0.7478, 2.79, 0.240, 276, 250, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
2212, d5dhjA_, 0.7478, 2.52, 0.268, 273, 246, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2213, d4ty1A_, 0.7478, 2.53, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2214, d3lm5A1, 0.7478, 2.67, 0.234, 267, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2215, d5telA_, 0.7477, 2.62, 0.263, 273, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2216, d5auwA_, 0.7477, 2.67, 0.276, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2217, d4pnkA2, 0.7477, 3.16, 0.271, 350, 255, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
2218, d3r02A_, 0.7477, 2.54, 0.264, 271, 246, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2219, d3hrcA_, 0.7477, 2.90, 0.283, 279, 251, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
2220, d2o3pA_, 0.7477, 2.62, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2221, d2j2iB_, 0.7477, 2.51, 0.268, 273, 246, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2222, d2fumA_, 0.7477, 2.37, 0.275, 263, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2223, d4xh6A_, 0.7476, 2.53, 0.268, 273, 246, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2224, d4ct1A_, 0.7476, 2.89, 0.287, 283, 251, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2225, d4aluA_, 0.7476, 2.63, 0.263, 274, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2226, d3vbxA_, 0.7476, 2.55, 0.264, 268, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2227, d3uokA_, 0.7476, 2.56, 0.302, 265, 245, AURORA A IN COMPLEX WITH YL5-81-1
2228, d3a7iA_, 0.7476, 3.00, 0.278, 286, 252, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2229, d3a62A_, 0.7476, 2.25, 0.321, 263, 243, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
2230, d2bzjA_, 0.7476, 2.52, 0.264, 273, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2231, d1yxvA_, 0.7476, 2.64, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2232, d4wsyA_, 0.7475, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2233, d4ll5A_, 0.7475, 2.52, 0.268, 268, 246, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2234, d3vs3B3, 0.7475, 2.54, 0.249, 271, 245, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
2235, d3uolB_, 0.7475, 2.43, 0.303, 263, 244, AURORA A IN COMPLEX WITH SO2-162
2236, d3uolA_, 0.7475, 2.43, 0.303, 263, 244, AURORA A IN COMPLEX WITH SO2-162
2237, d3uokB_, 0.7475, 2.56, 0.302, 265, 245, AURORA A IN COMPLEX WITH YL5-81-1
2238, d1yxuC_, 0.7475, 2.54, 0.264, 272, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2239, d1wvxA_, 0.7475, 2.51, 0.265, 275, 245, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2240, d5av4A_, 0.7474, 2.67, 0.272, 274, 246, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2241, d4alwA_, 0.7474, 2.66, 0.263, 273, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2242, d3vbyA_, 0.7474, 2.55, 0.264, 267, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2243, d3jxwA_, 0.7474, 2.63, 0.263, 274, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2244, d3g51A_, 0.7474, 2.32, 0.314, 280, 242, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
2245, d2rfeD_, 0.7474, 2.61, 0.219, 278, 247, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2246, d5kgeA_, 0.7473, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2247, d5eolA_, 0.7473, 2.55, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2248, d4mtaA_, 0.7473, 2.55, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2249, d4m0yA_, 0.7473, 2.83, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
2250, d4dtkA_, 0.7473, 2.55, 0.268, 273, 246, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2251, d4at5A1, 0.7473, 2.91, 0.231, 291, 255, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
2252, d4m15A_, 0.7472, 2.83, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
2253, d4as0A_, 0.7472, 2.52, 0.268, 273, 246, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2254, d1mq4A_, 0.7472, 2.65, 0.305, 261, 246, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2255, d5kgiA_, 0.7471, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2256, d3jyaA_, 0.7471, 2.65, 0.263, 274, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2257, d3c0gB_, 0.7471, 3.13, 0.290, 320, 252, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2258, d1yxuA_, 0.7471, 2.54, 0.264, 273, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2259, d4i6hA_, 0.7470, 2.87, 0.250, 285, 252, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2260, d3t9tA_, 0.7470, 2.88, 0.219, 263, 251, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
2261, d1yxuB_, 0.7470, 2.55, 0.264, 273, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2262, d5turA_, 0.7469, 2.62, 0.267, 270, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2263, d5lvmA_, 0.7469, 2.91, 0.283, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2264, d5kcxA_, 0.7469, 2.57, 0.268, 272, 246, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2265, d5cnoA_, 0.7469, 2.81, 0.221, 300, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
2266, d4zlyA_, 0.7469, 2.89, 0.199, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
2267, d4n70A_, 0.7469, 2.59, 0.268, 274, 246, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2268, d4k18A_, 0.7469, 2.58, 0.275, 277, 247, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2269, d4b9dA1, 0.7469, 2.92, 0.257, 286, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2270, d4aw0A_, 0.7469, 2.88, 0.284, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2271, d1jktB_, 0.7469, 2.53, 0.260, 276, 246, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2272, d5gtyG_, 0.7468, 2.77, 0.214, 299, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2273, d5ar4B_, 0.7468, 2.82, 0.226, 279, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2274, d3nayB_, 0.7468, 2.84, 0.276, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2275, d2ckeD_, 0.7468, 2.89, 0.264, 300, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2276, d5orlA_, 0.7467, 2.70, 0.290, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2277, d5dwrA_, 0.7467, 2.60, 0.264, 273, 246, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
2278, d3pvuA2, 0.7467, 3.11, 0.267, 340, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
2279, d1yxuD_, 0.7467, 2.56, 0.264, 273, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2280, d5m51A1, 0.7466, 1.86, 0.301, 253, 236, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
2281, d5dt4A_, 0.7466, 2.62, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2282, d4zy6B_, 0.7466, 2.81, 0.310, 280, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2283, d4wsqA_, 0.7466, 2.74, 0.243, 317, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2284, d4qmzA_, 0.7466, 2.89, 0.279, 286, 251, MST3 IN COMPLEX WITH SUNITINIB
2285, d4qmuA_, 0.7466, 2.91, 0.279, 286, 251, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2286, d3q52A_, 0.7466, 2.85, 0.298, 292, 252, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2287, d3c0hA_, 0.7466, 3.13, 0.290, 300, 252, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2288, d2ckeC_, 0.7466, 2.90, 0.264, 300, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2289, d2ckeA_, 0.7466, 2.90, 0.264, 301, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2290, d3uojB_, 0.7465, 2.51, 0.307, 263, 244, AURORA A IN COMPLEX WITH RPM1715
2291, d3uojA_, 0.7465, 2.51, 0.307, 263, 244, AURORA A IN COMPLEX WITH RPM1715
2292, d2gs7B_, 0.7465, 2.89, 0.212, 288, 250, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2293, d1yxtA_, 0.7465, 2.67, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2294, d5iisA_, 0.7464, 2.52, 0.269, 273, 245, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
2295, d4n6zA_, 0.7464, 2.53, 0.269, 272, 245, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2296, d4i6bA_, 0.7464, 2.95, 0.245, 285, 253, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2297, d3uo6B_, 0.7464, 2.48, 0.311, 264, 244, AURORA A IN COMPLEX WITH YL5-083
2298, d3uo6A_, 0.7464, 2.48, 0.311, 264, 244, AURORA A IN COMPLEX WITH YL5-083
2299, d3c4eC_, 0.7464, 2.55, 0.264, 272, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2300, d1yxsA_, 0.7464, 2.64, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2301, d5kziA_, 0.7463, 2.57, 0.264, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2302, d4qmvA_, 0.7463, 2.88, 0.279, 288, 251, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2303, d4k1bA_, 0.7463, 2.55, 0.268, 273, 246, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2304, d3f2aA_, 0.7463, 2.63, 0.267, 276, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
2305, d2x4fB_, 0.7463, 2.70, 0.278, 288, 248, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2306, d2jiuB_, 0.7463, 3.12, 0.180, 309, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2307, d4m13A_, 0.7462, 2.88, 0.223, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
2308, d4eqcA1, 0.7462, 2.92, 0.308, 292, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2309, d3uodA_, 0.7462, 2.85, 0.305, 266, 249, AURORA A IN COMPLEX WITH RPM1693
2310, d3c4eA_, 0.7461, 2.55, 0.264, 273, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2311, d1yhwA_, 0.7461, 3.07, 0.298, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2312, d5li9A1, 0.7460, 2.74, 0.293, 328, 249, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
2313, d3unzB_, 0.7460, 2.48, 0.311, 263, 244, AURORA A IN COMPLEX WITH RPM1679
2314, d3unzA_, 0.7460, 2.48, 0.311, 263, 244, AURORA A IN COMPLEX WITH RPM1679
2315, d3d14A1, 0.7460, 2.36, 0.288, 257, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
2316, d3bwfA_, 0.7460, 2.55, 0.264, 273, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2317, d2yabB_, 0.7460, 2.90, 0.280, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2318, d2xizA_, 0.7460, 2.60, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2319, d1ywvA_, 0.7460, 2.64, 0.267, 274, 247, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
2320, d5auzA_, 0.7459, 2.64, 0.278, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2321, d3c0hB_, 0.7459, 3.12, 0.290, 300, 252, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2322, d2xj2A_, 0.7459, 2.61, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2323, d1jktA_, 0.7459, 2.71, 0.286, 276, 248, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2324, d5toeA_, 0.7458, 2.66, 0.267, 272, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2325, d5m57A1, 0.7458, 1.88, 0.301, 253, 236, NEK2 BOUND TO ARYLAMINOPURINE 6
2326, d4i6fA_, 0.7458, 2.88, 0.246, 285, 252, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2327, d4ae6A_, 0.7458, 3.02, 0.276, 319, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2328, d2yaaB_, 0.7458, 2.91, 0.276, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2329, d2phkA_, 0.7458, 2.73, 0.291, 277, 247, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2330, d2o63A_, 0.7458, 2.64, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
2331, d5kgkA_, 0.7457, 2.55, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2332, d3qd4A_, 0.7457, 2.56, 0.276, 276, 246, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2333, d3nayA_, 0.7457, 2.84, 0.276, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2334, d3kexB_, 0.7457, 2.84, 0.195, 283, 251, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
2335, d2a2aA_, 0.7457, 2.91, 0.264, 304, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2336, d1eh4A_, 0.7457, 3.06, 0.188, 293, 255, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2337, d5vuaB_, 0.7456, 2.52, 0.265, 270, 245, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2338, d5mrbA1, 0.7456, 2.60, 0.302, 259, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
2339, d5auuA_, 0.7456, 2.65, 0.265, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2340, d4qmnA_, 0.7456, 2.91, 0.279, 283, 251, MST3 IN COMPLEX WITH BOSUTINIB
2341, d4btjA_, 0.7456, 3.27, 0.191, 292, 256, TTBK1 IN COMPLEX WITH ATP
2342, d3bgzA_, 0.7456, 2.52, 0.269, 267, 245, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
2343, d2yaaA_, 0.7456, 2.90, 0.272, 300, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2344, d4i5pA_, 0.7455, 2.89, 0.246, 284, 252, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2345, d3up2A_, 0.7455, 2.79, 0.305, 266, 249, AURORA A IN COMPLEX WITH RPM1686
2346, d3qd0A_, 0.7455, 2.59, 0.285, 274, 246, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2347, d5c1qB_, 0.7454, 2.54, 0.272, 273, 246, SERINE/THREONINE-PROTEIN KINASE PIM-1
2348, d4xhkB_, 0.7454, 2.52, 0.269, 269, 245, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
2349, d3u4wA_, 0.7454, 2.97, 0.254, 275, 252, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
2350, d3c4eB_, 0.7454, 2.57, 0.264, 273, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2351, d2yabA_, 0.7454, 2.91, 0.272, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2352, d2xj1A_, 0.7454, 2.62, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
2353, d2jiuA_, 0.7454, 2.91, 0.215, 303, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2354, d1yhvA_, 0.7454, 3.07, 0.298, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2355, d5he3A2, 0.7453, 3.19, 0.267, 346, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
2356, d5drdA_, 0.7453, 2.68, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2357, d4at3A1, 0.7453, 3.06, 0.234, 286, 256, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
2358, d2ckeB_, 0.7453, 2.94, 0.264, 300, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2359, d2a2aD_, 0.7453, 2.90, 0.264, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2360, d5t18A1, 0.7452, 2.74, 0.202, 259, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
2361, d4qmlA_, 0.7452, 2.82, 0.269, 280, 249, MST3 IN COMPLEX WITH AMP-PNP
2362, d4btjB_, 0.7452, 3.12, 0.191, 293, 256, TTBK1 IN COMPLEX WITH ATP
2363, d2xiyA_, 0.7452, 2.63, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2364, d2a2aC_, 0.7452, 2.92, 0.264, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2365, d1cmkE_, 0.7452, 2.89, 0.278, 348, 252, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
2366, d3m11A_, 0.7451, 2.49, 0.309, 256, 243, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
2367, d3dj7A_, 0.7451, 2.43, 0.300, 257, 243, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
2368, d3bgqA_, 0.7451, 2.55, 0.269, 272, 245, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
2369, d4n6yA_, 0.7450, 2.50, 0.269, 273, 245, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
2370, d4bzoA_, 0.7450, 2.54, 0.269, 272, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
2371, d4bznA_, 0.7450, 2.54, 0.265, 272, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
2372, d4wsqB_, 0.7449, 2.75, 0.243, 310, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2373, d4qmqA_, 0.7449, 2.95, 0.274, 289, 252, MST3 IN COMPLEX WITH CP-673451
2374, d5eymB_, 0.7448, 2.42, 0.258, 292, 244, MEK1 IN COMPLEX WITH BI 847325
2375, d4m0zA_, 0.7448, 2.87, 0.227, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
2376, d4a7cA_, 0.7448, 2.53, 0.269, 273, 245, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
2377, d5eymA_, 0.7447, 2.43, 0.258, 292, 244, MEK1 IN COMPLEX WITH BI 847325
2378, d5dosA_, 0.7447, 2.65, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2379, d5dfpA_, 0.7447, 2.93, 0.308, 292, 253, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2380, d4m12A_, 0.7447, 2.91, 0.223, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
2381, d4jbpA_, 0.7446, 2.46, 0.300, 255, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2382, d2bcjA3, 0.7446, 3.18, 0.267, 348, 255, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
2383, d5kggA_, 0.7445, 2.59, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
2384, d4txcA_, 0.7445, 2.74, 0.263, 276, 247, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2385, d2dwbA_, 0.7445, 2.66, 0.310, 259, 245, AURORA-A KINASE COMPLEXED WITH AMPPNP
2386, d5gtyA_, 0.7444, 2.79, 0.217, 300, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2387, d4a07A_, 0.7444, 2.88, 0.284, 282, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
2388, d3mfuA_, 0.7444, 3.08, 0.287, 302, 251, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2389, d4qmtA_, 0.7443, 2.96, 0.279, 284, 251, MST3 IN COMPLEX WITH HESPERADIN
2390, d2o65A_, 0.7443, 2.65, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
2391, d1ad5A3, 0.7443, 2.53, 0.234, 271, 244, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
2392, d5texA_, 0.7442, 2.68, 0.267, 274, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2393, d5gtyD_, 0.7442, 2.79, 0.214, 297, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2394, d3r21A_, 0.7442, 2.59, 0.306, 254, 245, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2395, d3bgpA_, 0.7442, 2.54, 0.269, 272, 245, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
2396, d2objA_, 0.7442, 2.55, 0.269, 272, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
2397, d5dewB_, 0.7441, 2.84, 0.310, 281, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2398, d4rpvA_, 0.7441, 2.56, 0.272, 273, 246, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
2399, d4rc4A_, 0.7441, 2.54, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2400, d4lm5A_, 0.7441, 2.56, 0.265, 264, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
2401, d4btmB_, 0.7441, 3.02, 0.184, 293, 255, TTBK1 IN COMPLEX WITH INHIBITOR
2402, d3we8A_, 0.7441, 2.59, 0.264, 273, 246, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
2403, d3f69B_, 0.7441, 2.62, 0.269, 282, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2404, d4o0tB_, 0.7440, 2.89, 0.302, 280, 252, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2405, d3mftA_, 0.7440, 3.12, 0.294, 302, 252, CASK-4M CAM KINASE DOMAIN MN2+
2406, d3cikA2, 0.7440, 3.20, 0.267, 347, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2407, d1xwsA_, 0.7440, 2.56, 0.268, 273, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
2408, d5autA_, 0.7439, 2.65, 0.269, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2409, d3dcvA_, 0.7439, 2.57, 0.269, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
2410, d2yakA_, 0.7439, 2.71, 0.267, 277, 247, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2411, d2w4kA_, 0.7438, 2.96, 0.268, 301, 250, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2412, d2f57B1, 0.7438, 3.16, 0.281, 293, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2413, d5gtyE_, 0.7437, 2.80, 0.214, 297, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2414, d3lmgA_, 0.7437, 2.63, 0.206, 268, 247, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2415, d2clqA_, 0.7437, 2.88, 0.291, 263, 247, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2416, d2bziB_, 0.7437, 2.54, 0.265, 272, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
2417, d3d2iA_, 0.7436, 2.44, 0.300, 255, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
2418, d5mrdA_, 0.7435, 2.95, 0.283, 283, 251, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
2419, d4o0rA_, 0.7435, 3.01, 0.296, 293, 253, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2420, d4btmA_, 0.7435, 3.21, 0.192, 292, 255, TTBK1 IN COMPLEX WITH INHIBITOR
2421, d1ad5B3, 0.7435, 2.54, 0.234, 271, 244, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
2422, d4lmuA_, 0.7434, 2.57, 0.273, 265, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
2423, d4enxA_, 0.7434, 2.51, 0.266, 266, 244, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
2424, d2a2aB_, 0.7434, 2.96, 0.264, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2425, d4j8nC_, 0.7433, 2.78, 0.302, 266, 248, AURORA A KINASE APO
2426, d4j8nB_, 0.7433, 2.78, 0.302, 266, 248, AURORA A KINASE APO
2427, d4i41A_, 0.7433, 2.55, 0.269, 272, 245, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
2428, d1yhsA_, 0.7433, 2.51, 0.270, 267, 244, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
2429, d5dr9A_, 0.7432, 2.53, 0.307, 257, 244, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2430, d3c0iA_, 0.7432, 3.18, 0.283, 298, 251, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
2431, d5gtyB_, 0.7431, 2.94, 0.208, 299, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2432, d4rc2A_, 0.7431, 2.57, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2433, d4j8nD_, 0.7431, 2.78, 0.302, 265, 248, AURORA A KINASE APO
2434, d4j8nA_, 0.7431, 2.78, 0.302, 266, 248, AURORA A KINASE APO
2435, d3vs3A3, 0.7431, 2.46, 0.244, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
2436, d2wzjB_, 0.7431, 2.89, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2437, d1j3hB_, 0.7431, 2.83, 0.275, 327, 251, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2438, d4debA_, 0.7430, 2.77, 0.306, 264, 248, AURORA A IN COMPLEX WITH RK2-17-01
2439, d2x6dA_, 0.7430, 2.62, 0.299, 255, 244, AURORA-A BOUND TO AN INHIBITOR
2440, d1ctpE_, 0.7430, 2.93, 0.282, 332, 252, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2441, d3gt8C_, 0.7429, 2.85, 0.210, 296, 248, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2442, d2xixA_, 0.7429, 2.62, 0.269, 272, 245, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2443, d5fbnC_, 0.7428, 2.70, 0.198, 256, 247, BTK KINASE DOMAIN WITH INHIBITOR 1
2444, d5drbA_, 0.7428, 2.90, 0.253, 273, 249, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
2445, d5ar7B_, 0.7428, 2.84, 0.219, 278, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2446, d3nyxA1, 0.7428, 2.98, 0.220, 285, 250, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
2447, d2hckA3, 0.7428, 2.55, 0.234, 271, 244, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
2448, d4qmwA_, 0.7427, 2.97, 0.279, 286, 251, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2449, d3vs4A3, 0.7427, 2.58, 0.250, 270, 244, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2450, d5vucB_, 0.7426, 2.54, 0.266, 269, 244, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2451, d4m14A_, 0.7426, 2.80, 0.228, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
2452, d4dhfA_, 0.7426, 2.71, 0.306, 258, 245, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2453, d3gt8B_, 0.7426, 2.83, 0.198, 292, 247, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2454, d5vubB_, 0.7425, 2.54, 0.266, 269, 244, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2455, d4tl0A_, 0.7425, 2.96, 0.272, 300, 250, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2456, d3vs6B3, 0.7425, 2.45, 0.244, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
2457, d1xr1A_, 0.7425, 2.70, 0.267, 277, 247, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
2458, d5u94A_, 0.7424, 2.54, 0.257, 263, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2459, d4o0wA_, 0.7424, 2.61, 0.302, 259, 245, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2460, d3zhpC1, 0.7424, 3.08, 0.272, 267, 254, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
2461, d2ya9A_, 0.7424, 2.96, 0.276, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2462, d1yi3A_, 0.7424, 2.52, 0.270, 267, 244, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
2463, d4rixC_, 0.7423, 2.98, 0.194, 275, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2464, d4ae9A_, 0.7423, 3.01, 0.277, 321, 253, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2465, d5dr6A_, 0.7422, 2.56, 0.307, 257, 244, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
2466, d4dhfB_, 0.7422, 2.68, 0.310, 258, 245, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2467, d3h0zA_, 0.7422, 2.26, 0.300, 248, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2468, d5o13A_, 0.7421, 2.53, 0.266, 270, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2469, d3jy0A_, 0.7421, 2.76, 0.263, 275, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2470, d4zs0A_, 0.7420, 2.61, 0.309, 257, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2471, d3mfsA_, 0.7420, 3.01, 0.281, 303, 249, CASK-4M CAM KINASE DOMAIN AMPPNP
2472, d3lmgB_, 0.7420, 2.66, 0.206, 268, 247, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2473, d3fxzA_, 0.7420, 2.97, 0.308, 292, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2474, d3fmeA1, 0.7420, 2.99, 0.248, 267, 250, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
2475, d5imeB_, 0.7419, 2.81, 0.309, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2476, d2bikB_, 0.7419, 2.54, 0.265, 272, 245, HUMAN PIM1 PHOSPHORYLATED ON SER261
2477, d5xgnA_, 0.7418, 3.04, 0.223, 302, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2478, d5j7bA_, 0.7418, 2.82, 0.231, 277, 251, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2479, d4xi2A2, 0.7418, 3.00, 0.203, 274, 251, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
2480, d4riyC_, 0.7418, 2.76, 0.201, 275, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2481, d3mfrA_, 0.7418, 3.15, 0.287, 302, 251, CASK-4M CAM KINASE DOMAIN NATIVE
2482, d1xjdA_, 0.7418, 2.72, 0.283, 280, 247, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2483, d5obrA_, 0.7417, 2.53, 0.313, 255, 243, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
2484, d5hu3A_, 0.7417, 2.67, 0.311, 266, 244, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2485, d5eakA_, 0.7417, 2.50, 0.307, 305, 244, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2486, d4medA_, 0.7417, 2.57, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
2487, d2xruA_, 0.7417, 2.48, 0.300, 253, 243, AURORA-A T288E COMPLEXED WITH PHA-828300
2488, d1zwsC_, 0.7417, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2489, d1wvwA_, 0.7417, 2.79, 0.283, 275, 247, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2490, d3o7lD_, 0.7416, 3.09, 0.272, 333, 254, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2491, d2r4bA_, 0.7416, 2.94, 0.222, 292, 248, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
2492, d3vs2B3, 0.7415, 2.42, 0.245, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
2493, d3uo4A_, 0.7415, 2.84, 0.305, 266, 249, AURORA A IN COMPLEX WITH RPM1680
2494, d3ikaA_, 0.7415, 3.09, 0.218, 310, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2495, d3d15A_, 0.7415, 2.45, 0.302, 256, 242, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
2496, d5gnkA_, 0.7414, 2.67, 0.229, 277, 245, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
2497, d4iaaA_, 0.7414, 2.56, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
2498, d3up7A_, 0.7412, 2.79, 0.308, 264, 247, AURORA A IN COMPLEX WITH YL1-038-09
2499, d3otuA_, 0.7412, 2.97, 0.277, 276, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2500, d2jitB_, 0.7412, 3.17, 0.180, 312, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
2501, d2hckB3, 0.7412, 2.58, 0.238, 271, 244, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
2502, d1ym7A3, 0.7412, 3.19, 0.256, 347, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2503, d4lg4C_, 0.7411, 3.19, 0.283, 288, 258, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2504, d1zwsB_, 0.7411, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2505, d5dpvA_, 0.7410, 2.58, 0.307, 257, 244, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2506, d4j8mA_, 0.7410, 2.81, 0.293, 265, 249, AURORA A IN COMPLEX WITH CD532
2507, d3vs6A3, 0.7410, 2.48, 0.244, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
2508, d3pscA2, 0.7410, 3.23, 0.267, 344, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2509, d3bhhB1, 0.7410, 2.89, 0.315, 288, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2510, d2wzjF_, 0.7410, 2.92, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2511, d1zwsD_, 0.7410, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2512, d1yi4A_, 0.7410, 2.54, 0.275, 267, 244, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
2513, d4riwC_, 0.7409, 2.72, 0.197, 275, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2514, p4d28B_, 0.7409, 2.84, 0.320, 277, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2515, d1wvyA_, 0.7409, 2.60, 0.273, 273, 245, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2516, d5vloA_, 0.7408, 2.87, 0.304, 290, 247, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2517, d4zjjC_, 0.7408, 2.76, 0.286, 276, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2518, d4ynzB1, 0.7408, 2.50, 0.290, 316, 245, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
2519, d4jbqA_, 0.7407, 2.59, 0.311, 257, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2520, d3umwA_, 0.7407, 2.57, 0.275, 264, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
2521, d2z7sA_, 0.7407, 1.95, 0.323, 256, 235, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
2522, d3vrzB3, 0.7406, 2.50, 0.252, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
2523, d3vryA3, 0.7406, 2.57, 0.251, 269, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
2524, d3a99A_, 0.7406, 2.68, 0.268, 273, 246, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
2525, d2qnjB1, 0.7406, 2.90, 0.317, 321, 252, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
2526, d2fumD_, 0.7406, 2.36, 0.260, 258, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2527, d3uixA_, 0.7405, 2.56, 0.266, 266, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2528, d3gt8D_, 0.7405, 2.87, 0.206, 295, 247, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2529, d3fdnA_, 0.7405, 2.66, 0.302, 261, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
2530, d1ym7C3, 0.7405, 3.15, 0.264, 346, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2531, d5dt0A_, 0.7404, 2.64, 0.307, 259, 244, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2532, d5cnnA_, 0.7404, 2.89, 0.213, 300, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
2533, d3vs4B3, 0.7404, 2.57, 0.251, 269, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2534, d3a7jA_, 0.7404, 2.99, 0.272, 286, 250, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2535, d2y7jB_, 0.7404, 2.82, 0.287, 281, 247, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2536, d2xngA_, 0.7404, 2.52, 0.310, 253, 242, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
2537, d4uv0A_, 0.7403, 2.98, 0.276, 300, 250, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2538, d5gtyF_, 0.7402, 2.83, 0.210, 297, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2539, d3vryB3, 0.7402, 2.50, 0.244, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
2540, d1zwsH_, 0.7402, 2.90, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2541, d1zwsF_, 0.7402, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2542, d1ym7D3, 0.7402, 3.16, 0.264, 340, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2543, d5fbnD_, 0.7401, 2.64, 0.200, 255, 245, BTK KINASE DOMAIN WITH INHIBITOR 1
2544, d4rc3A_, 0.7401, 2.56, 0.270, 271, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2545, d3zhpD_, 0.7401, 3.00, 0.269, 264, 253, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
2546, d2ya9B_, 0.7401, 2.99, 0.272, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2547, d1ym7B3, 0.7401, 3.16, 0.264, 347, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2548, d5hznG_, 0.7400, 3.08, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2549, d4enyA_, 0.7400, 2.51, 0.267, 261, 243, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
2550, d3k5uA_, 0.7400, 2.64, 0.316, 260, 244, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
2551, d3genA_, 0.7400, 2.87, 0.198, 264, 248, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
2552, d5u6bA_, 0.7399, 2.50, 0.221, 270, 244, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2553, d5hznC_, 0.7399, 3.08, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2554, d5aaeA_, 0.7399, 2.46, 0.310, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
2555, d3t9iA_, 0.7399, 2.62, 0.269, 273, 245, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
2556, d3gt8A_, 0.7399, 2.64, 0.200, 300, 245, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2557, d1mruB_, 0.7399, 2.41, 0.252, 271, 242, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2558, d5aadA_, 0.7398, 2.39, 0.299, 252, 241, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
2559, d3r22A_, 0.7398, 2.51, 0.306, 255, 242, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2560, d5xgnB_, 0.7397, 3.17, 0.188, 308, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2561, d4o0rB_, 0.7397, 2.90, 0.304, 282, 250, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2562, d2wzjC_, 0.7397, 2.94, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2563, d5cnoB_, 0.7396, 2.87, 0.213, 302, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
2564, d4rblA_, 0.7396, 2.56, 0.270, 271, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2565, d4gu6A_, 0.7396, 3.08, 0.243, 271, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
2566, d2x0gA_, 0.7396, 2.96, 0.279, 318, 251, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2567, d5d9hA_, 0.7395, 3.10, 0.260, 290, 250, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
2568, d4otwA_, 0.7395, 2.66, 0.202, 272, 247, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
2569, d2wzjD_, 0.7395, 2.93, 0.305, 313, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2570, d5u6bC_, 0.7394, 2.45, 0.230, 270, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2571, d3w2rA_, 0.7394, 2.85, 0.202, 297, 248, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
2572, d3vs2A3, 0.7394, 2.55, 0.252, 268, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
2573, d4ntsB_, 0.7393, 3.12, 0.272, 341, 254, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2574, d5ig1B_, 0.7392, 3.05, 0.276, 304, 250, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2575, d4usfB1, 0.7392, 2.91, 0.283, 283, 251, HUMAN SLK WITH SB-440719
2576, d2np8A_, 0.7392, 2.46, 0.302, 256, 242, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
2577, d5hznE_, 0.7391, 3.00, 0.214, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2578, d5hznA_, 0.7391, 3.00, 0.214, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2579, d4c8bB_, 0.7391, 2.90, 0.211, 281, 251, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2580, d2gdoA_, 0.7391, 2.96, 0.284, 269, 250, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
2581, d1zwsG_, 0.7391, 2.91, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2582, d1eh4B_, 0.7391, 3.10, 0.181, 293, 254, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2583, d5ig1A_, 0.7390, 2.99, 0.284, 300, 250, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2584, d4ewhA_, 0.7390, 3.00, 0.256, 274, 250, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2585, d4dedA_, 0.7390, 2.98, 0.305, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
2586, d3vs5B3, 0.7390, 2.46, 0.245, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2587, d3d5xA_, 0.7390, 2.57, 0.270, 279, 244, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
2588, d5ap7A1, 0.7389, 2.40, 0.300, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2589, d2r4bB_, 0.7389, 2.93, 0.223, 291, 247, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
2590, d2c0oB3, 0.7389, 2.45, 0.253, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
2591, d1ol5A_, 0.7389, 2.72, 0.311, 263, 244, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2592, d2a27C_, 0.7388, 3.01, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2593, d1zwsA_, 0.7388, 2.92, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2594, d3fe3B_, 0.7387, 3.12, 0.315, 317, 254, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
2595, d5hznF_, 0.7386, 3.10, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2596, d5hznB_, 0.7386, 3.10, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2597, d5ar5B_, 0.7386, 2.79, 0.225, 279, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2598, d4twcA_, 0.7386, 3.19, 0.177, 293, 254, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2599, d4tw9A_, 0.7386, 3.17, 0.173, 290, 254, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2600, d4nfnA_, 0.7386, 3.06, 0.181, 293, 254, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
2601, d2y7jC_, 0.7386, 2.83, 0.291, 284, 247, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2602, d2a27E_, 0.7386, 3.01, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2603, d2a27A_, 0.7386, 3.02, 0.264, 304, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2604, d5es1A_, 0.7385, 2.33, 0.324, 304, 241, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2605, d5deyA_, 0.7385, 2.97, 0.306, 295, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2606, d4zimB1, 0.7385, 3.05, 0.257, 292, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2607, d3vs5A3, 0.7385, 2.48, 0.245, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2608, d2c0tB3, 0.7385, 2.46, 0.245, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
2609, d5cf5B1, 0.7384, 3.05, 0.261, 292, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2610, d4o0uA_, 0.7384, 2.71, 0.301, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2611, d2c0iA3, 0.7384, 2.48, 0.245, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
2612, d5oneA_, 0.7383, 2.70, 0.306, 257, 245, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
2613, d1csnA_, 0.7383, 3.15, 0.187, 293, 252, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2614, d4uy9A_, 0.7382, 2.89, 0.281, 313, 249, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2615, d4i22A_, 0.7382, 2.71, 0.211, 297, 246, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
2616, d3vs0B3, 0.7382, 2.48, 0.245, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
2617, d3fy0A_, 0.7382, 3.07, 0.307, 292, 254, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
2618, d2c0tA3, 0.7382, 2.50, 0.253, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
2619, d2a27H_, 0.7382, 3.01, 0.264, 304, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2620, d2a27F_, 0.7382, 3.01, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2621, d4hnfB_, 0.7381, 3.17, 0.173, 290, 254, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2622, d4byiA_, 0.7381, 2.47, 0.310, 254, 242, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
2623, d2cgxA_, 0.7381, 3.13, 0.270, 265, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2624, d4zjjD_, 0.7380, 2.87, 0.288, 274, 250, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2625, d5aagA_, 0.7379, 2.51, 0.310, 253, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
2626, d4ewhB_, 0.7379, 2.93, 0.257, 273, 249, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2627, d3vrzA3, 0.7379, 2.48, 0.253, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
2628, d3v5wA2, 0.7379, 3.20, 0.276, 355, 254, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
2629, d3ppzA_, 0.7379, 2.88, 0.236, 264, 246, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2630, d2z7qA_, 0.7379, 1.94, 0.321, 255, 234, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
2631, d2y7jA_, 0.7379, 2.83, 0.291, 284, 247, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2632, d2c0iB3, 0.7379, 2.49, 0.253, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
2633, d2a27G_, 0.7379, 3.02, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2634, d2a27D_, 0.7379, 3.02, 0.264, 304, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2635, d3vs0A3, 0.7378, 2.49, 0.245, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
2636, d5d9hB_, 0.7377, 2.99, 0.262, 293, 248, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
2637, d4ythA_, 0.7376, 2.94, 0.235, 287, 251, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2638, d2ydiA_, 0.7376, 3.07, 0.271, 279, 251, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2639, d2cgvA_, 0.7376, 3.12, 0.286, 264, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2640, d2a27B_, 0.7376, 3.03, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2641, d1yvjA_, 0.7376, 3.10, 0.249, 288, 253, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
2642, d5hznH_, 0.7375, 3.12, 0.213, 303, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2643, d4i24A_, 0.7375, 2.74, 0.212, 295, 245, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
2644, d2c0oA3, 0.7375, 2.49, 0.245, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
2645, d5hznD_, 0.7374, 3.13, 0.213, 304, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2646, d2y0aA_, 0.7374, 3.11, 0.267, 300, 251, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
2647, d3mygA_, 0.7373, 2.40, 0.300, 252, 240, AURORA A KINASE COMPLEXED WITH SCH 1473759
2648, d2csnA_, 0.7373, 3.22, 0.182, 293, 253, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
2649, d5w4wC_, 0.7372, 3.21, 0.173, 284, 254, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2650, d3e63A_, 0.7372, 3.23, 0.256, 290, 254, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2651, d3bhhA1, 0.7372, 2.85, 0.321, 287, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2652, d5ng0B_, 0.7371, 3.15, 0.214, 282, 252, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2653, d5cf4B_, 0.7371, 3.05, 0.257, 291, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2654, d3bbtB_, 0.7370, 2.50, 0.227, 274, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
2655, d5hibA_, 0.7369, 3.25, 0.212, 314, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2656, d4prjA_, 0.7369, 2.42, 0.312, 251, 240, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
2657, d4nfmA_, 0.7369, 3.15, 0.188, 293, 255, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
2658, d4czuD1, 0.7368, 3.22, 0.297, 296, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
2659, d4bicA_, 0.7367, 2.70, 0.292, 260, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2660, d2w5aA1, 0.7367, 2.69, 0.291, 259, 247, HUMAN NEK2 KINASE ADP-BOUND
2661, d2w1gA1, 0.7367, 2.60, 0.309, 254, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2662, d2vn9B_, 0.7367, 2.95, 0.312, 301, 250, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2663, d2brnA_, 0.7366, 3.16, 0.271, 268, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2664, d1ckjA_, 0.7366, 3.12, 0.189, 296, 254, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2665, d4u42B_, 0.7365, 2.35, 0.253, 265, 241, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2666, d3ha6A1, 0.7365, 2.74, 0.307, 262, 244, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2667, d2clqB_, 0.7365, 2.68, 0.292, 259, 243, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2668, d5ukkA2, 0.7364, 3.22, 0.264, 348, 254, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
2669, d2cguA_, 0.7364, 3.08, 0.287, 263, 251, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2670, d1zysA_, 0.7364, 3.01, 0.272, 271, 250, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
2671, d5l8lA_, 0.7363, 2.92, 0.305, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2672, d5aafA_, 0.7363, 2.56, 0.310, 254, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
2673, d4twcB_, 0.7363, 3.18, 0.173, 292, 254, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2674, d3h0yA_, 0.7363, 2.39, 0.308, 250, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2675, d2x4fA_, 0.7363, 2.71, 0.265, 289, 245, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2676, d2w1fA1, 0.7363, 2.60, 0.309, 253, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2677, d1ia8A_, 0.7363, 3.12, 0.271, 272, 251, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
2678, d5uklA2, 0.7362, 3.16, 0.269, 353, 253, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
2679, d3iecB_, 0.7362, 2.83, 0.314, 313, 245, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2680, d2hxlA_, 0.7362, 3.04, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
2681, d4w9wA_, 0.7361, 2.86, 0.259, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2682, d4d0xA_, 0.7361, 3.22, 0.252, 291, 254, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2683, d3e62A_, 0.7361, 3.22, 0.244, 291, 254, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2684, d1ckiA_, 0.7361, 3.10, 0.189, 292, 254, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2685, d5k00A_, 0.7360, 2.38, 0.333, 311, 240, MELK IN COMPLEX WITH NVS-MELK5
2686, d3q32B1, 0.7360, 3.08, 0.257, 293, 253, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2687, d2vn9A_, 0.7360, 2.95, 0.312, 301, 250, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2688, d2hxqA_, 0.7360, 3.04, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
2689, d1o6yA_, 0.7360, 2.50, 0.252, 260, 242, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2690, d5kbqA_, 0.7359, 3.20, 0.303, 289, 254, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2691, d3uzpA_, 0.7359, 3.22, 0.169, 292, 254, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2692, d3pp0A_, 0.7359, 2.87, 0.214, 286, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2693, d2vz6A1, 0.7359, 2.92, 0.313, 285, 246, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2694, d5x17A_, 0.7358, 3.35, 0.184, 290, 255, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2695, d5v24B_, 0.7358, 2.89, 0.286, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2696, d4ztrA_, 0.7358, 2.33, 0.308, 249, 240, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
2697, d4gfmA_, 0.7358, 3.00, 0.259, 289, 251, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
2698, p4d28D_, 0.7358, 2.73, 0.310, 271, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2699, d1zwsE_, 0.7358, 2.94, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2700, d5ukmA2, 0.7357, 3.22, 0.272, 353, 254, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
2701, d5o23A_, 0.7357, 2.88, 0.242, 269, 248, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
2702, d4aqcB_, 0.7357, 3.08, 0.257, 295, 253, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
2703, d3e64A_, 0.7357, 3.23, 0.244, 291, 254, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2704, d2wzjA_, 0.7357, 2.88, 0.306, 310, 248, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2705, d1kobA_, 0.7357, 3.02, 0.266, 352, 252, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2706, d4hyiA_, 0.7356, 3.07, 0.271, 269, 251, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
2707, d3repA_, 0.7356, 2.77, 0.170, 268, 247, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
2708, d3kmwA_, 0.7356, 2.76, 0.170, 268, 247, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
2709, d1kobB_, 0.7356, 3.23, 0.252, 352, 254, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2710, d4ztsA_, 0.7355, 2.38, 0.308, 249, 240, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
2711, d1mruA_, 0.7354, 2.57, 0.259, 269, 243, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2712, d5te0A_, 0.7353, 2.88, 0.243, 316, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2713, d5ng2B_, 0.7353, 2.82, 0.214, 278, 248, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2714, d5cf6A_, 0.7353, 2.98, 0.263, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2715, d3q32A_, 0.7353, 3.01, 0.262, 291, 252, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2716, d3hmpA_, 0.7353, 2.54, 0.298, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
2717, d2x8dA_, 0.7353, 3.11, 0.271, 279, 251, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2718, d2w1eA1, 0.7353, 2.59, 0.309, 252, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2719, d4uy9B_, 0.7352, 2.91, 0.281, 315, 249, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2720, d4rwkA1, 0.7352, 3.34, 0.245, 307, 257, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2721, d5tq3B_, 0.7351, 2.93, 0.257, 285, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2722, d5lwnA_, 0.7351, 3.13, 0.234, 290, 252, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
2723, d4ludB3, 0.7351, 2.51, 0.253, 264, 241, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2724, d4fg8B_, 0.7351, 2.65, 0.286, 268, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
2725, d4e26A_, 0.7351, 2.85, 0.206, 270, 247, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2726, p4d28A_, 0.7351, 2.86, 0.302, 274, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2727, d3iecD_, 0.7351, 2.78, 0.313, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2728, d2cgwA_, 0.7351, 3.00, 0.269, 262, 249, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2729, d5ih5A_, 0.7350, 3.23, 0.180, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
2730, d2c6dA_, 0.7350, 2.65, 0.307, 254, 244, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
2731, d4usfA1, 0.7349, 3.12, 0.270, 275, 252, HUMAN SLK WITH SB-440719
2732, d2qvsE_, 0.7349, 3.15, 0.261, 323, 253, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2733, d2chlA_, 0.7349, 3.40, 0.206, 298, 257, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
2734, d1zltA_, 0.7349, 3.09, 0.268, 272, 250, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
2735, d5dewA_, 0.7348, 3.03, 0.306, 295, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2736, d4g5pB_, 0.7348, 3.20, 0.190, 303, 253, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
2737, d3vbwA_, 0.7348, 2.57, 0.264, 264, 242, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2738, d3a7gB_, 0.7348, 2.98, 0.276, 290, 250, HUMAN MST3 KINASE
2739, d5cf5A1, 0.7347, 2.98, 0.259, 286, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2740, d4zy4A_, 0.7347, 2.99, 0.284, 288, 250, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2741, d3zzeA_, 0.7347, 3.29, 0.222, 286, 252, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
2742, d3uytC_, 0.7347, 3.21, 0.169, 286, 254, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2743, d3f69A_, 0.7347, 2.57, 0.270, 270, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2744, d1koaA2, 0.7347, 3.21, 0.249, 350, 253, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2745, d5ar4A_, 0.7346, 2.78, 0.231, 274, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2746, d4wnpD_, 0.7346, 2.83, 0.295, 272, 244, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2747, d3q4zB_, 0.7346, 2.93, 0.301, 279, 249, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2748, d3iecC_, 0.7345, 2.78, 0.313, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2749, d5o11A_, 0.7344, 2.55, 0.269, 268, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2750, d5ih9A_, 0.7344, 2.44, 0.329, 308, 240, MELK IN COMPLEX WITH NVS-MELK8A
2751, d4c3rA_, 0.7344, 2.68, 0.313, 252, 243, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
2752, d4bbeC_, 0.7344, 3.10, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2753, d3vs1A3, 0.7344, 2.60, 0.252, 268, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
2754, d3pjcA_, 0.7344, 3.04, 0.252, 286, 250, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
2755, d3h0zC_, 0.7344, 2.15, 0.305, 246, 236, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2756, d2f57A1, 0.7344, 3.21, 0.269, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2757, d1omwA3, 0.7344, 3.21, 0.268, 344, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
2758, d5w5oM_, 0.7343, 2.77, 0.223, 276, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2759, d2wzjE_, 0.7343, 2.99, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2760, d5ng0A_, 0.7342, 2.73, 0.215, 274, 246, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2761, d5lwmA_, 0.7342, 3.34, 0.231, 290, 255, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2762, d3vs1B3, 0.7342, 2.54, 0.245, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
2763, d5oopA_, 0.7341, 2.94, 0.282, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
2764, d4kbkB_, 0.7341, 3.25, 0.173, 289, 254, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2765, d2xzsA_, 0.7341, 3.06, 0.276, 301, 250, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2766, d4tw9B_, 0.7340, 3.22, 0.169, 289, 254, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2767, d3krrA1, 0.7340, 3.24, 0.252, 290, 254, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
2768, d3eqrA_, 0.7340, 3.05, 0.256, 270, 250, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2769, d5tq3A_, 0.7339, 3.09, 0.252, 282, 250, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2770, d5jznA_, 0.7339, 2.78, 0.299, 268, 244, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2771, d4rwiA_, 0.7339, 3.48, 0.239, 305, 259, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
2772, d3ikaB_, 0.7339, 3.30, 0.176, 310, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2773, d2v7oA1, 0.7339, 2.94, 0.319, 297, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
2774, d2br1A_, 0.7339, 3.18, 0.271, 272, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2775, d2aypA_, 0.7339, 2.89, 0.286, 268, 248, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
2776, d5j79B_, 0.7337, 2.84, 0.222, 277, 248, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2777, d5cf6B1, 0.7337, 3.02, 0.259, 288, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2778, d2w5bA1, 0.7337, 2.88, 0.289, 263, 249, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
2779, d2vz6B1, 0.7337, 2.96, 0.312, 288, 247, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2780, d5uyjA1, 0.7336, 2.85, 0.289, 279, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2781, d5uoxA_, 0.7336, 2.90, 0.286, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2782, d5ih6A_, 0.7336, 3.22, 0.177, 286, 254, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
2783, d5gtyC_, 0.7336, 2.87, 0.207, 295, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2784, d4g5pA_, 0.7336, 3.00, 0.225, 299, 249, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
2785, d4bbeB_, 0.7336, 3.12, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2786, d3js2A_, 0.7336, 3.51, 0.232, 295, 259, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
2787, d1k2pA_, 0.7336, 2.83, 0.203, 258, 246, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
2788, d3umxA_, 0.7335, 2.58, 0.277, 261, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
2789, d4useA_, 0.7334, 2.86, 0.313, 286, 246, HUMAN STK10 (LOK) WITH SB-633825
2790, d4f08B_, 0.7334, 3.20, 0.256, 288, 254, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
2791, d4e4mD_, 0.7334, 3.12, 0.270, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2792, d6bkuA1, 0.7333, 2.82, 0.290, 264, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2793, d5op7A_, 0.7333, 2.84, 0.272, 261, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2794, d4qo9B_, 0.7333, 3.03, 0.269, 285, 249, MST3 IN COMPLEX WITH DANUSERTIB
2795, d2ywpA_, 0.7333, 3.02, 0.278, 269, 248, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
2796, d5jrqA1, 0.7332, 2.58, 0.215, 257, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
2797, d4zloA_, 0.7332, 2.70, 0.293, 277, 246, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
2798, d4wnpA_, 0.7332, 2.86, 0.294, 273, 245, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2799, d4gmyA_, 0.7332, 3.19, 0.253, 298, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2800, d3uytA_, 0.7332, 3.09, 0.171, 287, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2801, d3fe3A_, 0.7332, 3.16, 0.303, 317, 254, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
2802, d4ytiA_, 0.7330, 2.96, 0.252, 284, 250, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2803, d4w9xA_, 0.7330, 2.86, 0.260, 300, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2804, d4aqcA_, 0.7330, 3.07, 0.270, 289, 252, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
2805, d2e9oA_, 0.7330, 3.08, 0.289, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
2806, d4wnpC_, 0.7329, 2.84, 0.295, 271, 244, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2807, d4e4mB_, 0.7329, 3.13, 0.270, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2808, d2brbA_, 0.7329, 3.18, 0.271, 272, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2809, d5oq5A_, 0.7328, 3.01, 0.277, 265, 249, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2810, d4jiaA_, 0.7328, 3.28, 0.248, 298, 254, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
2811, d4czuA1, 0.7328, 3.23, 0.303, 291, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
2812, d3qc4A_, 0.7328, 3.04, 0.283, 276, 251, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2813, d5v19B_, 0.7327, 2.93, 0.294, 260, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2814, d5oorA_, 0.7327, 2.91, 0.283, 273, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
2815, d4f08A_, 0.7327, 3.22, 0.256, 288, 254, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
2816, d5tq5A_, 0.7326, 2.98, 0.257, 291, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2817, d5jznB_, 0.7326, 2.58, 0.290, 266, 241, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2818, d5ar2A_, 0.7326, 2.80, 0.223, 277, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2819, d4g16A1, 0.7326, 3.14, 0.183, 301, 252, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
2820, d4e4mE_, 0.7326, 3.29, 0.260, 296, 254, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2821, d4d0wA_, 0.7326, 3.00, 0.260, 289, 250, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2822, d2zmcA_, 0.7326, 2.64, 0.291, 260, 247, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
2823, d5aepA_, 0.7325, 2.99, 0.260, 287, 250, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
2824, d4e6qA_, 0.7325, 3.32, 0.267, 296, 255, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2825, d3sv0A_, 0.7325, 3.32, 0.194, 294, 253, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
2826, d3ppkB_, 0.7325, 2.63, 0.193, 264, 243, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
2827, d3a4pA_, 0.7325, 3.10, 0.223, 285, 251, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
2828, d2w1iB_, 0.7325, 3.23, 0.258, 284, 252, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2829, d2e9uA_, 0.7325, 3.10, 0.289, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
2830, d6babC_, 0.7324, 2.86, 0.302, 284, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2831, d4zsaA_, 0.7324, 3.41, 0.233, 289, 257, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
2832, d4bbeD_, 0.7324, 3.12, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2833, d4bbeA_, 0.7324, 3.13, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2834, d3uysC_, 0.7324, 3.20, 0.174, 286, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2835, d3oroA_, 0.7324, 2.96, 0.253, 272, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
2836, d3e5aA_, 0.7324, 2.92, 0.309, 264, 246, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2837, d2fgaA_, 0.7324, 2.97, 0.274, 269, 248,  
2838, d5x17B_, 0.7323, 3.22, 0.174, 289, 253, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2839, d5w5oO_, 0.7323, 2.80, 0.223, 276, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2840, d4hyhA_, 0.7323, 2.79, 0.276, 263, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
2841, d3sxsA1, 0.7323, 2.80, 0.224, 261, 246, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
2842, d2z2wA_, 0.7323, 2.53, 0.217, 260, 240, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
2843, d2y7jD_, 0.7323, 2.85, 0.289, 281, 246, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2844, d5ikwA_, 0.7322, 2.92, 0.259, 297, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2845, d5eakB_, 0.7322, 2.50, 0.320, 300, 241, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2846, d4b0gA_, 0.7322, 2.48, 0.305, 247, 239, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
2847, d5ih4A_, 0.7321, 3.28, 0.180, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
2848, d5ap1A1, 0.7321, 3.01, 0.288, 264, 250, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2849, d4bicB_, 0.7321, 2.73, 0.296, 259, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2850, d2gs6A2, 0.7321, 3.17, 0.202, 308, 252, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
2851, d2e9nA_, 0.7321, 2.91, 0.275, 269, 247, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
2852, d1ckjB_, 0.7321, 3.31, 0.188, 293, 255, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2853, d5tq8A_, 0.7320, 2.93, 0.254, 291, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2854, d5n93A1, 0.7320, 2.80, 0.289, 256, 246, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
2855, d4hgsA1, 0.7320, 3.14, 0.183, 301, 252, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
2856, d4e4mA_, 0.7320, 3.22, 0.261, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2857, d2w1dA1, 0.7320, 2.62, 0.310, 251, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2858, d2c3kA_, 0.7320, 3.07, 0.289, 262, 249, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2859, d4aoiA_, 0.7319, 3.29, 0.223, 289, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
2860, d4ji9B_, 0.7318, 3.05, 0.259, 288, 251, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
2861, d4cztA1, 0.7318, 3.25, 0.303, 289, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
2862, d3c4fA_, 0.7318, 3.55, 0.239, 290, 259, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
2863, d6babB_, 0.7317, 2.86, 0.307, 285, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2864, d4kbaC_, 0.7317, 3.23, 0.174, 277, 253, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2865, d4hglA1, 0.7317, 3.15, 0.183, 301, 252, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
2866, d4g17A1, 0.7317, 3.19, 0.206, 301, 253, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
2867, d4cztD1, 0.7317, 3.25, 0.302, 296, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
2868, d2brmA_, 0.7317, 3.09, 0.273, 263, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2869, d1tkiB_, 0.7317, 3.33, 0.227, 321, 255, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2870, d5w5oP_, 0.7316, 2.76, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2871, d3vs7A3, 0.7316, 2.54, 0.258, 267, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2872, d2j4zB_, 0.7316, 2.95, 0.302, 269, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
2873, d1tkiA_, 0.7316, 3.33, 0.227, 321, 255, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2874, d5j79A_, 0.7315, 3.15, 0.224, 283, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2875, d4ynzA1, 0.7315, 2.42, 0.295, 306, 241, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
2876, d4zegA_, 0.7314, 2.81, 0.293, 260, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2877, d3dlsD_, 0.7314, 3.04, 0.258, 284, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2878, d2hakF_, 0.7314, 3.11, 0.306, 318, 252, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
2879, d1x8bA_, 0.7314, 2.67, 0.220, 259, 241, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
2880, d5uy6A1, 0.7313, 2.84, 0.290, 280, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2881, d4zimA_, 0.7313, 3.07, 0.271, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2882, d4kb8C_, 0.7313, 3.24, 0.174, 277, 253, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2883, d3eyhA_, 0.7313, 3.18, 0.255, 285, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2884, d2w1iA_, 0.7313, 3.25, 0.262, 284, 252, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2885, d5w5oJ_, 0.7312, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2886, d5ei6A1, 0.7312, 2.82, 0.290, 261, 248, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2887, d4f09A_, 0.7312, 3.32, 0.235, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
2888, d3vapA_, 0.7312, 2.56, 0.312, 249, 240, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
2889, d3qc4B1, 0.7312, 3.00, 0.293, 268, 249, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2890, d5w5oB_, 0.7311, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2891, d4riyD_, 0.7311, 3.06, 0.217, 297, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2892, d4qyeA_, 0.7311, 2.99, 0.271, 271, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
2893, d4ivaA_, 0.7311, 3.15, 0.253, 290, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
2894, d4fg9B_, 0.7311, 2.81, 0.282, 279, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
2895, d3d4qA_, 0.7311, 2.65, 0.198, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2896, d3a7hB_, 0.7311, 3.04, 0.276, 290, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2897, d6bqpA1, 0.7310, 2.83, 0.294, 262, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2898, d5u6bB1, 0.7310, 3.04, 0.221, 289, 249, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2899, d5ew8A_, 0.7310, 3.51, 0.240, 291, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
2900, d4riwD_, 0.7310, 3.06, 0.217, 297, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2901, d3zclA_, 0.7310, 3.30, 0.223, 289, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
2902, d3d4qB_, 0.7310, 2.65, 0.193, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2903, d3a7gA_, 0.7310, 3.17, 0.287, 289, 251, HUMAN MST3 KINASE
2904, d2e9vA_, 0.7310, 2.85, 0.276, 268, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2905, d1ckiB_, 0.7310, 3.19, 0.178, 286, 253, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2906, d5op2A_, 0.7309, 2.97, 0.289, 263, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2907, d5lohB_, 0.7309, 2.59, 0.312, 250, 240, KINASE DOMAIN OF HUMAN GREATWALL
2908, d4wnoA_, 0.7309, 2.92, 0.294, 272, 245, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2909, d3zbxA_, 0.7309, 3.30, 0.223, 282, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
2910, d3eqpB_, 0.7309, 3.02, 0.253, 270, 249, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2911, d2broA_, 0.7309, 3.15, 0.272, 272, 250, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2912, d5jsmA1, 0.7308, 2.78, 0.212, 262, 245, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2913, d3eqrB_, 0.7308, 2.88, 0.260, 271, 246, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2914, d2j4zA_, 0.7308, 2.76, 0.306, 263, 245, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
2915, d4lqmA_, 0.7307, 3.29, 0.198, 305, 253, EGFR L858R IN COMPLEX WITH PD168393
2916, d3tt0A_, 0.7307, 3.49, 0.239, 305, 259, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
2917, d3cqeA_, 0.7307, 2.63, 0.232, 258, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
2918, d3c4fB_, 0.7307, 3.47, 0.225, 290, 258, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
2919, d6bleA1, 0.7306, 2.84, 0.294, 263, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2920, d5w5oL_, 0.7306, 2.84, 0.215, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2921, d5opuA_, 0.7306, 2.83, 0.282, 261, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2922, d4btkA_, 0.7306, 3.11, 0.187, 287, 252, TTBK1 IN COMPLEX WITH INHIBITOR
2923, d4bbfD_, 0.7306, 3.15, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2924, d3rhkA_, 0.7306, 2.96, 0.210, 298, 248, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
2925, d3nlbA_, 0.7306, 3.01, 0.287, 261, 247, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
2926, d2jitA_, 0.7306, 2.89, 0.202, 299, 247, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
2927, d5w5oH_, 0.7305, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2928, d5w4wD_, 0.7305, 3.11, 0.176, 287, 250, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2929, d4bbfC_, 0.7305, 3.17, 0.266, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2930, d1fgiA_, 0.7305, 3.49, 0.240, 283, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
2931, d5ugbA_, 0.7304, 3.28, 0.209, 307, 253, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2932, d5jzjA_, 0.7304, 2.68, 0.290, 271, 241, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2933, d3uytD_, 0.7304, 2.99, 0.175, 268, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2934, d4wnpB_, 0.7303, 2.89, 0.298, 272, 245, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2935, d4li5A1, 0.7303, 3.11, 0.221, 303, 249, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
2936, d5o12A_, 0.7302, 2.54, 0.262, 264, 240, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2937, d4zogA_, 0.7302, 3.28, 0.228, 269, 250, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2938, d4h58B_, 0.7302, 2.87, 0.200, 262, 245, BRAF IN COMPLEX WITH COMPOUND 3
2939, d4bbfA_, 0.7302, 3.16, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2940, d5w5oF_, 0.7301, 2.81, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2941, d5w5oE_, 0.7301, 2.79, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2942, d5u6bD1, 0.7301, 3.05, 0.221, 289, 249, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2943, d5mqvC_, 0.7301, 3.24, 0.181, 288, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2944, d5d41A_, 0.7301, 2.77, 0.209, 300, 244, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
2945, d3zxzA_, 0.7301, 3.14, 0.229, 289, 249, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
2946, d3iecA_, 0.7301, 2.83, 0.313, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2947, d3eqpA_, 0.7301, 2.92, 0.255, 268, 247, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2948, d5w5oK_, 0.7300, 2.77, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2949, d5w5oA_, 0.7300, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2950, d4ji9A_, 0.7300, 3.02, 0.268, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
2951, d3ma3A_, 0.7300, 2.57, 0.266, 266, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
2952, d3ky2A1, 0.7300, 3.39, 0.246, 305, 256, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2953, d3zosA_, 0.7299, 3.37, 0.207, 301, 256, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
2954, d3zc5A_, 0.7299, 3.20, 0.232, 289, 250, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
2955, d5fqdF_, 0.7298, 3.33, 0.186, 294, 253, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2956, d4e6qB_, 0.7298, 3.34, 0.243, 296, 255, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2957, d3iokA_, 0.7298, 3.01, 0.261, 285, 249, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2958, d5uorB_, 0.7297, 2.94, 0.291, 262, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2959, d5m53A1, 0.7297, 1.96, 0.293, 248, 232, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
2960, d5lohA_, 0.7297, 2.49, 0.311, 248, 238, KINASE DOMAIN OF HUMAN GREATWALL
2961, d5e8xA_, 0.7297, 3.20, 0.208, 304, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2962, d4lg4A_, 0.7297, 3.51, 0.281, 289, 260, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2963, d1u59A1, 0.7297, 3.23, 0.238, 276, 252, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2964, d5fqdC_, 0.7296, 3.43, 0.189, 294, 254, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2965, d4deiA_, 0.7296, 3.20, 0.223, 287, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
2966, d4bhnA_, 0.7296, 2.82, 0.298, 256, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2967, d2vwiD_, 0.7296, 2.88, 0.262, 284, 244, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
2968, d2iztA_, 0.7296, 3.32, 0.200, 296, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2969, d1lufA_, 0.7296, 2.98, 0.230, 275, 248, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
2970, d5up3A_, 0.7295, 2.85, 0.296, 258, 243, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2971, d4ytfA_, 0.7295, 3.00, 0.249, 283, 249, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2972, d4uwcA_, 0.7295, 3.57, 0.232, 300, 259, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
2973, d4rixD_, 0.7295, 3.10, 0.217, 297, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2974, d4c8bA_, 0.7295, 2.81, 0.207, 279, 246, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2975, d4bbfB_, 0.7295, 3.08, 0.267, 288, 251, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2976, d3ppzB_, 0.7295, 2.65, 0.233, 264, 240, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2977, d3kckA_, 0.7295, 3.00, 0.249, 285, 249, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
2978, d3is5E1, 0.7295, 1.99, 0.306, 243, 232, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2979, d1py5A_, 0.7295, 3.04, 0.222, 301, 248, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
2980, d1j3hA_, 0.7295, 2.91, 0.257, 329, 249, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2981, d5w5oI_, 0.7294, 2.82, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2982, d5w5oD_, 0.7294, 2.82, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2983, d5cf8B1, 0.7294, 3.17, 0.259, 287, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2984, d4r1vA_, 0.7294, 3.07, 0.217, 289, 249, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
2985, d4lg4F_, 0.7294, 2.83, 0.301, 276, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2986, d3tjcB_, 0.7294, 3.20, 0.258, 287, 252, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
2987, d3dlsA_, 0.7294, 3.02, 0.258, 285, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2988, d1p4fA_, 0.7294, 2.70, 0.261, 269, 241, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
2989, d5w5oC_, 0.7293, 2.79, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2990, d5op5A_, 0.7293, 2.81, 0.275, 259, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2991, d4at4A1, 0.7293, 3.24, 0.224, 289, 254, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
2992, d3gqiA_, 0.7293, 3.28, 0.238, 304, 252, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2993, d2wgjA_, 0.7293, 3.32, 0.223, 289, 251, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
2994, d5opbA_, 0.7292, 2.98, 0.289, 262, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2995, d5n9sA1, 0.7292, 2.65, 0.298, 256, 245, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
2996, d5l3aA_, 0.7292, 3.14, 0.263, 290, 251, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
2997, d4rwjA1, 0.7292, 3.35, 0.242, 306, 256, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
2998, d4rvkA_, 0.7292, 2.99, 0.287, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
2999, d4ftiA_, 0.7292, 3.03, 0.271, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
3000, d4bc6A_, 0.7292, 2.92, 0.317, 285, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3001, d3bi6A_, 0.7292, 2.58, 0.217, 258, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3002, d1rw8A_, 0.7292, 3.01, 0.222, 301, 248, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
3003, d4uwcB_, 0.7291, 3.51, 0.229, 301, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3004, d4rioA_, 0.7291, 3.16, 0.239, 285, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
3005, d2b7aB_, 0.7291, 3.21, 0.258, 287, 252, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3006, d5eydA_, 0.7290, 3.19, 0.229, 289, 249, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
3007, d5ci7A_, 0.7290, 2.86, 0.296, 276, 243, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3008, d4ft3A_, 0.7290, 2.84, 0.275, 269, 244, CRYSTAL STRUCTURE OF THE CHK1
3009, d4fsnA_, 0.7290, 3.04, 0.283, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
3010, d4c4eA1, 0.7290, 2.55, 0.296, 253, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3011, d3oriB_, 0.7290, 2.78, 0.263, 267, 243, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3012, d3js2B_, 0.7290, 3.43, 0.233, 291, 257, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3013, d3cr0A_, 0.7290, 2.54, 0.218, 257, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3014, d5w5oG_, 0.7289, 2.83, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3015, d5ng2A_, 0.7289, 2.72, 0.209, 274, 244, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3016, d5cf4A_, 0.7289, 3.03, 0.268, 283, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3017, d4p7eB_, 0.7289, 3.12, 0.259, 285, 251, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3018, d4aszA1, 0.7289, 3.20, 0.217, 286, 253, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3019, d3dakB_, 0.7289, 3.08, 0.262, 278, 244, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3020, d3bbtD_, 0.7289, 2.66, 0.224, 259, 241, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
3021, d2yexA_, 0.7289, 3.12, 0.280, 269, 250, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3022, d2wd1A_, 0.7289, 3.04, 0.218, 289, 248, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
3023, d5mqvF_, 0.7288, 3.31, 0.185, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3024, d5kbqB_, 0.7288, 2.74, 0.299, 273, 244, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3025, d5ar7A_, 0.7288, 3.20, 0.229, 278, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3026, d3zosB1, 0.7288, 3.35, 0.203, 301, 256, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3027, d5ootA_, 0.7287, 2.95, 0.280, 260, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3028, d5ihcA_, 0.7287, 2.18, 0.323, 305, 235, MELK IN COMPLEX WITH NVS-MELK12B
3029, d5ih8A_, 0.7287, 2.48, 0.324, 306, 238, MELK IN COMPLEX WITH NVS-MELK1
3030, d4rvmA_, 0.7287, 3.00, 0.287, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
3031, d4qyhB_, 0.7287, 3.00, 0.287, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3032, d3oriA_, 0.7287, 2.72, 0.264, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3033, d2bdwB_, 0.7287, 3.14, 0.323, 309, 251, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3034, d4qrcA_, 0.7286, 3.44, 0.242, 297, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
3035, d4ap7A_, 0.7286, 3.15, 0.229, 289, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
3036, d3dlsF_, 0.7286, 3.09, 0.258, 281, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3037, d3dlsE_, 0.7286, 3.08, 0.258, 282, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3038, d1iasA_, 0.7286, 3.29, 0.213, 330, 249, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3039, d4ytcA_, 0.7285, 3.01, 0.249, 284, 249, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3040, d4bibA_, 0.7285, 2.74, 0.296, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3041, d2xzsB_, 0.7285, 3.19, 0.267, 293, 251, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3042, d2fumC_, 0.7285, 2.44, 0.265, 254, 238, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3043, d5w4wB_, 0.7284, 3.33, 0.173, 291, 255, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3044, d5n87A1, 0.7284, 2.49, 0.298, 252, 242, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3045, d5bpyB1, 0.7284, 2.63, 0.204, 246, 240, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3046, d4ybkA_, 0.7284, 2.73, 0.255, 266, 243, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
3047, d4qo9A_, 0.7284, 3.12, 0.281, 280, 249, MST3 IN COMPLEX WITH DANUSERTIB
3048, d4h58A_, 0.7284, 2.68, 0.194, 263, 242, BRAF IN COMPLEX WITH COMPOUND 3
3049, d4bibB_, 0.7284, 2.75, 0.289, 258, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3050, d3tkiA_, 0.7284, 3.09, 0.286, 272, 248, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
3051, d1b6cD_, 0.7284, 3.16, 0.222, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3052, d5hesA_, 0.7283, 2.72, 0.253, 287, 241, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3053, d4cnhB_, 0.7283, 3.22, 0.199, 293, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3054, d3vs7B3, 0.7283, 2.53, 0.247, 266, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3055, d3f66B_, 0.7283, 3.11, 0.226, 269, 248, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3056, d2c3lA_, 0.7283, 3.05, 0.287, 265, 247, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3057, d5e8wA1, 0.7282, 3.25, 0.208, 302, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
3058, d4tn6A_, 0.7282, 3.27, 0.179, 292, 252, CK1D IN COMPLEX WITH INHIBITOR
3059, d4jjrA_, 0.7282, 2.94, 0.178, 284, 247, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3060, d3nz0A1, 0.7282, 3.00, 0.231, 283, 247, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
3061, d1muoA_, 0.7282, 2.74, 0.305, 251, 243, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
3062, d5w4wA_, 0.7281, 3.34, 0.176, 291, 255, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3063, d5e8uA1, 0.7281, 3.22, 0.212, 303, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
3064, d4qygB_, 0.7281, 3.02, 0.291, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3065, d4o6lB_, 0.7281, 2.50, 0.293, 256, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3066, d2wqnA_, 0.7281, 2.54, 0.326, 259, 239, STRUCTURE OF ADP-BOUND HUMAN NEK7
3067, d5wr7A_, 0.7280, 3.01, 0.221, 301, 249, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
3068, d5n84A1, 0.7280, 2.59, 0.300, 253, 243, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3069, d4hgeB_, 0.7280, 3.04, 0.256, 288, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3070, d3dlsC_, 0.7280, 2.92, 0.252, 281, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3071, d2xneA_, 0.7280, 2.48, 0.301, 246, 239, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3072, d2izsA_, 0.7280, 3.34, 0.176, 298, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3073, d5vndB_, 0.7279, 3.61, 0.224, 295, 259, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3074, d2e9vB_, 0.7279, 2.93, 0.276, 268, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3075, d1fotA_, 0.7279, 3.14, 0.254, 299, 252, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
3076, d4riyA_, 0.7278, 2.65, 0.206, 269, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3077, d3lzbB_, 0.7278, 2.71, 0.215, 265, 242, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3078, d4xcuA1, 0.7277, 3.21, 0.246, 287, 252, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
3079, d4uwbA_, 0.7277, 3.68, 0.235, 299, 260, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3080, d4bidB_, 0.7277, 2.77, 0.289, 258, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3081, d4qygA_, 0.7276, 3.04, 0.291, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3082, d4czuC_, 0.7276, 3.42, 0.302, 281, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3083, d3rhxA_, 0.7276, 3.56, 0.240, 289, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3084, d3q4uD_, 0.7276, 3.09, 0.243, 299, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3085, d3jy9A_, 0.7276, 2.98, 0.250, 282, 248, JANUS KINASE 2 INHIBITORS
3086, d3q4uB1, 0.7275, 3.01, 0.244, 298, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3087, d3kulB_, 0.7275, 2.71, 0.180, 271, 244, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3088, d3fupB_, 0.7275, 3.22, 0.258, 287, 252, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3089, d3dbqA_, 0.7275, 2.73, 0.298, 259, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
3090, d2ghgA1, 0.7275, 3.02, 0.274, 269, 248, H-CHK1 COMPLEXED WITH A431994
3091, d5p9lA_, 0.7274, 2.64, 0.195, 252, 241, BTK1 IN COMPLEX WITH CC 292
3092, d5am7A_, 0.7274, 3.46, 0.239, 294, 255, FGFR1 MUTANT WITH AN INHIBITOR
3093, d5am6A1, 0.7274, 3.45, 0.239, 294, 255, NATIVE FGFR1 WITH AN INHIBITOR
3094, d4rixA_, 0.7274, 2.76, 0.205, 269, 244, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3095, d3dakA_, 0.7274, 3.19, 0.261, 279, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3096, d2yerA_, 0.7274, 3.08, 0.281, 268, 249, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3097, d5cf8A1, 0.7273, 3.01, 0.269, 284, 249, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3098, d2j50B_, 0.7273, 2.63, 0.311, 249, 241, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3099, d2j50A_, 0.7273, 2.63, 0.311, 249, 241, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3100, d2hy0A_, 0.7273, 3.08, 0.271, 272, 247, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
3101, d5em8A_, 0.7272, 3.33, 0.206, 303, 253, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
3102, d5a46B_, 0.7272, 3.60, 0.236, 297, 259, FGFR1 IN COMPLEX WITH DOVITINIB
3103, d4xyfA_, 0.7272, 3.36, 0.223, 290, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
3104, d3a7hA_, 0.7272, 3.18, 0.276, 289, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3105, d2j7tA_, 0.7272, 2.71, 0.322, 285, 242, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
3106, d2izuA_, 0.7272, 3.33, 0.201, 297, 254, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3107, d2in6A_, 0.7272, 2.59, 0.230, 256, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3108, d3vquA_, 0.7271, 2.88, 0.293, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3109, d3c4dA1, 0.7271, 2.51, 0.209, 257, 239,  
3110, d5eycA_, 0.7270, 3.19, 0.222, 288, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
3111, d4qyhA_, 0.7270, 2.99, 0.276, 264, 246, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3112, d4ft7A_, 0.7270, 3.03, 0.272, 270, 246, CRYSTAL STRUCTURE OF THE CHK1
3113, d3uzpB_, 0.7270, 3.00, 0.171, 284, 246, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3114, d3d94A_, 0.7270, 3.28, 0.212, 288, 250, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3115, d2zmdA_, 0.7270, 2.68, 0.297, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
3116, d2hogA_, 0.7270, 3.13, 0.286, 272, 248, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
3117, d1iasB_, 0.7270, 3.07, 0.211, 324, 247, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3118, d4dehA_, 0.7269, 3.13, 0.222, 286, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
3119, d3eygA_, 0.7269, 3.06, 0.262, 280, 248, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3120, d1b6cB_, 0.7269, 3.20, 0.222, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3121, d5x18A_, 0.7268, 3.45, 0.191, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3122, d5oq7A_, 0.7268, 2.95, 0.296, 259, 247, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3123, d5hcxA_, 0.7268, 3.07, 0.197, 298, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
3124, d5ew8B_, 0.7268, 3.56, 0.236, 290, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3125, d1gzoA_, 0.7268, 2.54, 0.293, 271, 239, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
3126, d4kb8A_, 0.7267, 3.00, 0.181, 265, 249, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3127, d2b7aA_, 0.7267, 3.10, 0.272, 284, 250, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3128, d1u4dB_, 0.7267, 2.72, 0.264, 262, 242, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3129, d1iasE_, 0.7267, 3.25, 0.214, 330, 248, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3130, d5ttvA_, 0.7266, 3.27, 0.255, 280, 251, JAK3 WITH COVALENT INHIBITOR 6
3131, d5f1zA1, 0.7266, 2.83, 0.238, 280, 244, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3132, d4tygA1, 0.7266, 3.40, 0.250, 290, 256, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3133, d4qyfA_, 0.7266, 2.98, 0.272, 269, 246, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
3134, d3q6wA1, 0.7266, 3.28, 0.223, 293, 251, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
3135, d3ppkA_, 0.7266, 2.63, 0.203, 262, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3136, d4ntsA_, 0.7265, 3.25, 0.250, 341, 252, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3137, d4hgeA_, 0.7265, 3.08, 0.272, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3138, d3tjcA_, 0.7265, 3.10, 0.272, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3139, d3io7A_, 0.7265, 2.98, 0.250, 282, 248, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3140, d2j5fA_, 0.7265, 3.29, 0.198, 308, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
3141, d5cenA_, 0.7264, 3.08, 0.278, 281, 245, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
3142, d4zy5A_, 0.7264, 2.82, 0.303, 283, 244, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3143, d4ymjB1, 0.7264, 3.07, 0.230, 272, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3144, d4uwbB_, 0.7264, 3.49, 0.233, 299, 257, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3145, d4py1A_, 0.7264, 3.30, 0.237, 289, 253, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
3146, d3kfaB1, 0.7264, 3.23, 0.230, 283, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3147, d3kfaA1, 0.7264, 3.23, 0.230, 283, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3148, d3fupA_, 0.7264, 3.33, 0.265, 284, 253, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3149, d2x9fA_, 0.7264, 2.84, 0.220, 265, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3150, d2hz0A_, 0.7264, 3.21, 0.224, 265, 250, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3151, d2g15A_, 0.7264, 3.22, 0.207, 301, 251, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
3152, d5vdkA_, 0.7263, 2.74, 0.250, 260, 240, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3153, d5usyA_, 0.7263, 3.32, 0.259, 287, 251, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3154, d5opvA_, 0.7263, 2.90, 0.275, 261, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3155, d5gtzA_, 0.7263, 3.36, 0.213, 317, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
3156, d4riwA_, 0.7263, 2.65, 0.202, 269, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3157, d4bidA_, 0.7263, 2.84, 0.295, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3158, d3wyxA_, 0.7263, 2.80, 0.294, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
3159, d3lcdA_, 0.7263, 3.03, 0.234, 290, 248, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
3160, d3c4cA1, 0.7263, 2.60, 0.208, 257, 240, B-RAF KINASE IN COMPLEX WITH PLX4720
3161, d5e90A1, 0.7262, 3.31, 0.213, 300, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
3162, d4ftuA_, 0.7262, 3.08, 0.287, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
3163, d4e6dB_, 0.7262, 3.08, 0.264, 286, 250, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3164, d2z8cA1, 0.7262, 3.28, 0.211, 297, 251, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
3165, d5jzjB_, 0.7261, 2.66, 0.289, 261, 239, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3166, d4z16B_, 0.7261, 3.13, 0.254, 276, 248, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3167, d4x7nA_, 0.7261, 2.83, 0.270, 259, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
3168, d4bieA_, 0.7261, 2.74, 0.296, 257, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3169, d3r7oA1, 0.7261, 3.29, 0.227, 295, 251, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
3170, d2g2hA_, 0.7261, 3.40, 0.242, 272, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3171, d1zy5A1, 0.7261, 3.07, 0.275, 269, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
3172, d1nvsA_, 0.7261, 3.05, 0.287, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
3173, d1nvqA_, 0.7261, 3.05, 0.287, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
3174, d1gznA_, 0.7261, 2.56, 0.293, 271, 239, STRUCTURE OF PKB KINASE DOMAIN
3175, d5vndA_, 0.7260, 3.56, 0.236, 302, 258, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3176, d5tozA_, 0.7260, 3.15, 0.253, 278, 249, JAK3 WITH COVALENT INHIBITOR PF-06651600
3177, d5canA_, 0.7260, 3.07, 0.201, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
3178, d4hvgA_, 0.7260, 3.20, 0.244, 281, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
3179, d1iasD_, 0.7260, 3.28, 0.210, 330, 248, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3180, d1gzkA_, 0.7260, 2.55, 0.293, 271, 239, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
3181, d5opsA_, 0.7259, 2.83, 0.284, 258, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3182, d5n7vA1, 0.7259, 2.81, 0.289, 257, 246, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
3183, d4byjA_, 0.7259, 2.35, 0.314, 246, 236, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3184, d2x8eA_, 0.7259, 2.89, 0.269, 259, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3185, d5w5oN_, 0.7258, 2.74, 0.222, 272, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3186, d5i3oA_, 0.7258, 3.02, 0.259, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3187, d4zogB_, 0.7258, 3.31, 0.223, 268, 251, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3188, d3rvgA_, 0.7258, 2.96, 0.263, 285, 247, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
3189, d3mvjB_, 0.7258, 3.22, 0.243, 320, 251, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3190, d3f66A_, 0.7258, 3.12, 0.216, 288, 250, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3191, d3f3zA_, 0.7258, 2.99, 0.275, 271, 247, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3192, d2welA_, 0.7258, 3.07, 0.317, 304, 249, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
3193, d1b6cH_, 0.7258, 3.12, 0.223, 326, 247, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3194, d6b16A_, 0.7257, 2.89, 0.301, 285, 246, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3195, d5walA1, 0.7257, 3.22, 0.231, 285, 251, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3196, d3oriD_, 0.7257, 2.79, 0.260, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3197, d1zycD1, 0.7257, 2.78, 0.267, 254, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3198, d1iasC_, 0.7257, 3.19, 0.219, 330, 247, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3199, d5oq8A_, 0.7256, 2.96, 0.279, 261, 247, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3200, d5mqvA_, 0.7256, 3.23, 0.183, 286, 252, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3201, d5hicA_, 0.7256, 3.08, 0.197, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
3202, d5e8sA1, 0.7256, 3.25, 0.214, 299, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
3203, d4czuB1, 0.7256, 3.47, 0.294, 283, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3204, d4bggB_, 0.7256, 2.84, 0.243, 293, 243, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3205, d3d2kA_, 0.7256, 2.39, 0.297, 245, 236, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
3206, d2x9eA_, 0.7256, 2.41, 0.301, 253, 239, HUMAN MPS1 IN COMPLEX WITH NMS-P715
3207, d2wkmA_, 0.7256, 3.13, 0.228, 286, 250, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
3208, d2izrA_, 0.7256, 3.34, 0.177, 298, 254, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3209, d5ap4A1, 0.7255, 2.72, 0.296, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3210, d4ymjA1, 0.7255, 3.11, 0.234, 267, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3211, d4p7eA_, 0.7255, 3.11, 0.272, 281, 250, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3212, d3oriC_, 0.7255, 2.79, 0.260, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3213, d2qnjA1, 0.7255, 3.03, 0.320, 317, 250, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3214, d5ehlA1, 0.7254, 2.60, 0.305, 254, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3215, d3ormA_, 0.7254, 2.72, 0.257, 266, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
3216, d3kcfC_, 0.7254, 3.33, 0.209, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3217, d2v7aA_, 0.7254, 3.29, 0.228, 269, 250, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
3218, d6brcA1, 0.7253, 2.86, 0.292, 263, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3219, d6bqqA1, 0.7253, 2.85, 0.288, 269, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
3220, d5i4nA1, 0.7253, 2.95, 0.206, 273, 247, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
3221, d5calA_, 0.7253, 3.08, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
3222, d4x7kA_, 0.7253, 2.85, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
3223, d4bkjB1, 0.7253, 3.22, 0.190, 296, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3224, d4bi0A1, 0.7253, 2.51, 0.303, 251, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3225, d3p86A_, 0.7253, 2.36, 0.228, 250, 237, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
3226, d3dakC_, 0.7253, 3.05, 0.255, 281, 243, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3227, d5i3rA_, 0.7252, 3.03, 0.259, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3228, d5capA_, 0.7252, 3.07, 0.201, 303, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
3229, d3hmoA_, 0.7252, 2.53, 0.302, 257, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
3230, d3dajA_, 0.7252, 2.32, 0.305, 245, 236, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
3231, d2j5eA_, 0.7252, 3.29, 0.198, 309, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
3232, d2fb8A_, 0.7252, 2.72, 0.202, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3233, d2c6eA_, 0.7252, 2.59, 0.306, 251, 242, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3234, d5hcyA_, 0.7251, 3.09, 0.197, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
3235, d4l7sA1, 0.7251, 2.56, 0.226, 248, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
3236, d4j96B_, 0.7251, 3.35, 0.236, 305, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
3237, d4gj2A1, 0.7251, 3.24, 0.231, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3238, d4ft9A_, 0.7251, 3.02, 0.269, 270, 245, CRYSTAL STRUCTURE OF THE CHK1
3239, d4bggA_, 0.7251, 2.84, 0.243, 296, 243, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3240, d3lzbA_, 0.7251, 2.60, 0.216, 265, 241, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3241, d1vjyA_, 0.7251, 3.08, 0.198, 299, 247, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
3242, d5hczA_, 0.7250, 3.08, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
3243, d5a46A_, 0.7250, 3.49, 0.242, 289, 256, FGFR1 IN COMPLEX WITH DOVITINIB
3244, d4lueA3, 0.7250, 2.52, 0.257, 261, 237, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
3245, d1k2pB_, 0.7250, 3.03, 0.203, 258, 246, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3246, p5osmA2, 0.7249, 0.40, 0.995, 214, 214, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
3247, p5osjA2, 0.7249, 0.40, 1.000, 214, 214, CDK2(WT) WITH COVALENT ADDUCT AT C177
3248, d5ap6A1, 0.7249, 2.97, 0.294, 259, 248, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3249, d4x7lA_, 0.7249, 2.86, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
3250, d4x2nA1, 0.7249, 3.28, 0.209, 302, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3251, d3dlsB_, 0.7249, 2.92, 0.253, 280, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3252, d2qu5A_, 0.7249, 2.88, 0.232, 292, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
3253, d2qohB2, 0.7249, 3.36, 0.231, 280, 251, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3254, d5wevA_, 0.7248, 3.12, 0.257, 293, 249, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3255, d4kbkC_, 0.7248, 3.25, 0.175, 280, 251, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3256, d3vw6A_, 0.7248, 2.74, 0.296, 255, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3257, d3q4uC_, 0.7248, 2.88, 0.242, 296, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3258, d3lpbA_, 0.7248, 3.08, 0.265, 278, 249, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3259, d3lcsA_, 0.7248, 3.29, 0.186, 304, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3260, d3kcfD_, 0.7248, 3.38, 0.209, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3261, d5usyB_, 0.7247, 3.24, 0.272, 287, 250, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3262, d3ue4A_, 0.7247, 3.33, 0.240, 270, 250, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
3263, d3tjdB_, 0.7247, 3.26, 0.258, 287, 252, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3264, d3prfA_, 0.7247, 2.70, 0.199, 262, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3265, d3lw0A_, 0.7247, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3266, d2wotA_, 0.7247, 3.34, 0.217, 303, 249, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3267, d2wotA1, 0.7247, 3.34, 0.217, 301, 249, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3268, d5ehoA1, 0.7246, 2.85, 0.294, 255, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3269, d4gihA1, 0.7246, 3.24, 0.231, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
3270, d4fsrA_, 0.7246, 3.01, 0.269, 269, 245, CRYSTAL STRUCTURE OF THE CHK1
3271, d3lw0C_, 0.7246, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3272, d1zycC1, 0.7246, 2.97, 0.264, 269, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3273, d4qpsC_, 0.7245, 2.81, 0.243, 276, 243, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3274, d4js8A_, 0.7245, 2.82, 0.294, 259, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
3275, d3zz2A_, 0.7245, 2.91, 0.324, 281, 244,  
3276, d3lxnA_, 0.7245, 3.27, 0.235, 287, 251, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3277, d3lw0D_, 0.7245, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3278, d1nvrA_, 0.7245, 3.07, 0.287, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
3279, d5op4A_, 0.7244, 2.84, 0.280, 259, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
3280, d5grnA_, 0.7244, 3.20, 0.198, 285, 252, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
3281, d5em7A_, 0.7244, 3.12, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3282, d4gj3A1, 0.7244, 3.25, 0.231, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3283, d3w1fA_, 0.7244, 2.89, 0.297, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
3284, d3lxlA_, 0.7244, 3.24, 0.256, 281, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3285, d3kcfB_, 0.7244, 3.11, 0.203, 324, 246, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3286, d3kcfA_, 0.7244, 3.26, 0.214, 328, 248, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3287, d5usqA_, 0.7243, 3.26, 0.214, 299, 248, ALK-5 KINASE INHIBITOR COMPLEX
3288, d5jsmB1, 0.7243, 2.87, 0.217, 259, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3289, d5ap0A1, 0.7243, 2.46, 0.300, 250, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3290, d4nt4A1, 0.7243, 3.26, 0.202, 299, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
3291, d3lw0B_, 0.7243, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3292, d3dakD_, 0.7243, 3.09, 0.259, 284, 243, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3293, d2c30A_, 0.7243, 3.39, 0.251, 289, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
3294, d5l8kA_, 0.7242, 3.18, 0.305, 266, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
3295, d5jsmD1, 0.7242, 2.92, 0.217, 255, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3296, d5imeA1, 0.7242, 2.91, 0.284, 279, 243, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3297, d4e26B_, 0.7242, 2.79, 0.210, 264, 243, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3298, d5e8zA1, 0.7241, 3.35, 0.213, 300, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
3299, d5e8tA1, 0.7241, 3.33, 0.213, 300, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
3300, d4yhtB_, 0.7241, 2.68, 0.203, 258, 241, BRAF COMPLEXED WITH AN INHIBITOR
3301, d4rj7A_, 0.7241, 3.01, 0.198, 295, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
3302, d4rixB_, 0.7241, 2.82, 0.210, 293, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3303, d3u6iA_, 0.7241, 2.92, 0.216, 281, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
3304, d1zycB1, 0.7241, 2.94, 0.266, 252, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3305, d5xdkA_, 0.7240, 3.37, 0.213, 307, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
3306, d5oprA_, 0.7240, 2.85, 0.276, 258, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
3307, d4yhtA_, 0.7240, 2.61, 0.204, 256, 240, BRAF COMPLEXED WITH AN INHIBITOR
3308, d4x2fA1, 0.7240, 3.29, 0.209, 302, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3309, d4u0iA_, 0.7240, 3.09, 0.213, 297, 249, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
3310, d4e20A_, 0.7240, 3.34, 0.239, 282, 251, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3311, d3wzkA_, 0.7240, 2.81, 0.286, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
3312, d3uytB_, 0.7240, 3.13, 0.176, 286, 250, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3313, d3kcfE_, 0.7240, 3.46, 0.213, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3314, d1zy4A1, 0.7240, 3.10, 0.275, 269, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
3315, d4x2kA1, 0.7239, 3.30, 0.209, 302, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3316, d4x2jA1, 0.7239, 3.30, 0.209, 302, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3317, d4x2gA1, 0.7239, 3.29, 0.213, 302, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3318, d4mkcA_, 0.7239, 3.28, 0.187, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
3319, d3prfB_, 0.7239, 2.71, 0.195, 262, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3320, d3ot3A_, 0.7239, 3.01, 0.286, 259, 245, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
3321, d3hmiA_, 0.7239, 3.23, 0.213, 268, 249, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3322, d2wtvD_, 0.7239, 3.14, 0.297, 262, 249, AURORA-A INHIBITOR STRUCTURE
3323, d5na0A1, 0.7238, 2.46, 0.296, 250, 240, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
3324, d4u5jB_, 0.7238, 2.72, 0.240, 267, 242, C-SRC IN COMPLEX WITH RUXOLITINIB
3325, d4o2pA_, 0.7238, 2.81, 0.254, 265, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3326, d4id7A_, 0.7238, 2.91, 0.240, 268, 246, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
3327, d4cztB1, 0.7238, 3.51, 0.294, 283, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3328, d3u6hA_, 0.7238, 2.88, 0.217, 280, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
3329, d3lzbD_, 0.7238, 2.69, 0.224, 261, 241, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3330, d5em6A_, 0.7237, 3.11, 0.197, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3331, d4mnfB_, 0.7237, 2.66, 0.196, 257, 240, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3332, d4aojA_, 0.7237, 2.71, 0.226, 260, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3333, d3lzbC_, 0.7237, 2.64, 0.225, 259, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3334, d2wtvB_, 0.7237, 3.15, 0.301, 261, 249, AURORA-A INHIBITOR STRUCTURE
3335, d2wtvA_, 0.7237, 3.15, 0.297, 262, 249, AURORA-A INHIBITOR STRUCTURE
3336, d1zmwB_, 0.7237, 2.74, 0.306, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3337, d1k9aA3, 0.7237, 2.70, 0.224, 267, 241, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3338, d5i3oB_, 0.7236, 2.97, 0.260, 302, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3339, d4cztC_, 0.7236, 3.49, 0.271, 286, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3340, d3wyyA_, 0.7236, 2.82, 0.290, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
3341, d3rhkB_, 0.7236, 3.11, 0.205, 299, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3342, d2e9pA_, 0.7236, 3.05, 0.275, 269, 247, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
3343, d5mqvB_, 0.7235, 3.33, 0.182, 287, 253, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3344, d5eobA_, 0.7235, 3.42, 0.215, 288, 251, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3345, d4rfmA1, 0.7235, 2.60, 0.224, 248, 241, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
3346, d4ludA3, 0.7235, 2.37, 0.251, 261, 235, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3347, d4e6dA_, 0.7235, 3.09, 0.277, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3348, d4ckrA1, 0.7235, 3.33, 0.209, 294, 254, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
3349, d4bkiA1, 0.7235, 3.33, 0.209, 294, 254,  
3350, d6eixA_, 0.7234, 3.03, 0.241, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
3351, d5oq6A_, 0.7234, 2.92, 0.279, 257, 244, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3352, d5ia2A_, 0.7234, 3.21, 0.187, 287, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
3353, d5flfA_, 0.7234, 3.38, 0.239, 296, 251, DISEASE LINKED MUTATION IN FGFR
3354, d5am7B_, 0.7234, 3.36, 0.237, 287, 253, FGFR1 MUTANT WITH AN INHIBITOR
3355, d4u5jA_, 0.7234, 2.91, 0.242, 267, 244, C-SRC IN COMPLEX WITH RUXOLITINIB
3356, d2xvdA_, 0.7234, 2.96, 0.230, 270, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3357, d2wtvC_, 0.7234, 3.16, 0.301, 261, 249, AURORA-A INHIBITOR STRUCTURE
3358, d2itpA_, 0.7234, 3.32, 0.215, 305, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
3359, d1k9aB3, 0.7234, 2.72, 0.227, 267, 242, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3360, d5nadA1, 0.7233, 2.78, 0.288, 253, 243, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
3361, d4x0mA1, 0.7233, 3.29, 0.209, 302, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3362, d4tn6B_, 0.7233, 3.39, 0.168, 285, 256, CK1D IN COMPLEX WITH INHIBITOR
3363, d4riyB_, 0.7233, 2.84, 0.214, 293, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3364, d4qqtA_, 0.7233, 3.43, 0.232, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
3365, d4iwdA1, 0.7233, 3.34, 0.227, 295, 251, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
3366, d3ii5A_, 0.7233, 3.01, 0.207, 262, 246, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3367, d4kbcA_, 0.7232, 3.30, 0.172, 288, 250, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3368, d4ft0A_, 0.7232, 3.01, 0.290, 266, 245, CRYSTAL STRUCTURE OF THE CHK1
3369, d3zepD_, 0.7232, 3.03, 0.262, 272, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3370, d2itxA_, 0.7232, 3.40, 0.202, 307, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
3371, d5vc6A_, 0.7231, 2.88, 0.223, 259, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3372, d5ihaA_, 0.7231, 2.38, 0.328, 303, 235, MELK IN COMPLEX WITH NVS-MELK8F
3373, d5eg3A_, 0.7231, 3.28, 0.239, 301, 251, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
3374, d4v05A_, 0.7231, 3.43, 0.235, 287, 255, FGFR1 IN COMPLEX WITH AZD4547.
3375, d4fsuA_, 0.7231, 3.03, 0.286, 260, 245, CRYSTAL STRUCTURE OF THE CHK1
3376, d2v7aB_, 0.7231, 3.32, 0.232, 268, 250, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
3377, d2dq7X_, 0.7231, 2.91, 0.230, 262, 243, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3378, d1uwhA_, 0.7231, 2.98, 0.196, 264, 245, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3379, d1b6cF_, 0.7231, 3.21, 0.222, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3380, d5oxgB_, 0.7230, 2.87, 0.243, 296, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3381, d5csxA_, 0.7230, 3.09, 0.203, 261, 246, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
3382, d4x7hA_, 0.7230, 2.69, 0.273, 256, 238, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
3383, d4kbcB_, 0.7230, 3.15, 0.192, 277, 250, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3384, d4giiA1, 0.7230, 3.27, 0.231, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3385, d3d7uC1, 0.7230, 2.59, 0.229, 255, 240, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3386, d3d7uA1, 0.7230, 2.59, 0.229, 255, 240, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3387, d3cohB_, 0.7230, 2.53, 0.310, 247, 239, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3388, d2fb8B_, 0.7230, 2.75, 0.198, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3389, d5oy6D_, 0.7229, 3.12, 0.243, 292, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3390, d5oq7B_, 0.7229, 2.82, 0.276, 256, 243, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3391, d5mqvD_, 0.7229, 3.31, 0.175, 287, 252, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3392, d5i9yA_, 0.7229, 3.16, 0.191, 287, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
3393, d5friA1, 0.7229, 3.19, 0.215, 299, 247, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
3394, d4j98B_, 0.7229, 3.42, 0.240, 304, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
3395, d4hniA_, 0.7229, 3.08, 0.194, 284, 247, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3396, d4bf2A_, 0.7229, 2.68, 0.298, 253, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3397, d3tjdA_, 0.7229, 3.14, 0.272, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3398, d3p08B_, 0.7229, 2.96, 0.192, 258, 245, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3399, d2pvfA_, 0.7229, 3.23, 0.233, 285, 249, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
3400, d6bu6A_, 0.7228, 3.49, 0.154, 322, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3401, d5ljjA1, 0.7228, 3.00, 0.293, 260, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
3402, d4qt1A_, 0.7228, 2.93, 0.245, 277, 245, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
3403, d4fvrA_, 0.7228, 2.96, 0.202, 274, 247, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
3404, d3tkhA_, 0.7228, 3.05, 0.290, 269, 245, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
3405, d2brgA_, 0.7228, 2.97, 0.270, 257, 244, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3406, d5ehyA1, 0.7227, 2.54, 0.303, 251, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3407, d4uxlA_, 0.7227, 2.86, 0.228, 288, 246, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
3408, d4hvdA_, 0.7227, 3.15, 0.246, 276, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
3409, d4bkjA1, 0.7227, 3.25, 0.186, 294, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3410, d3mpmA_, 0.7227, 3.14, 0.220, 257, 250, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
3411, d3lpbB1, 0.7227, 3.23, 0.261, 283, 249, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3412, d3l8pA_, 0.7227, 2.70, 0.259, 292, 239, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
3413, d5tq4A_, 0.7226, 3.05, 0.254, 290, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3414, d5oxgC1, 0.7226, 2.94, 0.242, 299, 244, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3415, d5caqA_, 0.7226, 3.12, 0.197, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
3416, d4mnfA_, 0.7226, 2.67, 0.204, 257, 240, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3417, d4lg4E_, 0.7226, 3.13, 0.280, 275, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3418, d4itjB_, 0.7226, 3.45, 0.234, 276, 252, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3419, d5cauA_, 0.7225, 3.10, 0.202, 297, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
3420, d4xmoA_, 0.7225, 3.37, 0.217, 289, 249, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
3421, d4jq8A_, 0.7225, 3.22, 0.217, 303, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
3422, d4i23A_, 0.7225, 3.27, 0.208, 304, 250, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
3423, d4hvhA_, 0.7225, 3.15, 0.246, 278, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
3424, d2i1mA_, 0.7225, 3.28, 0.203, 311, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3425, d5c8nA_, 0.7224, 3.11, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
3426, d5c8kA_, 0.7224, 3.12, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
3427, d4qqjA_, 0.7224, 3.45, 0.240, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
3428, d4l7sB1, 0.7224, 2.58, 0.222, 248, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
3429, d3q4uA_, 0.7224, 2.97, 0.242, 298, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3430, d3p9jA_, 0.7224, 2.63, 0.318, 249, 239, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
3431, d3cohA_, 0.7224, 2.53, 0.310, 247, 239, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3432, d5oxgD_, 0.7223, 2.94, 0.242, 293, 244, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3433, d4kbaB_, 0.7223, 3.14, 0.177, 285, 248, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3434, d1zmwA_, 0.7223, 2.77, 0.314, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3435, d5ui0B_, 0.7222, 3.51, 0.230, 304, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
3436, d5i3rB_, 0.7222, 3.10, 0.259, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3437, d4z55A_, 0.7222, 3.29, 0.187, 294, 251, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
3438, d1t46A_, 0.7222, 3.10, 0.221, 297, 249, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3439, d5ttsA_, 0.7221, 3.17, 0.258, 274, 248, JAK3 WITH COVALENT INHIBITOR 4
3440, d5oxgA_, 0.7221, 2.91, 0.243, 293, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3441, d5nkgA_, 0.7221, 3.23, 0.187, 292, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
3442, d5mqvE_, 0.7221, 3.31, 0.175, 287, 252, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3443, d5flfD_, 0.7221, 3.39, 0.244, 290, 250, DISEASE LINKED MUTATION IN FGFR
3444, d4ztqA_, 0.7221, 2.54, 0.315, 247, 238, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
3445, d4mneB_, 0.7221, 2.85, 0.198, 270, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3446, d4kbaA_, 0.7221, 2.97, 0.182, 263, 247, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3447, d3zfxI_, 0.7221, 2.73, 0.222, 263, 243, CRYSTAL STRUCTURE OF EPHB1
3448, d3hmnA_, 0.7221, 2.60, 0.302, 255, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
3449, d2j6mA_, 0.7221, 3.21, 0.217, 306, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
3450, d1t45A_, 0.7221, 3.13, 0.213, 331, 249, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
3451, d5f20A_, 0.7220, 2.90, 0.239, 274, 243, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3452, d5casA_, 0.7220, 3.10, 0.202, 299, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
3453, d4rwlB_, 0.7220, 3.49, 0.227, 285, 255, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3454, d4k33A_, 0.7220, 3.34, 0.232, 293, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
3455, d4gfgA1, 0.7220, 2.96, 0.199, 273, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
3456, d4cd0A_, 0.7220, 3.32, 0.187, 295, 251, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
3457, d3wzuA_, 0.7220, 2.78, 0.242, 270, 244, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
3458, d2g2hB_, 0.7220, 3.37, 0.226, 272, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3459, d4c4fA1, 0.7219, 2.50, 0.300, 250, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3460, d3wzjA_, 0.7219, 2.77, 0.287, 257, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
3461, d2jfmA_, 0.7219, 2.55, 0.269, 287, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
3462, d1m52B_, 0.7219, 3.40, 0.247, 272, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3463, d4ithB_, 0.7218, 3.03, 0.228, 270, 246, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
3464, d4hniB_, 0.7218, 3.02, 0.192, 284, 245, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3465, d4aojC_, 0.7218, 2.77, 0.226, 261, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3466, d3oy3B1, 0.7218, 3.27, 0.230, 283, 252, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3467, d3bceC_, 0.7218, 2.97, 0.211, 286, 246, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3468, d2bujB1, 0.7218, 3.11, 0.243, 277, 247, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3469, d1m52A_, 0.7218, 3.27, 0.248, 271, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3470, d6bu6D_, 0.7217, 3.45, 0.153, 318, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3471, d6b4wA_, 0.7217, 2.85, 0.294, 259, 245, TTK IN COMPLEX WITH INHIBITOR
3472, d5vc4A_, 0.7217, 2.94, 0.222, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3473, d5a4cB1, 0.7217, 3.54, 0.234, 284, 256, FGFR1 LIGAND COMPLEX
3474, d4fszA_, 0.7217, 2.92, 0.259, 268, 243, CRYSTAL STRUCTURE OF THE CHK1
3475, d3oy3A1, 0.7217, 3.19, 0.231, 283, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3476, d2ivsA_, 0.7217, 3.32, 0.253, 284, 249, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3477, d1uwhB_, 0.7217, 3.00, 0.196, 264, 245, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3478, d1rqqA_, 0.7217, 3.33, 0.212, 294, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
3479, d5gmpA_, 0.7216, 3.21, 0.201, 305, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
3480, d4rj8A_, 0.7216, 3.10, 0.202, 298, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
3481, d4riwB_, 0.7216, 2.84, 0.210, 293, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3482, d2ptkA3, 0.7216, 2.39, 0.247, 259, 235, CHICKEN SRC TYROSINE KINASE
3483, d5caoA_, 0.7215, 3.07, 0.194, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
3484, d4pmmA1, 0.7215, 3.04, 0.219, 281, 247, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
3485, d4jrvA_, 0.7215, 3.24, 0.213, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
3486, d4c3fA_, 0.7215, 3.11, 0.217, 257, 249, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
3487, d4bggC_, 0.7215, 2.87, 0.244, 279, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3488, d3lctA_, 0.7215, 3.32, 0.186, 308, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3489, d2r0iB_, 0.7215, 2.47, 0.315, 300, 238, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3490, d2c3jA_, 0.7215, 3.00, 0.266, 257, 244, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3491, d1u4dA_, 0.7215, 2.56, 0.256, 258, 238, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3492, d4uwyA_, 0.7214, 3.41, 0.237, 296, 253, FGFR1 APO STRUCTURE
3493, d4hviA_, 0.7214, 3.21, 0.258, 274, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
3494, d4ftjA_, 0.7214, 2.97, 0.276, 266, 243, CRYSTAL STRUCTURE OF THE CHK1
3495, d4degA_, 0.7214, 3.04, 0.216, 286, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
3496, d3u51A_, 0.7214, 2.58, 0.244, 256, 238, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
3497, d2c6eB_, 0.7214, 2.50, 0.312, 246, 237, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3498, d1zydA1, 0.7214, 3.02, 0.264, 268, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
3499, d4f0iB_, 0.7213, 3.18, 0.224, 294, 250, CRYSTAL STRUCTURE OF APO TRKA
3500, d4dfyE_, 0.7213, 3.05, 0.269, 312, 249, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3501, d3w8qA_, 0.7213, 2.67, 0.270, 318, 241, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
3502, d3dk7B_, 0.7213, 3.33, 0.237, 268, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3503, d2w5hA1, 0.7213, 2.82, 0.283, 257, 244, HUMAN NEK2 KINASE APO
3504, d1xbcA1, 0.7213, 3.05, 0.211, 267, 246, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
3505, d5jsmC1, 0.7212, 2.64, 0.217, 259, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3506, d4bieB_, 0.7212, 2.80, 0.299, 257, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3507, d3zfxH_, 0.7212, 2.75, 0.218, 266, 243, CRYSTAL STRUCTURE OF EPHB1
3508, d3zepA_, 0.7212, 3.03, 0.262, 274, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3509, d3w2qA1, 0.7212, 3.38, 0.198, 306, 253, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
3510, d3w16A_, 0.7212, 2.68, 0.318, 249, 239, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
3511, d2ydkA_, 0.7212, 3.11, 0.268, 263, 246, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3512, d2wqmA_, 0.7212, 2.44, 0.335, 258, 236, STRUCTURE OF APO HUMAN NEK7
3513, d5tq6A_, 0.7211, 3.16, 0.267, 274, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3514, d5cy3A1, 0.7211, 2.96, 0.203, 274, 246, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
3515, d4c2vA_, 0.7211, 3.00, 0.308, 270, 247, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
3516, d3g0fB_, 0.7211, 3.18, 0.217, 293, 249, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3517, d3bu6A_, 0.7211, 3.36, 0.211, 294, 251, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
3518, d1y57A3, 0.7211, 3.09, 0.252, 285, 246, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
3519, d1fmkA3, 0.7211, 2.74, 0.249, 270, 241, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
3520, d4fsyA_, 0.7210, 3.03, 0.279, 267, 244, CRYSTAL STRUCTURE OF THE CHK1
3521, d4asxB1, 0.7210, 3.22, 0.227, 296, 247, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3522, d3ik3B1, 0.7210, 3.16, 0.224, 285, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3523, d3dkfA1, 0.7210, 3.15, 0.230, 293, 248, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3524, d4rj4A_, 0.7209, 3.17, 0.197, 299, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
3525, d4gvjA1, 0.7209, 3.32, 0.235, 288, 251, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
3526, d4fg9A_, 0.7209, 2.78, 0.278, 278, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
3527, d4bi1A1, 0.7209, 2.47, 0.301, 249, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3528, d1m17A_, 0.7209, 3.29, 0.204, 312, 250, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
3529, d5ukfA_, 0.7208, 3.50, 0.154, 322, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3530, d5oy6B_, 0.7208, 2.91, 0.243, 292, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3531, d5e1eA_, 0.7208, 3.14, 0.262, 279, 248, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3532, d4equB_, 0.7208, 2.89, 0.322, 282, 242, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3533, d3kulA_, 0.7208, 2.68, 0.187, 267, 241, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3534, d2qohA2, 0.7208, 3.31, 0.222, 270, 248, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3535, d6bruA_, 0.7207, 3.52, 0.154, 322, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3536, d5hx8A_, 0.7207, 3.22, 0.256, 291, 250, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3537, d4x7jA_, 0.7207, 2.81, 0.268, 257, 239, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
3538, d3q4zA1, 0.7207, 2.86, 0.273, 281, 242, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3539, d3fzrA_, 0.7207, 2.79, 0.221, 261, 244, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
3540, d3ag9A_, 0.7207, 3.39, 0.238, 323, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
3541, d2wouA_, 0.7207, 3.19, 0.215, 299, 246, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3542, d2wouA1, 0.7207, 3.19, 0.215, 297, 246, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3543, d2itzA_, 0.7207, 3.20, 0.201, 302, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3544, d1sykA_, 0.7207, 3.21, 0.248, 348, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3545, d1ol6A_, 0.7207, 2.42, 0.301, 245, 236, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3546, d6eimB_, 0.7206, 2.86, 0.311, 295, 244, HUMAN STK10 BOUND TO GW683134A
3547, d5kmnA1, 0.7206, 3.22, 0.220, 290, 250, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3548, d5itaA_, 0.7206, 2.38, 0.213, 250, 235, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3549, d4jjrB_, 0.7206, 3.22, 0.156, 283, 250, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3550, d4bi2A1, 0.7206, 2.53, 0.304, 250, 240, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3551, d3o50A_, 0.7206, 2.44, 0.309, 246, 236, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
3552, d3naxA_, 0.7206, 2.91, 0.273, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP7
3553, d3et7A_, 0.7206, 2.78, 0.225, 261, 244, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
3554, d3op5A_, 0.7205, 3.47, 0.151, 320, 258, HUMAN VACCINIA-RELATED KINASE 1
3555, d3bceB_, 0.7205, 3.05, 0.207, 286, 246, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3556, d2j51A_, 0.7205, 2.66, 0.268, 288, 239, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
3557, d2gs2A_, 0.7205, 3.34, 0.210, 305, 252, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
3558, d1rqqB_, 0.7205, 3.30, 0.212, 294, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
3559, d5jfsA_, 0.7204, 2.71, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
3560, d4i6qA_, 0.7204, 3.19, 0.258, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
3561, d3tzmA_, 0.7204, 3.00, 0.221, 295, 244, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
3562, d3q4tA1, 0.7204, 2.97, 0.230, 294, 243, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3563, d3en4B_, 0.7204, 2.90, 0.247, 266, 243, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
3564, d2f4jA_, 0.7204, 3.32, 0.232, 287, 250, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
3565, d5nkfA_, 0.7203, 3.26, 0.187, 291, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
3566, d3o50B_, 0.7203, 2.64, 0.301, 249, 239, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
3567, d4fvqA_, 0.7202, 3.09, 0.198, 274, 248, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
3568, d3zfxA_, 0.7202, 2.71, 0.219, 267, 242, CRYSTAL STRUCTURE OF EPHB1
3569, d3qgyB1, 0.7202, 2.58, 0.214, 244, 238, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
3570, d3oomA_, 0.7202, 3.19, 0.243, 297, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
3571, d5k9iA_, 0.7201, 2.59, 0.244, 258, 238, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
3572, d4kb8B_, 0.7201, 3.08, 0.178, 285, 247, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3573, d4hvsA1, 0.7201, 3.18, 0.205, 323, 249, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
3574, d4c4jA1, 0.7201, 2.84, 0.290, 258, 245, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3575, d4bhnB_, 0.7201, 2.96, 0.298, 257, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3576, d3my0L1, 0.7201, 3.02, 0.246, 295, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3577, d3lxpA_, 0.7201, 3.21, 0.242, 285, 248, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3578, d3h10D_, 0.7201, 2.88, 0.302, 255, 245, AURORA A INHIBITOR COMPLEX
3579, d2bvaB_, 0.7201, 3.08, 0.249, 274, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3580, d4rj6A_, 0.7200, 3.12, 0.202, 297, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
3581, d4jq7A_, 0.7200, 3.27, 0.217, 303, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
3582, d1mryA_, 0.7200, 2.48, 0.287, 270, 237, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
3583, d5ek7B_, 0.7199, 3.09, 0.202, 286, 248, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3584, d4zy6A_, 0.7199, 2.98, 0.309, 284, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3585, d4pmpA1, 0.7199, 2.96, 0.216, 276, 245, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
3586, d4l00A_, 0.7199, 3.15, 0.225, 277, 249, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
3587, d4ckiA1, 0.7199, 3.34, 0.253, 288, 249, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
3588, d3mdyA_, 0.7199, 3.33, 0.224, 320, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3589, d3h9rA_, 0.7199, 3.05, 0.235, 312, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
3590, d2rfsA_, 0.7199, 3.06, 0.230, 264, 243, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
3591, d2gqgB1, 0.7199, 3.22, 0.225, 270, 249, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3592, d5ei2A_, 0.7198, 2.70, 0.296, 256, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3593, d5c8mA_, 0.7198, 3.16, 0.193, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
3594, d4jr3A_, 0.7198, 3.27, 0.213, 303, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
3595, d4fobA_, 0.7198, 3.28, 0.187, 295, 251, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
3596, d3wzeA_, 0.7198, 3.22, 0.204, 298, 250, KDR IN COMPLEX WITH LIGAND SORAFENIB
3597, d3w10A_, 0.7198, 2.94, 0.293, 263, 246, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
3598, d3vntA_, 0.7198, 3.21, 0.204, 301, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3599, d2z60A1, 0.7198, 3.43, 0.236, 280, 250, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
3600, d1r0pA_, 0.7198, 3.34, 0.229, 301, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
3601, d6brcB_, 0.7197, 2.98, 0.292, 260, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3602, d5v5yA_, 0.7197, 2.90, 0.232, 259, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3603, d5o26A_, 0.7197, 3.06, 0.253, 271, 245, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
3604, d5ap3A1, 0.7197, 2.56, 0.300, 250, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3605, d4kioC1, 0.7197, 2.66, 0.229, 249, 240, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
3606, d4d1sA_, 0.7197, 2.87, 0.254, 280, 244, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3607, d3zfxD_, 0.7197, 2.72, 0.219, 265, 242, CRYSTAL STRUCTURE OF EPHB1
3608, d3txoA_, 0.7197, 2.73, 0.293, 317, 239, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
3609, d2itqA_, 0.7197, 3.24, 0.217, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
3610, d5flfB_, 0.7196, 3.44, 0.244, 292, 250, DISEASE LINKED MUTATION IN FGFR
3611, d5cavA_, 0.7196, 3.24, 0.217, 306, 249, EGFR KINASE DOMAIN WITH COMPOUND 41A
3612, d4hnfA_, 0.7196, 3.20, 0.176, 289, 250, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3613, d3lxkA_, 0.7196, 3.22, 0.257, 279, 249, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3614, d5vamB_, 0.7195, 3.11, 0.216, 260, 245, BRAF IN COMPLEX WITH RAF709
3615, d5jfxA_, 0.7195, 2.72, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
3616, d4l01A_, 0.7195, 3.16, 0.225, 274, 249, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
3617, d4l00B_, 0.7195, 3.19, 0.221, 278, 249, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
3618, d4cv8A1, 0.7195, 2.68, 0.298, 252, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3619, d4ae6B_, 0.7195, 3.45, 0.238, 321, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3620, d3mtfB_, 0.7195, 3.00, 0.242, 298, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3621, d5tehB_, 0.7194, 2.65, 0.238, 262, 239, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
3622, d4wnmA1, 0.7194, 3.13, 0.215, 269, 247, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
3623, d4asdA_, 0.7194, 3.21, 0.204, 305, 250, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
3624, d4ag8A_, 0.7194, 3.22, 0.204, 296, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
3625, d2fo0A3, 0.7194, 3.32, 0.244, 291, 250, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
3626, d5kmkA1, 0.7193, 3.15, 0.230, 302, 248, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
3627, d4zsaB_, 0.7193, 3.34, 0.230, 282, 252, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3628, d3uysD_, 0.7193, 3.12, 0.170, 284, 247, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3629, d3u9nA_, 0.7193, 2.92, 0.276, 257, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3630, d5jfvA_, 0.7192, 2.72, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
3631, d5e1eB_, 0.7192, 3.18, 0.257, 280, 249, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3632, d3dqwD_, 0.7192, 3.19, 0.256, 276, 246, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3633, d2j0mB_, 0.7192, 2.71, 0.257, 257, 241, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
3634, d1sykB_, 0.7192, 3.23, 0.252, 323, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3635, d5kmjA_, 0.7191, 3.34, 0.233, 300, 249, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3636, d5khwA_, 0.7191, 3.09, 0.260, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3637, d4v05B_, 0.7191, 3.53, 0.227, 286, 255, FGFR1 IN COMPLEX WITH AZD4547.
3638, d4knbA_, 0.7191, 2.98, 0.212, 273, 245, C-MET IN COMPLEX WITH OSI LIGAND
3639, d4j99C_, 0.7191, 3.47, 0.224, 291, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3640, d3dk3B_, 0.7191, 3.35, 0.229, 269, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3641, d2x2kA1, 0.7191, 3.33, 0.253, 284, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3642, d2ivtA1, 0.7191, 3.33, 0.253, 283, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3643, d5j9yA_, 0.7190, 3.24, 0.217, 300, 249, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
3644, d5i9xA_, 0.7190, 3.15, 0.189, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
3645, d3u51B_, 0.7190, 2.57, 0.245, 255, 237, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
3646, d4uzhA1, 0.7189, 2.54, 0.308, 250, 237, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3647, d3ugcA_, 0.7189, 3.09, 0.255, 274, 247, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
3648, d5nk1A_, 0.7188, 3.24, 0.184, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
3649, d4fg8A_, 0.7188, 2.36, 0.289, 263, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3650, d3og7B_, 0.7188, 2.79, 0.212, 254, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3651, d2pwlA_, 0.7188, 3.35, 0.233, 284, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3652, d5cxhA1, 0.7187, 3.10, 0.211, 273, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
3653, d4gg7A_, 0.7187, 3.05, 0.214, 278, 248, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3654, d3wj6A_, 0.7187, 3.44, 0.234, 282, 252,  
3655, d3my0M1, 0.7187, 3.04, 0.241, 297, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3656, d3l9pA_, 0.7187, 3.35, 0.186, 303, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3657, d3gqlA_, 0.7187, 3.22, 0.240, 287, 250, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3658, d2wtkC1, 0.7187, 2.86, 0.285, 261, 242, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3659, d1snuB_, 0.7187, 2.44, 0.226, 241, 235, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3660, d5vc5A_, 0.7186, 2.92, 0.226, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3661, d5tq7A_, 0.7186, 3.07, 0.265, 275, 245, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3662, d5hu9A1, 0.7186, 3.21, 0.211, 262, 247, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
3663, d4z16A_, 0.7186, 3.02, 0.263, 271, 243, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3664, d4hgtA_, 0.7186, 3.16, 0.173, 283, 248, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3665, d4bb4A_, 0.7186, 2.90, 0.220, 265, 245, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3666, d3vf8A_, 0.7186, 3.12, 0.211, 265, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
3667, d2r0iA_, 0.7186, 2.63, 0.314, 300, 239, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3668, d2psqA_, 0.7186, 3.50, 0.218, 287, 252, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
3669, d2jflA_, 0.7186, 2.48, 0.274, 286, 237, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
3670, d5oy6C_, 0.7185, 2.94, 0.243, 291, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3671, d5jrsB1, 0.7185, 2.32, 0.210, 239, 233, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
3672, d4z16D_, 0.7185, 3.05, 0.272, 271, 243, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3673, d4focA_, 0.7185, 3.37, 0.187, 296, 251, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
3674, d1uwjA_, 0.7185, 3.13, 0.212, 264, 245, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3675, d5y8uA_, 0.7184, 2.75, 0.241, 267, 241, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
3676, d5nk6A_, 0.7184, 3.17, 0.185, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
3677, d5edqA_, 0.7184, 3.11, 0.206, 298, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
3678, d4k6zA_, 0.7184, 3.18, 0.258, 279, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
3679, d4itiA_, 0.7184, 3.29, 0.222, 272, 248, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3680, d4e5wB_, 0.7184, 3.19, 0.261, 278, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3681, d4cv9A1, 0.7184, 2.59, 0.300, 250, 240, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3682, d3g0eA1, 0.7184, 3.35, 0.215, 330, 251, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3683, d2xa4B_, 0.7184, 2.98, 0.270, 275, 244, INHIBITORS OF JAK2 KINASE DOMAIN
3684, d2hakE_, 0.7184, 3.10, 0.307, 318, 251, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3685, d2zvaA1, 0.7183, 3.11, 0.234, 260, 248, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
3686, p5x02A_, 0.7182, 3.10, 0.210, 305, 248, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
3687, d5ui0A_, 0.7182, 3.44, 0.228, 301, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
3688, d5tq7B_, 0.7182, 2.92, 0.263, 269, 243, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3689, d5nkbA_, 0.7182, 3.26, 0.184, 285, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
3690, d5nk9A_, 0.7182, 3.16, 0.185, 285, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
3691, d5nk2A_, 0.7182, 3.24, 0.184, 290, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
3692, d5kmiA_, 0.7182, 3.14, 0.226, 300, 248, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
3693, d5k9iB_, 0.7182, 2.73, 0.250, 262, 240, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
3694, d4jt3A_, 0.7182, 2.57, 0.296, 254, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
3695, d3k5vA1, 0.7182, 3.29, 0.224, 281, 250, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3696, d3fpqA_, 0.7182, 3.08, 0.259, 262, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
3697, d5wo4A_, 0.7181, 3.26, 0.256, 292, 250, JAK1 COMPLEXED WITH COMPOUND 28
3698, d4fvpA_, 0.7181, 3.11, 0.202, 274, 248, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
3699, d4fg7A_, 0.7181, 2.38, 0.279, 250, 233, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
3700, d3pa3A_, 0.7181, 2.95, 0.280, 259, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
3701, d3cekA1, 0.7181, 2.66, 0.298, 252, 242, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
3702, d3bu3A_, 0.7181, 3.33, 0.212, 294, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
3703, d2j0lA_, 0.7181, 3.19, 0.233, 274, 249, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
3704, d1qpjA_, 0.7181, 3.25, 0.235, 265, 247, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
3705, d5nk7A_, 0.7180, 3.33, 0.187, 284, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
3706, d5kmlA1, 0.7180, 3.24, 0.224, 290, 250, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3707, d4rwlA_, 0.7180, 3.47, 0.225, 282, 253, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3708, d4mneG_, 0.7180, 2.76, 0.200, 259, 240, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3709, d4d4sB_, 0.7180, 2.89, 0.242, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3710, d4cvaA1, 0.7180, 2.57, 0.300, 250, 240, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3711, d3my0B_, 0.7180, 3.05, 0.246, 295, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3712, d3dk7A_, 0.7180, 3.24, 0.239, 265, 247, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3713, d2x8iA_, 0.7180, 2.93, 0.272, 261, 243, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3714, d2hyyA_, 0.7180, 2.99, 0.228, 263, 246, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3715, d5nkcA_, 0.7179, 3.25, 0.184, 286, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
3716, d5jfwA_, 0.7179, 2.74, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
3717, d5hhwA_, 0.7179, 3.07, 0.196, 306, 250, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
3718, d5b7vA_, 0.7179, 3.37, 0.235, 282, 251, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3719, d4rx7A1, 0.7179, 3.17, 0.211, 270, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
3720, d4fk6B_, 0.7179, 3.31, 0.254, 284, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3721, d4c02A_, 0.7179, 3.18, 0.221, 313, 244, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
3722, d3socA1, 0.7179, 3.09, 0.234, 296, 244, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3723, d2hziB_, 0.7179, 3.33, 0.242, 264, 248, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3724, d6bu6B_, 0.7178, 3.37, 0.142, 307, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3725, d5am6B_, 0.7178, 3.03, 0.244, 280, 246, NATIVE FGFR1 WITH AN INHIBITOR
3726, d3rhxB_, 0.7178, 3.36, 0.243, 275, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3727, d2itnA_, 0.7178, 3.18, 0.214, 304, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
3728, d5cxzA1, 0.7177, 3.03, 0.196, 267, 245, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
3729, d4z16C_, 0.7177, 3.04, 0.263, 271, 243, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3730, d4p90A_, 0.7177, 2.74, 0.310, 272, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3731, d3g0fA_, 0.7177, 3.25, 0.221, 291, 249, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3732, d2pwlB_, 0.7177, 3.36, 0.233, 286, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3733, d2eb2A_, 0.7177, 3.32, 0.208, 305, 250, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
3734, d1xbaA1, 0.7177, 3.13, 0.211, 265, 246, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
3735, d5ugxB_, 0.7176, 3.25, 0.222, 282, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3736, d5khwB_, 0.7176, 3.09, 0.264, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3737, d4xliA_, 0.7176, 3.25, 0.228, 264, 246, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3738, d4bhzA1, 0.7176, 2.48, 0.303, 248, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3739, d3vo3A_, 0.7176, 3.30, 0.211, 303, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
3740, d3bceA_, 0.7176, 3.05, 0.211, 285, 246, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3741, d2xynA_, 0.7176, 3.16, 0.220, 264, 246, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3742, d5tq6B_, 0.7175, 3.02, 0.275, 271, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3743, d5lmbA_, 0.7175, 3.00, 0.212, 264, 245, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3744, d4bf2B_, 0.7175, 2.73, 0.307, 252, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3745, d3my0U1, 0.7175, 2.92, 0.244, 284, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3746, d3mtfA_, 0.7175, 2.91, 0.240, 296, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3747, d3beaA_, 0.7175, 3.19, 0.205, 310, 249, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
3748, d2ittA_, 0.7175, 3.22, 0.218, 302, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
3749, d2hziA_, 0.7175, 3.47, 0.235, 268, 251, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3750, d2c47D1, 0.7175, 3.31, 0.198, 289, 252, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3751, d1sm2A_, 0.7175, 2.52, 0.233, 245, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3752, d4rj5A_, 0.7174, 3.11, 0.198, 296, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
3753, d4o6lA_, 0.7174, 2.87, 0.296, 257, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3754, d4nk9B_, 0.7174, 3.49, 0.229, 282, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3755, d3dqwC_, 0.7174, 3.21, 0.256, 275, 246, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3756, d2etmA_, 0.7174, 3.00, 0.240, 262, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3757, d1f3mC_, 0.7174, 3.58, 0.297, 287, 256, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3758, p6c3eA_, 0.7173, 3.12, 0.230, 258, 244, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
3759, d5b2lA_, 0.7173, 3.28, 0.228, 288, 254, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
3760, d4k77A_, 0.7173, 3.22, 0.253, 282, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3761, d3lauA1, 0.7173, 2.52, 0.308, 250, 237, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3762, d2zv2A_, 0.7173, 2.81, 0.287, 256, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3763, d2xa4A_, 0.7173, 3.00, 0.275, 276, 244, INHIBITORS OF JAK2 KINASE DOMAIN
3764, d1uwjB_, 0.7173, 3.16, 0.208, 263, 245, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3765, d1pkgA_, 0.7173, 3.24, 0.243, 290, 247, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3766, d1m14A_, 0.7173, 3.22, 0.206, 307, 248, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
3767, d5oy6A_, 0.7172, 2.96, 0.243, 291, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3768, d5e8yA_, 0.7172, 3.05, 0.238, 298, 244, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
3769, d4k77B_, 0.7172, 3.23, 0.261, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3770, d4e5wA1, 0.7172, 3.21, 0.257, 291, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3771, d3my0N1, 0.7172, 3.02, 0.242, 299, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3772, d3ckwA_, 0.7172, 2.74, 0.271, 255, 240, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
3773, d2x2lA1, 0.7172, 3.36, 0.253, 282, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3774, d2wmrA_, 0.7172, 2.95, 0.289, 254, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3775, d2qhmA_, 0.7172, 3.04, 0.263, 268, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
3776, d4f0iA_, 0.7171, 3.09, 0.223, 284, 247, CRYSTAL STRUCTURE OF APO TRKA
3777, d4e4nB_, 0.7171, 3.24, 0.261, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3778, d3w2oA1, 0.7171, 3.26, 0.191, 304, 251, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
3779, d3nsvA_, 0.7171, 3.18, 0.224, 264, 246,  
3780, d2brhA_, 0.7171, 2.91, 0.277, 257, 242, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3781, d2b4sB_, 0.7171, 3.36, 0.205, 294, 249, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3782, d1pkgB_, 0.7171, 2.95, 0.218, 277, 243, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3783, p4e3cF1, 0.7170, 3.27, 0.271, 290, 251, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3784, d3my0A1, 0.7170, 3.03, 0.242, 295, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3785, d5kmmA1, 0.7169, 3.24, 0.233, 300, 249, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
3786, d5flfC_, 0.7169, 3.74, 0.241, 283, 253, DISEASE LINKED MUTATION IN FGFR
3787, d3pxkB_, 0.7169, 2.79, 0.241, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
3788, d3my0V1, 0.7169, 2.98, 0.243, 281, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3789, d3mdyC_, 0.7169, 3.12, 0.215, 320, 246, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3790, d3h10A_, 0.7169, 3.23, 0.306, 268, 248, AURORA A INHIBITOR COMPLEX
3791, d5aaaA_, 0.7168, 3.34, 0.192, 294, 250, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3792, d1oplB2, 0.7168, 3.33, 0.213, 267, 249, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3793, d4nkaB_, 0.7167, 3.47, 0.225, 287, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3794, d3zfxE_, 0.7167, 2.74, 0.220, 262, 241, CRYSTAL STRUCTURE OF EPHB1
3795, d3hmmA_, 0.7167, 2.90, 0.207, 293, 241, STRUCTURE OF ALK5 + GW855857
3796, d3bqrA1, 0.7167, 2.67, 0.253, 273, 237, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
3797, d3b2tA_, 0.7167, 3.32, 0.241, 288, 249, STRUCTURE OF PHOSPHOTRANSFERASE
3798, d1u54B_, 0.7167, 2.82, 0.262, 261, 240, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3799, d1sm2B_, 0.7167, 2.54, 0.226, 241, 235, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3800, d5xdlA_, 0.7166, 3.11, 0.195, 292, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
3801, d5t3qA1, 0.7166, 2.85, 0.216, 277, 241, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3802, d4bggD_, 0.7166, 2.93, 0.245, 286, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3803, d3en5B_, 0.7166, 2.64, 0.248, 261, 238, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
3804, d3clyA_, 0.7166, 3.42, 0.244, 289, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
3805, d2vwiC_, 0.7166, 2.65, 0.263, 270, 236, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
3806, d2ituA_, 0.7166, 3.21, 0.197, 304, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
3807, d2etmB_, 0.7166, 2.85, 0.239, 263, 243, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3808, d5tr6A1, 0.7165, 3.06, 0.212, 268, 245, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
3809, d2ja0A_, 0.7165, 2.63, 0.266, 285, 237,  
3810, d2eb3A_, 0.7165, 3.08, 0.199, 294, 246, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
3811, d1iepA1, 0.7165, 3.03, 0.223, 270, 247, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3812, d5xp7B_, 0.7164, 2.82, 0.242, 267, 240, C-SRC IN COMPLEX WITH ATP-CHCL
3813, d5vamA_, 0.7164, 3.32, 0.201, 269, 249, BRAF IN COMPLEX WITH RAF709
3814, d4twpA_, 0.7164, 3.11, 0.224, 266, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3815, d4mneC_, 0.7164, 2.79, 0.200, 260, 240, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3816, d4ivdB_, 0.7164, 3.24, 0.261, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3817, d4ivbB_, 0.7164, 3.24, 0.261, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3818, d3ztxA_, 0.7164, 3.08, 0.308, 269, 247, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
3819, d3krjA_, 0.7164, 3.07, 0.199, 304, 246, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
3820, d3eknA_, 0.7164, 3.51, 0.201, 297, 254, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3821, d2cmwA_, 0.7164, 3.26, 0.202, 294, 248, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
3822, d1opjB1, 0.7164, 3.18, 0.229, 284, 249, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3823, d5nkdA_, 0.7163, 3.23, 0.185, 287, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
3824, d5ek7A_, 0.7163, 3.17, 0.197, 286, 249, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3825, d4pp9B1, 0.7163, 2.63, 0.227, 246, 238, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
3826, d4j99B_, 0.7163, 3.41, 0.233, 291, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3827, d2xynC_, 0.7163, 3.19, 0.227, 262, 247, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3828, d2qhnA_, 0.7163, 3.06, 0.263, 268, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
3829, d1opjA1, 0.7163, 3.16, 0.226, 282, 248, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3830, d4rx8A1, 0.7162, 3.07, 0.200, 266, 245, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
3831, d4pmsA1, 0.7162, 3.08, 0.220, 279, 246, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
3832, d3efjA_, 0.7162, 2.94, 0.210, 276, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3833, d2ivuA1, 0.7162, 3.33, 0.254, 283, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
3834, d1snxB_, 0.7162, 2.56, 0.224, 245, 237, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3835, d5owrA_, 0.7161, 2.76, 0.325, 282, 240, HUMAN STK10 BOUND TO DASATINIB
3836, d5l4qB_, 0.7161, 2.67, 0.249, 287, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3837, d5edpA_, 0.7161, 3.20, 0.197, 295, 249, EGFR KINASE (T790M/L858R) APO
3838, d4r7hA_, 0.7161, 3.23, 0.205, 308, 249, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
3839, d4l01B_, 0.7161, 3.14, 0.227, 274, 247, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
3840, d4j96A_, 0.7161, 3.47, 0.232, 302, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
3841, d4fk6A_, 0.7161, 3.38, 0.250, 285, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3842, d4dymA_, 0.7161, 3.18, 0.245, 293, 245, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
3843, d4d58B_, 0.7161, 2.98, 0.242, 261, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3844, d3qgwA_, 0.7161, 2.59, 0.215, 244, 237, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
3845, d3dqwA_, 0.7161, 3.27, 0.259, 278, 247, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3846, d3dk6A_, 0.7161, 3.20, 0.241, 262, 245, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3847, d2uv2A1, 0.7161, 2.64, 0.274, 286, 237, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
3848, d1u54A_, 0.7161, 2.88, 0.266, 262, 241, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3849, d1snxA_, 0.7161, 2.58, 0.224, 245, 237, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3850, d1agwA_, 0.7161, 3.45, 0.234, 278, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3851, d5dlsA_, 0.7160, 2.93, 0.273, 257, 242, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
3852, d5c26A1, 0.7160, 3.00, 0.200, 271, 245, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
3853, d4i5cA_, 0.7160, 3.26, 0.261, 279, 249, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3854, d4gh2A_, 0.7160, 2.90, 0.278, 266, 241, CRYSTAL STRUCTURE OF THE CHK1
3855, d4fttA_, 0.7160, 3.08, 0.284, 266, 243, CRYSTAL STRUCTURE OF THE CHK1
3856, d3wj6B_, 0.7160, 3.24, 0.229, 277, 249,  
3857, d2vgoB_, 0.7160, 3.06, 0.301, 277, 246, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
3858, d1zycA1, 0.7160, 3.21, 0.271, 259, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3859, d5w86D_, 0.7159, 3.03, 0.255, 272, 243, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3860, d4nk9A_, 0.7159, 3.52, 0.233, 281, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3861, d3geqA1, 0.7159, 2.75, 0.247, 269, 239, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
3862, d2gqgA1, 0.7159, 3.33, 0.229, 271, 249, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3863, d5c03B_, 0.7158, 2.94, 0.218, 260, 243, CRYSTAL STRUCTURE OF KINASE
3864, d4othA_, 0.7158, 2.25, 0.293, 305, 232, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
3865, d3qtiA_, 0.7158, 3.29, 0.237, 292, 249, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3866, d2hznA2, 0.7158, 3.15, 0.223, 268, 247, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
3867, d2a19B1, 0.7158, 2.78, 0.266, 261, 237, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
3868, d5b7vB_, 0.7157, 3.25, 0.229, 277, 249, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3869, d4uxqA_, 0.7157, 3.66, 0.254, 286, 256, FGFR4 IN COMPLEX WITH PONATINIB
3870, d4twpB_, 0.7157, 3.36, 0.224, 271, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3871, d4fgbA_, 0.7157, 3.25, 0.262, 282, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
3872, p4e3cC1, 0.7157, 3.28, 0.275, 290, 251, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3873, d4e1zA_, 0.7157, 3.30, 0.236, 288, 250, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3874, d4asxA1, 0.7157, 2.87, 0.221, 295, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3875, d4aseA_, 0.7157, 3.25, 0.212, 305, 250, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
3876, d3vw6B_, 0.7157, 2.80, 0.301, 253, 239, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3877, d3dk3A_, 0.7157, 3.39, 0.237, 266, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3878, d2itwA_, 0.7157, 3.30, 0.221, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
3879, d1fgkA_, 0.7157, 3.44, 0.234, 278, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3880, d4cmoA_, 0.7156, 3.25, 0.189, 295, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
3881, d3vf9A_, 0.7156, 3.16, 0.211, 265, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
3882, d2ivsB1, 0.7156, 3.16, 0.241, 272, 245, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3883, d5t0pA_, 0.7155, 2.75, 0.243, 264, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3884, d5hieB_, 0.7155, 3.00, 0.206, 259, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3885, d4fodA_, 0.7155, 3.40, 0.187, 308, 251, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
3886, d4ckjA1, 0.7155, 3.40, 0.253, 287, 249, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
3887, d3efkA_, 0.7155, 2.92, 0.210, 276, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
3888, d3dqwB_, 0.7155, 3.29, 0.259, 278, 247, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3889, d2io6A_, 0.7155, 2.59, 0.226, 252, 235, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
3890, d4xliB_, 0.7154, 3.19, 0.216, 264, 245, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3891, d3nsvC_, 0.7154, 3.15, 0.220, 262, 246,  
3892, d3geqB1, 0.7154, 2.83, 0.250, 270, 240, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
3893, d3efjB_, 0.7154, 2.90, 0.215, 275, 242, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3894, d5hx6A_, 0.7153, 3.23, 0.228, 259, 246, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
3895, d4j95B_, 0.7153, 3.49, 0.237, 282, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3896, d4ivcB_, 0.7153, 3.24, 0.253, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3897, d4dfyA_, 0.7153, 3.05, 0.271, 310, 247, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3898, d4cljA_, 0.7153, 3.39, 0.187, 295, 251, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3899, d3socB1, 0.7153, 2.90, 0.217, 294, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3900, d3ri1A_, 0.7153, 3.34, 0.236, 285, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
3901, d3my0W1, 0.7153, 2.95, 0.244, 280, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3902, d5v19A_, 0.7152, 2.85, 0.305, 250, 239, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3903, d5ut4A_, 0.7152, 3.13, 0.198, 273, 248, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
3904, d5edrA_, 0.7152, 3.19, 0.198, 299, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
3905, d4ftrA_, 0.7152, 3.00, 0.289, 258, 242, CRYSTAL STRUCTURE OF THE CHK1
3906, d4dggB_, 0.7152, 2.61, 0.253, 259, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
3907, d4c4iA1, 0.7152, 2.60, 0.296, 250, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3908, d2ityA1, 0.7152, 3.08, 0.220, 299, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
3909, d2itvA_, 0.7152, 3.35, 0.209, 303, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
3910, d2c47B_, 0.7152, 3.36, 0.191, 289, 251, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3911, d3op5B_, 0.7151, 3.46, 0.141, 319, 256, HUMAN VACCINIA-RELATED KINASE 1
3912, d3k5vB1, 0.7151, 3.18, 0.219, 279, 247, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3913, d3dqxB_, 0.7151, 3.03, 0.242, 268, 244, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3914, d2zv8A1, 0.7151, 3.07, 0.211, 256, 246, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
3915, d5jt2B1, 0.7150, 2.72, 0.222, 250, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3916, d5j7hA_, 0.7150, 3.16, 0.190, 291, 247, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
3917, d5htiA_, 0.7150, 3.46, 0.214, 290, 252, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
3918, d5hesB_, 0.7150, 2.61, 0.256, 278, 234, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3919, d5e91A_, 0.7150, 3.27, 0.240, 297, 246, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
3920, d4j98A_, 0.7150, 3.53, 0.232, 304, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
3921, d4f64A_, 0.7150, 3.47, 0.234, 278, 252, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3922, d4ccbA_, 0.7150, 3.25, 0.190, 287, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
3923, d4c61B_, 0.7150, 3.01, 0.276, 274, 243, INHIBITORS OF JAK2 KINASE DOMAIN
3924, d3kf4A_, 0.7150, 3.30, 0.223, 281, 247, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3925, d5x18B_, 0.7149, 3.62, 0.195, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3926, d5kz0A_, 0.7149, 3.31, 0.189, 293, 249, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
3927, d4xg3B_, 0.7149, 2.94, 0.193, 267, 243, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3928, d4cliA_, 0.7149, 3.36, 0.188, 294, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3929, d2ym6A_, 0.7149, 2.95, 0.290, 253, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3930, d2hiwA1, 0.7149, 3.16, 0.238, 270, 248, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3931, d1iepB1, 0.7149, 3.06, 0.223, 270, 247, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3932, d5ghvB_, 0.7148, 3.00, 0.201, 265, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3933, d5ftoA1, 0.7148, 3.42, 0.187, 297, 252, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
3934, d5ew9A_, 0.7148, 3.02, 0.288, 257, 243, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
3935, d4xg5B_, 0.7148, 3.00, 0.201, 265, 244,  
3936, d3lvpB_, 0.7148, 3.33, 0.214, 295, 252, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3937, d2bdjA_, 0.7148, 2.82, 0.246, 254, 240, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
3938, d1zydB1, 0.7148, 2.82, 0.271, 251, 240, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
3939, d5nk4A_, 0.7147, 3.17, 0.185, 290, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
3940, d5hx8B_, 0.7147, 3.23, 0.246, 279, 248, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3941, d5c03A_, 0.7147, 2.87, 0.216, 260, 241, CRYSTAL STRUCTURE OF KINASE
3942, d4d4yB_, 0.7147, 3.00, 0.242, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3943, d4agcA_, 0.7147, 3.41, 0.210, 304, 252, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
3944, d1zxeC1, 0.7147, 3.10, 0.265, 265, 245, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
3945, d1snuA_, 0.7147, 2.61, 0.228, 245, 237, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3946, d1opkA3, 0.7147, 3.57, 0.243, 291, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3947, d1oecA_, 0.7147, 3.32, 0.243, 280, 247, FGFR2 KINASE DOMAIN
3948, d5nkeA_, 0.7146, 3.54, 0.196, 292, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
3949, d5c27A1, 0.7146, 3.12, 0.199, 271, 246, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
3950, d5aa9A_, 0.7146, 3.37, 0.192, 295, 250, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3951, d4f63A_, 0.7146, 3.47, 0.234, 278, 252, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3952, d3ms9B1, 0.7146, 2.98, 0.229, 267, 245, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
3953, d5lmaA_, 0.7145, 3.07, 0.204, 267, 245, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3954, d4ft5A_, 0.7145, 3.05, 0.277, 265, 242, CRYSTAL STRUCTURE OF THE CHK1
3955, d4fsmA_, 0.7145, 3.00, 0.270, 265, 241, CRYSTAL STRUCTURE OF THE CHK1
3956, d4cmuA_, 0.7145, 3.37, 0.188, 294, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3957, d3i5nA_, 0.7145, 3.47, 0.222, 280, 248, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
3958, d3f6xA_, 0.7145, 2.72, 0.248, 264, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3959, d3etaB_, 0.7145, 3.28, 0.201, 292, 249, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3960, d5wo4B_, 0.7144, 3.27, 0.261, 280, 249, JAK1 COMPLEXED WITH COMPOUND 28
3961, d4jikA_, 0.7144, 2.94, 0.290, 256, 241, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
3962, d4ivbA1, 0.7144, 3.23, 0.254, 290, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3963, d4gt5A_, 0.7144, 3.27, 0.232, 290, 250, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
3964, d4f64B_, 0.7144, 3.20, 0.242, 272, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3965, d4ei4B_, 0.7144, 3.27, 0.261, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3966, d4d5hB_, 0.7144, 3.01, 0.242, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3967, d4ae9B_, 0.7144, 3.36, 0.249, 321, 249, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3968, d3zewA_, 0.7144, 3.07, 0.220, 269, 245, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
3969, d3srvB_, 0.7144, 2.98, 0.193, 263, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3970, d3g6hA_, 0.7144, 2.87, 0.249, 266, 241, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
3971, d3b2wA_, 0.7144, 2.99, 0.225, 261, 244, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
3972, d2b4sD_, 0.7144, 3.38, 0.205, 294, 249, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3973, d1mqbB_, 0.7144, 2.86, 0.210, 265, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3974, d6eimA_, 0.7143, 2.72, 0.324, 286, 238, HUMAN STK10 BOUND TO GW683134A
3975, d5ct7A_, 0.7143, 3.00, 0.202, 257, 242, BRAF IN COMPLEX WITH RAF265
3976, d4rwkB_, 0.7143, 3.41, 0.231, 282, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3977, d4px6A1, 0.7143, 3.00, 0.202, 261, 243, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
3978, d4hw7A_, 0.7143, 3.22, 0.206, 289, 248, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
3979, d5imxA_, 0.7142, 2.91, 0.191, 266, 241, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
3980, d4xg4A_, 0.7142, 2.77, 0.203, 264, 241, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3981, d3q4tB1, 0.7142, 2.90, 0.221, 293, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3982, d3f6xC_, 0.7142, 2.75, 0.248, 265, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3983, d5ghvA_, 0.7141, 3.01, 0.201, 265, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3984, d4xg5A_, 0.7141, 3.01, 0.201, 265, 244,  
3985, d4fswA_, 0.7141, 2.97, 0.290, 265, 241, CRYSTAL STRUCTURE OF THE CHK1
3986, d4dfnA1, 0.7141, 3.14, 0.199, 268, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
3987, d4b8mA_, 0.7141, 3.10, 0.308, 270, 247, AURORA B KINASE IN COMPLEX WITH VX-680
3988, d3w2pA1, 0.7141, 3.36, 0.194, 307, 252, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
3989, d3srvA_, 0.7141, 2.97, 0.202, 262, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3990, d3pa4A_, 0.7141, 2.96, 0.277, 257, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
3991, d3orkA1, 0.7141, 2.74, 0.266, 272, 237, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
3992, d3cs9A_, 0.7141, 3.13, 0.224, 264, 246, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3993, d2ofuA_, 0.7141, 3.38, 0.234, 272, 248, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
3994, d5jrqB1, 0.7140, 2.43, 0.219, 245, 233, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3995, d5amnA1, 0.7140, 3.36, 0.254, 282, 248, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
3996, d4v0gA_, 0.7140, 3.18, 0.258, 267, 244, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3997, d4aojB_, 0.7140, 2.73, 0.229, 258, 240, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3998, d3zepC_, 0.7140, 3.00, 0.256, 276, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3999, d3h10B_, 0.7140, 3.17, 0.308, 267, 247, AURORA A INHIBITOR COMPLEX
4000, d3fqeA1, 0.7140, 3.01, 0.202, 265, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
4001, d4yznA_, 0.7139, 3.21, 0.225, 269, 244, HUMANIZED ROCO4 BOUND TO COMPOUND 19
4002, d4wkqA1, 0.7139, 3.17, 0.213, 294, 244, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
4003, d4m7iA1, 0.7139, 2.46, 0.266, 246, 233, CRYSTAL STRUCTURE OF GSK6157 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.34A RESOLUTION
4004, d4lueB3, 0.7139, 2.42, 0.263, 256, 232, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
4005, d4ftcA_, 0.7139, 2.93, 0.267, 266, 240, CRYSTAL STRUCTURE OF THE CHK1
4006, d3orpA_, 0.7139, 2.89, 0.259, 274, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4007, d1oplA3, 0.7139, 3.57, 0.243, 291, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4008, d1fgiB_, 0.7139, 3.27, 0.241, 272, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4009, d4xg9B_, 0.7138, 3.02, 0.201, 265, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4010, d4v04B_, 0.7138, 3.51, 0.213, 287, 253, FGFR1 IN COMPLEX WITH PONATINIB.
4011, d4ftaA_, 0.7138, 2.94, 0.287, 264, 240, CRYSTAL STRUCTURE OF THE CHK1
4012, d1fpuA1, 0.7138, 3.21, 0.225, 271, 249, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4013, d5kmoA1, 0.7137, 3.11, 0.229, 290, 245, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
4014, d5itaB_, 0.7137, 2.55, 0.204, 252, 235, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4015, d4xeyA_, 0.7137, 3.22, 0.240, 269, 246, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
4016, d4ehzA_, 0.7137, 3.30, 0.256, 290, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4017, d3c4dB1, 0.7137, 2.76, 0.201, 256, 239,  
4018, d3bizA_, 0.7137, 2.63, 0.226, 250, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
4019, d5a4cA_, 0.7136, 3.51, 0.234, 294, 252, FGFR1 LIGAND COMPLEX
4020, d4r7iA_, 0.7136, 3.22, 0.206, 290, 248, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
4021, d4kbkA_, 0.7136, 3.09, 0.180, 283, 245, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4022, d3my0F1, 0.7136, 2.97, 0.244, 293, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4023, d3lvpA_, 0.7136, 3.29, 0.215, 289, 251, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4024, d3ik3A1, 0.7136, 3.35, 0.221, 279, 249, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4025, d4j97A_, 0.7135, 3.35, 0.232, 282, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4026, d4hzrA_, 0.7135, 2.91, 0.257, 261, 241, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
4027, d4e4lD_, 0.7135, 3.25, 0.257, 281, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4028, d3v8tB1, 0.7135, 2.50, 0.226, 242, 235, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4029, d3my0G1, 0.7135, 2.98, 0.244, 293, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4030, d3my0C1, 0.7135, 3.03, 0.243, 298, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4031, d2psqB_, 0.7135, 3.48, 0.224, 286, 250, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
4032, d1qpdA_, 0.7135, 3.49, 0.230, 270, 248, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4033, d1gjoA_, 0.7135, 3.34, 0.243, 280, 247, THE FGFR2 TYROSINE KINASE DOMAIN
4034, d1fvrB_, 0.7135, 3.32, 0.233, 300, 249, TIE2 KINASE DOMAIN
4035, d5w86C_, 0.7134, 2.95, 0.261, 273, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4036, d5ugxA_, 0.7134, 3.43, 0.222, 297, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
4037, d5bvkA_, 0.7134, 3.62, 0.215, 278, 256, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4038, d3my0R1, 0.7134, 2.98, 0.244, 293, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4039, d3my0Q1, 0.7134, 2.98, 0.244, 293, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4040, d3alnA_, 0.7134, 2.63, 0.254, 270, 236, CRYSTAL STRUCTURE OF HUMAN NON-PHOSPHORYLATED MKK4 KINASE DOMAIN COMPLEXED WITH AMP-PNP
4041, d2qluA1, 0.7134, 3.35, 0.211, 295, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
4042, d2hakD_, 0.7134, 2.90, 0.322, 309, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4043, d5k3yB_, 0.7133, 3.14, 0.312, 277, 247, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
4044, d3zmmB_, 0.7133, 3.05, 0.280, 274, 243, INHIBITORS OF JAK2 KINASE DOMAIN
4045, d2i0yA_, 0.7133, 3.20, 0.206, 289, 247, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4046, d4e4nA1, 0.7132, 3.26, 0.254, 290, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4047, d3v5lD1, 0.7132, 2.66, 0.228, 244, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4048, d3kk8A_, 0.7132, 3.37, 0.280, 283, 250, CAMKII SUBSTRATE COMPLEX A
4049, d3db8A_, 0.7132, 2.63, 0.264, 261, 235, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4050, d1k9aE3, 0.7132, 2.72, 0.226, 268, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4051, d5hieA_, 0.7131, 2.97, 0.195, 258, 241, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4052, d5c9cA_, 0.7131, 2.98, 0.199, 254, 241, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4053, d4ypsA1, 0.7131, 3.01, 0.222, 275, 243, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4054, d4i0sA1, 0.7131, 3.02, 0.214, 263, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
4055, d4g31A1, 0.7131, 2.59, 0.261, 247, 234, CRYSTAL STRUCTURE OF GSK6414 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.28 A RESOLUTION
4056, d3ug1A_, 0.7131, 3.26, 0.212, 296, 245, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
4057, d3sxrA1, 0.7131, 2.92, 0.219, 257, 242, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4058, d3qgyA1, 0.7131, 2.57, 0.216, 244, 236, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4059, d3gfwA1, 0.7131, 2.63, 0.297, 249, 239, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4060, d2vgoA_, 0.7131, 3.12, 0.308, 268, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
4061, d2bfxA_, 0.7131, 3.13, 0.308, 269, 247, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
4062, d1u46B_, 0.7131, 2.71, 0.270, 257, 237, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4063, d5ut1A_, 0.7130, 3.12, 0.194, 272, 247, JAK2 JH2 IN COMPLEX WITH BI-D1870
4064, d5nkhA_, 0.7130, 3.56, 0.200, 295, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
4065, d5fboA_, 0.7130, 2.88, 0.198, 255, 243, BTK-INHIBITOR CO-STRUCTURE
4066, d4f63B_, 0.7130, 3.25, 0.238, 271, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4067, d3gvuA1, 0.7130, 3.22, 0.219, 261, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
4068, d2ivvA1, 0.7130, 3.29, 0.256, 277, 246, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
4069, d2c47A_, 0.7130, 3.35, 0.188, 288, 250, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4070, d1agwB_, 0.7130, 3.23, 0.238, 272, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4071, d5uszA_, 0.7129, 3.13, 0.198, 272, 247, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
4072, d5l4qA_, 0.7129, 2.71, 0.249, 293, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4073, d5aabA_, 0.7129, 3.31, 0.194, 293, 248, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4074, d4nksB_, 0.7129, 3.26, 0.238, 271, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
4075, d4kabB_, 0.7129, 2.98, 0.238, 258, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4076, d4itiB_, 0.7129, 3.27, 0.219, 270, 247, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
4077, d4gg5A_, 0.7129, 3.20, 0.224, 274, 245, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4078, d4c62A_, 0.7129, 2.98, 0.277, 273, 242, INHIBITORS OF JAK2 KINASE DOMAIN
4079, d3my0H1, 0.7129, 2.99, 0.244, 293, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4080, d5vd2A_, 0.7128, 2.89, 0.216, 258, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
4081, d5vc3A_, 0.7128, 2.94, 0.211, 260, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4082, d4yneA1, 0.7128, 3.08, 0.237, 276, 245, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4083, d3kmmA_, 0.7128, 3.44, 0.230, 270, 248, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
4084, d3h9fA1, 0.7128, 2.96, 0.290, 256, 245, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4085, d3bymA_, 0.7128, 3.48, 0.234, 271, 248, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
4086, d5xy1A1, 0.7127, 2.97, 0.218, 252, 243, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
4087, d5ut6A_, 0.7127, 3.13, 0.198, 272, 247, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
4088, d4mxcA_, 0.7127, 3.43, 0.203, 290, 251, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4089, d4c4gA1, 0.7127, 2.49, 0.300, 247, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4090, d3vjnA_, 0.7127, 3.23, 0.211, 297, 246, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
4091, d3ue4B_, 0.7127, 3.43, 0.254, 268, 248, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
4092, d3my0E1, 0.7127, 3.00, 0.240, 293, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4093, d3c4cB1, 0.7127, 2.76, 0.205, 256, 239, B-RAF KINASE IN COMPLEX WITH PLX4720
4094, d2bfyA_, 0.7127, 3.13, 0.312, 270, 247, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
4095, d5ut5A_, 0.7126, 3.12, 0.198, 272, 247, JAK2 JH2 IN COMPLEX WITH GLPG0634
4096, d5ttuA_, 0.7126, 3.15, 0.258, 271, 244, JAK3 WITH COVALENT INHIBITOR 7
4097, d5o26B_, 0.7126, 3.11, 0.255, 265, 243, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
4098, d4mxzA_, 0.7126, 2.94, 0.249, 266, 241, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4099, d4mxyA_, 0.7126, 2.94, 0.249, 266, 241, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4100, d4gu9B_, 0.7126, 2.97, 0.238, 255, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4101, d3zmmA_, 0.7126, 2.98, 0.273, 273, 242, INHIBITORS OF JAK2 KINASE DOMAIN
4102, d3my0S1, 0.7126, 3.00, 0.244, 293, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4103, d2c47C_, 0.7126, 3.10, 0.200, 282, 245, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4104, d1yi6B_, 0.7126, 3.20, 0.236, 274, 246, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4105, d5ut0A_, 0.7125, 3.14, 0.198, 272, 247, JAK2 JH2 IN COMPLEX WITH AT9283
4106, d4xlvA_, 0.7125, 3.27, 0.206, 307, 248, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
4107, d4v0gB_, 0.7125, 3.23, 0.262, 272, 244, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
4108, d4trlA_, 0.7125, 3.02, 0.197, 268, 244, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4109, d3kf4B_, 0.7125, 3.42, 0.222, 270, 248, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4110, d2r0uA_, 0.7125, 3.08, 0.267, 269, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4111, d2bfyB_, 0.7125, 3.16, 0.312, 278, 247, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
4112, d4rssA_, 0.7124, 3.21, 0.202, 269, 247, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
4113, d4puzA_, 0.7124, 3.13, 0.197, 263, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4114, d4j99A_, 0.7124, 3.42, 0.234, 280, 248, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4115, d4ehzB_, 0.7124, 3.27, 0.253, 280, 249, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4116, d4dggA_, 0.7124, 2.69, 0.252, 261, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4117, d3v5lC1, 0.7124, 2.59, 0.225, 242, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4118, d3bhhD1, 0.7124, 3.13, 0.318, 285, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4119, d1fgkB_, 0.7124, 3.23, 0.242, 272, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4120, d5ut3A_, 0.7123, 3.14, 0.198, 272, 247, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
4121, d4uynA_, 0.7123, 2.59, 0.311, 249, 238, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4122, d4useB_, 0.7123, 2.88, 0.318, 278, 239, HUMAN STK10 (LOK) WITH SB-633825
4123, d4itjA_, 0.7123, 3.10, 0.239, 261, 243, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4124, d3g6gB_, 0.7123, 2.86, 0.246, 263, 240, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4125, d3efkB_, 0.7123, 2.94, 0.215, 272, 242, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4126, d3cc6A_, 0.7123, 2.93, 0.215, 269, 246, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
4127, d6bqlA1, 0.7122, 3.21, 0.291, 276, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
4128, d5i9zA_, 0.7122, 3.00, 0.197, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
4129, d3vjoA_, 0.7122, 3.46, 0.213, 298, 249, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
4130, d2vwiB_, 0.7122, 2.95, 0.262, 264, 237, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4131, d2a1aB1, 0.7122, 2.84, 0.257, 266, 237, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4132, d5ut2A_, 0.7121, 3.15, 0.206, 273, 247, JAK2 JH2 IN COMPLEX WITH PRT062607
4133, d5uhnA_, 0.7121, 3.77, 0.215, 282, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4134, d5j9zA_, 0.7121, 3.01, 0.205, 291, 244, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
4135, d5i9vA_, 0.7121, 2.97, 0.197, 279, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
4136, d5hlwA_, 0.7121, 3.22, 0.220, 284, 246, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
4137, d4i5cB1, 0.7121, 3.27, 0.254, 290, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4138, d3dqxA_, 0.7121, 3.02, 0.247, 267, 243, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4139, d3dbdA_, 0.7121, 2.65, 0.264, 261, 235, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4140, d2ijmB_, 0.7121, 2.89, 0.244, 261, 242, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4141, d5tf9A_, 0.7120, 2.60, 0.253, 262, 233, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4142, d5k3yA_, 0.7120, 3.13, 0.312, 267, 247, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
4143, d4mneF_, 0.7120, 2.93, 0.204, 258, 240, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4144, d4fyoA1, 0.7120, 2.90, 0.203, 263, 241, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
4145, d3my0D1, 0.7120, 3.01, 0.244, 297, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4146, d3kxzA_, 0.7120, 3.26, 0.236, 263, 246, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
4147, d2jkmA_, 0.7120, 2.86, 0.244, 260, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4148, d4ivcA1, 0.7119, 3.26, 0.254, 290, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4149, d4b8mB_, 0.7119, 3.25, 0.300, 279, 247, AURORA B KINASE IN COMPLEX WITH VX-680
4150, d2vrxA_, 0.7119, 3.13, 0.308, 268, 247, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
4151, d5iuiA_, 0.7118, 3.48, 0.186, 303, 253, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
4152, d5em5A_, 0.7118, 3.18, 0.198, 298, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4153, d4j95C_, 0.7118, 3.56, 0.233, 281, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4154, d1qpcA_, 0.7118, 3.35, 0.235, 270, 247, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4155, d5tx5A_, 0.7117, 3.17, 0.233, 259, 245, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4156, d5mjbA_, 0.7117, 3.17, 0.219, 276, 247, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
4157, d3h3cA_, 0.7117, 2.89, 0.206, 263, 243, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
4158, d3gxjA_, 0.7117, 3.08, 0.202, 288, 242,  
4159, d1zmuB_, 0.7117, 2.53, 0.311, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4160, d5cswA_, 0.7116, 2.75, 0.210, 254, 238, B-RAF IN COMPLEX WITH DABRAFENIB
4161, d4tt7A_, 0.7116, 3.27, 0.186, 291, 247, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
4162, d4hzrB_, 0.7116, 2.79, 0.261, 258, 238, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
4163, d5dg5B_, 0.7115, 3.48, 0.213, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4164, d3cd8A_, 0.7115, 3.44, 0.232, 278, 246, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4165, d2of4A_, 0.7115, 3.50, 0.230, 271, 248, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
4166, d4rwjB_, 0.7114, 3.35, 0.232, 282, 250, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4167, d4j95D_, 0.7114, 3.13, 0.230, 271, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4168, d3fqsA1, 0.7114, 3.04, 0.202, 264, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
4169, d5e92A_, 0.7113, 3.31, 0.233, 298, 245, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
4170, d4rvlA_, 0.7113, 3.00, 0.278, 258, 241, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
4171, d4pv0A1, 0.7113, 3.09, 0.209, 266, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
4172, d4knbB_, 0.7113, 3.03, 0.242, 256, 240, C-MET IN COMPLEX WITH OSI LIGAND
4173, d4j97C_, 0.7113, 3.50, 0.223, 283, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4174, d3efwB_, 0.7113, 2.39, 0.306, 242, 232, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4175, d4j95A_, 0.7112, 3.62, 0.224, 279, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4176, d4i0tA1, 0.7112, 2.82, 0.204, 262, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
4177, d3nsvB_, 0.7112, 3.35, 0.226, 264, 248,  
4178, d3my0I1, 0.7112, 2.97, 0.241, 292, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4179, d3ii5B_, 0.7112, 2.93, 0.195, 257, 241, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4180, d2fgiB_, 0.7112, 3.24, 0.234, 272, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4181, d4puzB_, 0.7111, 2.96, 0.202, 265, 242, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4182, d4k8aB_, 0.7111, 2.84, 0.240, 258, 242, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4183, d4ibmA_, 0.7111, 3.32, 0.208, 301, 250, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4184, d4hgtB_, 0.7111, 3.04, 0.177, 280, 243, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4185, d4c61A_, 0.7111, 3.06, 0.277, 272, 242, INHIBITORS OF JAK2 KINASE DOMAIN
4186, d3f6xD_, 0.7110, 2.89, 0.242, 267, 240, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4187, d2py3A_, 0.7110, 3.35, 0.220, 282, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4188, d1f3mD_, 0.7110, 3.55, 0.289, 285, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4189, d5ceoA_, 0.7109, 2.56, 0.291, 269, 234, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
4190, d4xg6A1, 0.7109, 3.05, 0.201, 270, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4191, d4kspA_, 0.7109, 2.81, 0.206, 257, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4192, d4ivdA1, 0.7109, 3.24, 0.259, 289, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4193, d4c2wA_, 0.7109, 3.15, 0.308, 268, 247, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4194, d3ug2A_, 0.7109, 3.28, 0.215, 299, 247, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
4195, d3gxlA_, 0.7109, 2.96, 0.200, 285, 240, ALK-5 KINASE COMPLEX WITH GW857175
4196, d5ct7B_, 0.7108, 2.74, 0.203, 254, 237, BRAF IN COMPLEX WITH RAF265
4197, d4c2vB_, 0.7108, 3.17, 0.305, 280, 246, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
4198, d3l8vA_, 0.7108, 3.33, 0.211, 293, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
4199, d3jvrA_, 0.7108, 3.02, 0.278, 258, 241, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4200, d2fgiA_, 0.7108, 3.52, 0.231, 274, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4201, d6bp0D_, 0.7107, 3.55, 0.155, 311, 252, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4202, d5uvfA_, 0.7107, 3.38, 0.142, 317, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4203, d2oiqA_, 0.7107, 2.89, 0.241, 265, 241, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4204, d1p4oA_, 0.7107, 3.39, 0.204, 308, 250, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4205, d5tt7A1, 0.7106, 3.09, 0.209, 270, 244, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
4206, d5jt2A1, 0.7106, 2.86, 0.222, 253, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4207, d5hieC_, 0.7106, 2.91, 0.204, 253, 240, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4208, d4j99D_, 0.7106, 3.28, 0.244, 281, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4209, d4ccuA_, 0.7106, 3.22, 0.187, 292, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
4210, d3ac5A_, 0.7106, 3.40, 0.231, 270, 247, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4211, d3ac1A_, 0.7106, 3.40, 0.228, 270, 246, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4212, d2vwyA_, 0.7106, 3.08, 0.203, 274, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4213, d1fpuB1, 0.7106, 3.33, 0.222, 266, 248, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4214, d6b8uA_, 0.7105, 2.89, 0.197, 253, 239, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4215, d5c01B_, 0.7105, 2.96, 0.219, 260, 242, CRYSTAL STRUCTURE OF KINASE
4216, d5b2kA_, 0.7105, 2.76, 0.237, 264, 240, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4217, d4f65A_, 0.7105, 3.52, 0.235, 279, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4218, d2zv9A1, 0.7105, 3.09, 0.216, 255, 245, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
4219, d2xynB_, 0.7105, 3.28, 0.227, 264, 247, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4220, d2x81A_, 0.7105, 2.41, 0.309, 242, 233, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4221, d4xg3A_, 0.7104, 2.82, 0.200, 262, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4222, d4v01B_, 0.7104, 3.42, 0.217, 275, 249, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4223, d3v5lA1, 0.7104, 2.42, 0.227, 238, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4224, d3qlgB_, 0.7104, 2.71, 0.245, 260, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4225, d2oiqB_, 0.7104, 2.88, 0.246, 265, 240, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4226, d4pp9A1, 0.7103, 2.67, 0.224, 245, 237, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4227, d4j97B_, 0.7103, 3.30, 0.233, 283, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4228, d4fynA1, 0.7103, 2.90, 0.199, 263, 241, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
4229, d4agdA_, 0.7103, 3.33, 0.208, 303, 250, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
4230, d3ac4A_, 0.7103, 3.38, 0.235, 270, 247, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4231, d2of2A_, 0.7103, 3.37, 0.231, 271, 247, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
4232, d1p4oB_, 0.7103, 3.39, 0.212, 314, 250, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4233, d1mrvA_, 0.7103, 2.28, 0.294, 261, 231, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4234, d5j5sB_, 0.7102, 2.60, 0.247, 258, 235, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4235, d5fedA_, 0.7102, 3.18, 0.213, 288, 244, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
4236, d3gqlB_, 0.7102, 3.19, 0.239, 276, 247, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4237, d2i0vA_, 0.7102, 3.21, 0.206, 303, 247, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
4238, d2e2bA1, 0.7102, 3.30, 0.224, 266, 246, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4239, d1u46A_, 0.7102, 2.90, 0.273, 255, 238, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4240, d5uafA_, 0.7101, 3.28, 0.231, 291, 242, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4241, d5uadA_, 0.7101, 3.28, 0.231, 291, 242, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4242, d5kbrA_, 0.7101, 2.61, 0.313, 259, 233, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4243, d3og7A_, 0.7101, 2.49, 0.210, 247, 233, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4244, d3ad4A_, 0.7101, 3.41, 0.231, 270, 247, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4245, d4xeyB2, 0.7100, 3.17, 0.235, 264, 243, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
4246, d4c2wB_, 0.7100, 3.18, 0.305, 277, 246, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4247, d4anqA_, 0.7100, 3.35, 0.190, 293, 248, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4248, d3f6xB_, 0.7100, 2.92, 0.246, 267, 240, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4249, d6bp0B_, 0.7099, 3.48, 0.151, 304, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4250, d5c01A_, 0.7099, 2.89, 0.217, 258, 240, CRYSTAL STRUCTURE OF KINASE
4251, d3idpA_, 0.7099, 3.04, 0.194, 255, 242, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4252, d2zv7A1, 0.7099, 3.09, 0.216, 256, 245, LYN TYROSINE KINASE DOMAIN APO FORM
4253, d5v24A_, 0.7098, 2.89, 0.298, 249, 238, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4254, d5t0pB_, 0.7098, 2.83, 0.251, 263, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4255, d5nk3A_, 0.7098, 3.30, 0.201, 281, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
4256, d5j5sA_, 0.7098, 2.69, 0.253, 258, 237, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4257, d5ceqA_, 0.7098, 2.59, 0.291, 269, 234, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
4258, d4d55A_, 0.7098, 3.06, 0.238, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4259, d3v5qB1, 0.7098, 3.02, 0.219, 262, 242, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4260, d3acjA_, 0.7098, 3.41, 0.228, 270, 246, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4261, d2x2mA1, 0.7098, 3.38, 0.252, 281, 246, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4262, d2vx1A_, 0.7098, 3.09, 0.203, 274, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4263, d1bygA_, 0.7098, 2.62, 0.229, 246, 236, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
4264, d6bp0A_, 0.7097, 3.40, 0.146, 317, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4265, d3my0T1, 0.7097, 2.95, 0.242, 291, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4266, d3ac2A_, 0.7097, 3.47, 0.231, 270, 247, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4267, d2zm1A_, 0.7097, 3.46, 0.231, 270, 247, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4268, d6btwA_, 0.7096, 3.48, 0.154, 317, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4269, d5w5jB_, 0.7096, 2.74, 0.214, 257, 238, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4270, d5vo1A_, 0.7096, 2.60, 0.291, 269, 234, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
4271, d4knbC_, 0.7096, 3.35, 0.234, 271, 244, C-MET IN COMPLEX WITH OSI LIGAND
4272, d4g34A1, 0.7096, 2.54, 0.283, 247, 233, CRYSTAL STRUCTURE OF GSK6924 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.70 A RESOLUTION
4273, d2wmvA_, 0.7096, 2.92, 0.276, 251, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4274, d5uglA_, 0.7095, 3.60, 0.225, 285, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4275, d5cepA_, 0.7095, 2.58, 0.291, 269, 234, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
4276, d4fsqA_, 0.7095, 3.03, 0.283, 263, 240, CRYSTAL STRUCTURE OF THE CHK1
4277, d4e4lE_, 0.7095, 3.28, 0.258, 280, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4278, d4cqeA_, 0.7095, 2.72, 0.198, 250, 237, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4279, d3lckA_, 0.7095, 3.41, 0.228, 270, 246, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
4280, d3ac3A_, 0.7095, 3.46, 0.235, 270, 247, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4281, d5ftqA1, 0.7094, 3.29, 0.190, 292, 248, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
4282, d5ap5A1, 0.7094, 2.59, 0.298, 248, 238, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4283, d3p08A_, 0.7094, 2.69, 0.194, 252, 237, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4284, d3fzpA_, 0.7094, 2.88, 0.219, 259, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
4285, d3el8B_, 0.7094, 2.69, 0.250, 259, 236, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4286, d2xb7A_, 0.7094, 3.13, 0.193, 286, 244, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
4287, d2vgpB_, 0.7094, 3.28, 0.300, 277, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4288, d2bfxB_, 0.7094, 3.18, 0.306, 275, 245, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
4289, d6bruD_, 0.7093, 3.49, 0.151, 311, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4290, d4f1tA1, 0.7093, 3.14, 0.238, 267, 244, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
4291, d4dbnA_, 0.7093, 3.00, 0.203, 257, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4292, d4ansA_, 0.7093, 3.36, 0.190, 293, 248, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4293, d2vwzA_, 0.7093, 3.10, 0.199, 274, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4294, d2rfnB_, 0.7093, 2.81, 0.206, 269, 238, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4295, d2py3B_, 0.7093, 3.31, 0.224, 284, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4296, d1xbbA1, 0.7093, 2.97, 0.202, 266, 242, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
4297, d4ehzD_, 0.7092, 3.33, 0.257, 280, 249, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4298, d3ri1B_, 0.7092, 3.54, 0.224, 283, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
4299, d2xeyA_, 0.7092, 2.98, 0.264, 252, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4300, d5o1vA_, 0.7091, 2.98, 0.239, 278, 238, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4301, d5khxA_, 0.7091, 3.21, 0.256, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
4302, d5dg5A_, 0.7091, 3.53, 0.213, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4303, d4qpsA_, 0.7091, 2.66, 0.258, 270, 236, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4304, d3bu5A_, 0.7091, 3.29, 0.203, 291, 246, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
4305, d5uoxB_, 0.7090, 2.94, 0.290, 252, 238, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4306, d5bvnA_, 0.7090, 3.51, 0.213, 278, 254, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4307, d4ftkA_, 0.7090, 3.04, 0.279, 263, 240, CRYSTAL STRUCTURE OF THE CHK1
4308, d4d4vA_, 0.7090, 2.80, 0.246, 256, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4309, d3byoA_, 0.7090, 3.35, 0.228, 270, 246, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
4310, d1zmvB_, 0.7090, 2.59, 0.315, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4311, d5lmbB_, 0.7089, 2.75, 0.192, 261, 239, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4312, d4rwiB_, 0.7089, 3.45, 0.228, 280, 250, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
4313, d4mwiA_, 0.7089, 2.95, 0.184, 266, 244, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
4314, d3comA_, 0.7089, 3.37, 0.290, 264, 248, CRYSTAL STRUCTURE OF MST1 KINASE
4315, d3ad6A_, 0.7089, 3.48, 0.235, 272, 247, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4316, d3ackA_, 0.7089, 3.47, 0.231, 270, 247, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4317, d2zybA_, 0.7089, 3.47, 0.235, 270, 247, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4318, d2yjrA_, 0.7089, 3.03, 0.194, 278, 242, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
4319, d2rfnA_, 0.7089, 2.81, 0.202, 268, 238, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4320, d1szmB_, 0.7089, 3.36, 0.254, 320, 248, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
4321, d1fvrA_, 0.7089, 3.19, 0.240, 299, 246, TIE2 KINASE DOMAIN
4322, d5a9uA_, 0.7088, 3.34, 0.186, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4323, d4b8lA_, 0.7088, 2.78, 0.314, 249, 239, AURORA B KINASE P353G MUTANT
4324, d3f9nA_, 0.7088, 2.91, 0.264, 253, 239, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
4325, d5ap2A1, 0.7087, 2.89, 0.293, 253, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4326, d4mxzB_, 0.7087, 2.98, 0.249, 264, 241, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4327, d4mxyB_, 0.7087, 2.98, 0.249, 264, 241, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4328, d3ky2B_, 0.7087, 3.54, 0.236, 280, 250, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4329, d3ccnA_, 0.7087, 3.34, 0.230, 275, 243, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4330, d3ac8A_, 0.7087, 3.42, 0.232, 270, 246, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4331, d2ydjA_, 0.7087, 2.83, 0.269, 252, 238, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4332, d5d12A_, 0.7086, 2.76, 0.249, 260, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4333, d4r5sA_, 0.7086, 3.22, 0.198, 299, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
4334, d4pwnA_, 0.7086, 2.44, 0.264, 245, 231, CRYSTAL STRUCTURE OF ACTIVE WNK1 KINASE
4335, d4lg4D_, 0.7086, 2.27, 0.283, 250, 230, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4336, d3zbfA_, 0.7086, 2.80, 0.225, 281, 240, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
4337, d3v8wB1, 0.7086, 2.47, 0.232, 240, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4338, d3qtiB_, 0.7086, 3.19, 0.246, 280, 244, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4339, d3my0P_, 0.7086, 3.03, 0.241, 290, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4340, d2p2iA2, 0.7086, 2.96, 0.231, 283, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4341, d4kioD1, 0.7085, 2.50, 0.226, 240, 234, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4342, d4fc0A_, 0.7085, 2.81, 0.197, 254, 238, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4343, d5nk5A_, 0.7084, 3.37, 0.208, 287, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
4344, d3qgwB_, 0.7083, 2.59, 0.222, 240, 234, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4345, d3my0O1, 0.7083, 3.03, 0.249, 296, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4346, d2ogvA_, 0.7083, 3.37, 0.217, 317, 249, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
4347, d1y8gB_, 0.7083, 2.77, 0.312, 292, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4348, d5aa8A_, 0.7082, 3.34, 0.190, 292, 247, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4349, d4otiA_, 0.7082, 2.28, 0.296, 303, 230, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
4350, d3qlfB_, 0.7082, 2.77, 0.248, 258, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4351, d3etaA_, 0.7082, 3.41, 0.196, 293, 250, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4352, d2vx0A_, 0.7082, 3.27, 0.202, 273, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4353, d2ijmA_, 0.7082, 2.96, 0.244, 260, 242, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4354, d2hiwB1, 0.7082, 3.22, 0.230, 270, 248, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4355, d1qpeA_, 0.7082, 3.55, 0.234, 270, 248, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4356, d4hokM_, 0.7081, 3.67, 0.176, 291, 255, CRYSTAL STRUCTURE OF APO CK1E
4357, d3pixA_, 0.7081, 3.56, 0.190, 268, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
4358, d3ad5A_, 0.7081, 3.41, 0.232, 270, 246, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4359, d2zm4A_, 0.7081, 3.38, 0.232, 270, 246, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
4360, d2vgpA_, 0.7081, 3.06, 0.307, 265, 244, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4361, d5vo2A_, 0.7080, 2.63, 0.291, 269, 234, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
4362, d3uqfB_, 0.7080, 2.34, 0.248, 253, 230, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4363, d3u6jA1, 0.7080, 3.31, 0.208, 305, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4364, d3op5C_, 0.7080, 3.38, 0.152, 308, 250, HUMAN VACCINIA-RELATED KINASE 1
4365, d2vwxA_, 0.7080, 3.12, 0.199, 274, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4366, d5ia0C_, 0.7079, 2.96, 0.207, 269, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4367, d5uvfB_, 0.7078, 3.48, 0.154, 316, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4368, d5uhnB_, 0.7078, 3.20, 0.206, 269, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4369, d5lpvA_, 0.7078, 3.20, 0.225, 282, 244, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
4370, d4wovA_, 0.7078, 2.91, 0.221, 258, 240, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4371, d4ftlA_, 0.7078, 3.00, 0.264, 263, 239, CRYSTAL STRUCTURE OF THE CHK1
4372, d1gagA_, 0.7078, 3.44, 0.201, 300, 249, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
4373, d4ei4A1, 0.7077, 3.21, 0.260, 288, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4374, d4ehzC_, 0.7077, 3.31, 0.258, 278, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4375, d4dbnB_, 0.7077, 3.11, 0.202, 263, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4376, d3uqgA_, 0.7077, 2.88, 0.251, 263, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4377, d2zm3B2, 0.7077, 3.32, 0.209, 295, 249, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
4378, d5ukfC_, 0.7076, 3.63, 0.152, 317, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4379, d4nkaA_, 0.7076, 3.55, 0.220, 279, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4380, d3bhhC1, 0.7076, 3.15, 0.311, 284, 244, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4381, d6btwD_, 0.7075, 3.56, 0.155, 307, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4382, d5we8A_, 0.7075, 2.56, 0.254, 270, 232, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4383, d5ia3A_, 0.7075, 3.02, 0.193, 275, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
4384, d3oxzA1, 0.7074, 3.17, 0.226, 267, 243, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
4385, d1rjbA_, 0.7074, 3.06, 0.210, 298, 243, CRYSTAL STRUCTURE OF FLT3
4386, d1k3aA_, 0.7074, 3.49, 0.216, 288, 250, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
4387, d4rx9A1, 0.7073, 3.10, 0.198, 264, 243, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
4388, d4oa9A_, 0.7073, 3.24, 0.230, 280, 243,  
4389, d4h58C_, 0.7073, 3.36, 0.196, 272, 245, BRAF IN COMPLEX WITH COMPOUND 3
4390, d4ftqA_, 0.7073, 2.77, 0.292, 254, 236, CRYSTAL STRUCTURE OF THE CHK1
4391, d4ftmA_, 0.7073, 3.06, 0.279, 263, 240, CRYSTAL STRUCTURE OF THE CHK1
4392, d4dflA1, 0.7073, 3.06, 0.211, 262, 242, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
4393, d3lvpC_, 0.7073, 3.30, 0.217, 293, 249, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4394, d2yfxA_, 0.7073, 3.39, 0.181, 292, 248, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4395, d2xp2A_, 0.7073, 3.27, 0.188, 285, 245, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
4396, d2hz4A_, 0.7073, 3.39, 0.220, 262, 245, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4397, d5ew3A_, 0.7072, 2.95, 0.212, 274, 241, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4398, d3zepB_, 0.7072, 3.17, 0.260, 268, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4399, d3v5jA1, 0.7072, 2.55, 0.227, 239, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4400, d3q96B_, 0.7072, 3.18, 0.198, 262, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4401, d4o2pB_, 0.7071, 2.88, 0.247, 265, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4402, d3svvA_, 0.7071, 2.93, 0.251, 261, 239, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4403, d5aacA_, 0.7070, 3.35, 0.186, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4404, d4pqnA_, 0.7070, 2.63, 0.235, 240, 234, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
4405, d4kspB_, 0.7070, 3.01, 0.200, 256, 240, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4406, d4e4lB_, 0.7070, 3.27, 0.259, 279, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4407, d5uvfC_, 0.7069, 3.39, 0.153, 301, 249, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4408, d5eykB_, 0.7069, 3.23, 0.312, 275, 247, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4409, d4mxoA_, 0.7069, 3.01, 0.245, 266, 241, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4410, d4mf1B1, 0.7069, 2.64, 0.220, 244, 236, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4411, d4gt4B_, 0.7069, 3.16, 0.201, 273, 244, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4412, d3f61A_, 0.7069, 2.81, 0.263, 271, 236, CRYSTAL STRUCTURE OF M. TUBERCULOSIS PKNB LEU33ASP/VAL222ASP DOUBLE MUTANT IN COMPLEX WITH ADP
4413, d4yjoA_, 0.7068, 3.04, 0.198, 267, 243, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
4414, d4d4vB_, 0.7068, 2.83, 0.247, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4415, d3qriA1, 0.7068, 3.20, 0.227, 270, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4416, d1m7nB_, 0.7068, 3.47, 0.212, 299, 250, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4417, d1zmuA_, 0.7067, 2.57, 0.316, 293, 234, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4418, d4mxxA_, 0.7066, 3.00, 0.241, 266, 241, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4419, d4f1mA1, 0.7066, 3.34, 0.229, 274, 245, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
4420, d4d5kB_, 0.7066, 2.83, 0.247, 256, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4421, d3mssD1, 0.7066, 2.92, 0.232, 260, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4422, d2bdfB_, 0.7066, 2.98, 0.241, 265, 241, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4423, d5vo6A_, 0.7065, 2.94, 0.229, 271, 240, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
4424, d5ia0B_, 0.7065, 3.00, 0.189, 266, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4425, d4oa2A_, 0.7065, 3.24, 0.226, 280, 243,  
4426, d4j97D_, 0.7065, 3.33, 0.230, 285, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4427, d3qupA_, 0.7065, 2.54, 0.250, 241, 232, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
4428, d3mssB1, 0.7065, 2.93, 0.232, 260, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4429, d5eykA_, 0.7064, 3.21, 0.312, 263, 247, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4430, d3f3tB_, 0.7064, 2.77, 0.246, 259, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4431, d1m7nA_, 0.7064, 3.46, 0.212, 299, 250, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4432, d1ir3A_, 0.7064, 3.43, 0.201, 300, 249, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
4433, d5xgmA_, 0.7063, 3.08, 0.210, 288, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
4434, d4mf1A1, 0.7063, 2.48, 0.227, 241, 233, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4435, d3mssA1, 0.7063, 2.93, 0.228, 260, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4436, d2hz4C_, 0.7063, 3.37, 0.234, 259, 244, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4437, d5uglB_, 0.7062, 3.26, 0.217, 271, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4438, d5hieD_, 0.7062, 2.89, 0.197, 253, 238, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4439, d5e1sA_, 0.7062, 3.00, 0.198, 284, 243, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
4440, d4fl1A_, 0.7062, 3.14, 0.205, 268, 244, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
4441, d3v5lB1, 0.7062, 2.45, 0.224, 239, 232, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4442, d3oezB_, 0.7062, 2.83, 0.244, 261, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4443, d1y8gA_, 0.7062, 2.81, 0.316, 292, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4444, d4p90B_, 0.7061, 2.79, 0.316, 262, 237, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4445, d4fnyA_, 0.7061, 2.96, 0.188, 273, 239, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4446, d4f1oA1, 0.7061, 3.35, 0.233, 274, 245, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
4447, d3v8wA1, 0.7061, 2.66, 0.226, 241, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4448, d3q96A_, 0.7061, 2.87, 0.202, 253, 238, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4449, d3fqhA_, 0.7061, 2.89, 0.196, 262, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4450, d2vrxB_, 0.7061, 3.19, 0.307, 274, 244, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
4451, d5cswB_, 0.7060, 2.77, 0.216, 252, 236, B-RAF IN COMPLEX WITH DABRAFENIB
4452, d3d5vA_, 0.7060, 2.66, 0.265, 260, 234, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
4453, d4kbaD_, 0.7059, 3.24, 0.167, 274, 246, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4454, d4fz7A1, 0.7059, 3.01, 0.200, 261, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
4455, d4ctbA_, 0.7059, 3.37, 0.186, 292, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
4456, d4c62B_, 0.7059, 2.94, 0.272, 271, 239, INHIBITORS OF JAK2 KINASE DOMAIN
4457, d3el8A_, 0.7059, 2.95, 0.246, 263, 240, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4458, d5wdyA_, 0.7058, 2.72, 0.246, 260, 232, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4459, d4fz6A1, 0.7058, 2.93, 0.200, 262, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
4460, d4d4yA_, 0.7058, 2.85, 0.247, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4461, d4anlA_, 0.7058, 3.40, 0.190, 292, 248, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
4462, d3zonA_, 0.7058, 2.90, 0.218, 261, 239, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
4463, d2helA_, 0.7058, 3.05, 0.189, 256, 243, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
4464, d2hakC_, 0.7058, 3.11, 0.317, 310, 246, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4465, d4kbkD_, 0.7057, 3.13, 0.173, 281, 243, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4466, d4d5kA_, 0.7057, 2.85, 0.247, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4467, d3uqfA_, 0.7057, 2.81, 0.248, 260, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4468, d5vt1A1, 0.7056, 3.25, 0.288, 264, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
4469, d5jt2C1, 0.7056, 2.81, 0.224, 247, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4470, d5hezB_, 0.7056, 3.36, 0.249, 289, 245, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4471, d5feeA_, 0.7056, 3.18, 0.214, 287, 243, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
4472, d4g5jA_, 0.7056, 3.06, 0.212, 307, 240, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
4473, d3sxrB1, 0.7056, 2.94, 0.217, 255, 240, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4474, d3mssC1, 0.7056, 2.94, 0.232, 260, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4475, d2q0bA_, 0.7056, 3.29, 0.221, 280, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4476, d5wfjA_, 0.7055, 3.15, 0.252, 265, 242, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
4477, d5l8jA_, 0.7055, 2.80, 0.261, 253, 238, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4478, d4kb8D_, 0.7055, 3.13, 0.173, 278, 243, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4479, d4i0rA1, 0.7055, 2.90, 0.201, 260, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
4480, d3ztxB_, 0.7055, 3.21, 0.296, 272, 243, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
4481, d3ortA_, 0.7055, 2.97, 0.257, 271, 237, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 6)
4482, d3f82A_, 0.7055, 3.04, 0.208, 278, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4483, d5owqA_, 0.7054, 2.61, 0.328, 255, 232, HUMAN STK10 BOUND TO DOVITINIB
4484, d5o2bA1, 0.7054, 2.87, 0.246, 268, 236, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN A COMPLEX WITH THE INHIBITOR PP-121
4485, d5lpzA_, 0.7054, 3.25, 0.226, 283, 243, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4486, d5bvoA_, 0.7054, 3.50, 0.209, 276, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4487, d3jvsA_, 0.7054, 3.02, 0.285, 256, 239, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4488, d4e4lA_, 0.7053, 3.25, 0.256, 277, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4489, d4d5hA_, 0.7053, 2.86, 0.247, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4490, d3w18A_, 0.7053, 2.20, 0.308, 234, 227, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4491, d4r1yA_, 0.7052, 3.20, 0.221, 265, 240, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
4492, d3v5qA1, 0.7052, 3.01, 0.220, 260, 241, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4493, d4xg8A_, 0.7051, 3.14, 0.202, 258, 242, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4494, d4hokW_, 0.7051, 3.64, 0.171, 289, 252, CRYSTAL STRUCTURE OF APO CK1E
4495, d4ctcA_, 0.7051, 3.30, 0.188, 288, 245, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4496, d3uysA_, 0.7051, 3.13, 0.169, 281, 243, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4497, d3dtcA_, 0.7051, 2.10, 0.288, 245, 226, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
4498, d4v04A_, 0.7050, 3.54, 0.220, 290, 250, FGFR1 IN COMPLEX WITH PONATINIB.
4499, d4oa6A_, 0.7050, 3.25, 0.226, 279, 243,  
4500, d3a60A_, 0.7050, 2.62, 0.309, 263, 233, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
4501, d2r2pA1, 0.7050, 3.21, 0.203, 276, 246, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
4502, d5tf9B_, 0.7049, 2.51, 0.252, 266, 230, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4503, d5mjbB_, 0.7049, 3.26, 0.215, 278, 246, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
4504, d4p2wB_, 0.7049, 2.92, 0.197, 253, 239,  
4505, d2xf0A_, 0.7049, 2.88, 0.278, 251, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4506, d2x7fE_, 0.7049, 2.33, 0.270, 251, 230, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4507, d1zmvA_, 0.7049, 2.63, 0.321, 293, 234, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4508, d5t68A1, 0.7048, 3.22, 0.205, 264, 244, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
4509, d4zauA_, 0.7048, 3.18, 0.223, 283, 242, AZD9291 COMPLEX WITH WILD TYPE EGFR
4510, d2oh4A1, 0.7048, 3.59, 0.193, 296, 254, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
4511, d5o1vB_, 0.7047, 2.90, 0.236, 270, 237, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4512, d5ia4A_, 0.7047, 3.28, 0.190, 269, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
4513, d4fc0B_, 0.7047, 3.12, 0.199, 263, 241, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4514, d4c7tA_, 0.7047, 3.10, 0.238, 259, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4515, d5w86B_, 0.7046, 3.01, 0.261, 267, 238, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4516, d5t68B_, 0.7046, 3.24, 0.216, 264, 245, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
4517, d4mxxB_, 0.7046, 2.89, 0.234, 260, 239, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4518, d4hokU_, 0.7046, 3.51, 0.171, 289, 251, CRYSTAL STRUCTURE OF APO CK1E
4519, d3tudA1, 0.7046, 2.83, 0.200, 255, 240, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
4520, d5njzA_, 0.7045, 3.05, 0.189, 273, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
4521, d4v01A_, 0.7045, 3.47, 0.218, 273, 248, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4522, d3zfxB_, 0.7045, 2.68, 0.220, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4523, d3g6gA_, 0.7045, 3.01, 0.241, 264, 241, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4524, d4oacA_, 0.7044, 3.33, 0.230, 280, 244,  
4525, d3b8qA1, 0.7044, 2.88, 0.217, 285, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4526, d1irkA_, 0.7044, 3.45, 0.196, 303, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
4527, d5bvwA_, 0.7043, 3.65, 0.221, 274, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4528, d4hokI_, 0.7043, 3.49, 0.175, 291, 251, CRYSTAL STRUCTURE OF APO CK1E
4529, d3o23A_, 0.7043, 3.46, 0.209, 293, 249, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
4530, d2zm3D2, 0.7043, 3.33, 0.211, 292, 247, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
4531, d5xp7A_, 0.7041, 2.98, 0.246, 265, 240, C-SRC IN COMPLEX WITH ATP-CHCL
4532, d3v5jB1, 0.7041, 2.44, 0.225, 239, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4533, d3aqvA_, 0.7041, 3.27, 0.253, 267, 245, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
4534, d2pzpA_, 0.7041, 3.41, 0.233, 280, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
4535, d5swhB_, 0.7040, 2.80, 0.246, 261, 236, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4536, d5hezD_, 0.7040, 3.53, 0.239, 289, 247, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4537, d4uwyB_, 0.7040, 3.13, 0.247, 273, 243, FGFR1 APO STRUCTURE
4538, d3tucA_, 0.7040, 2.83, 0.201, 257, 239, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4539, d3ms9A1, 0.7040, 3.01, 0.224, 261, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4540, d2pzrA_, 0.7040, 3.41, 0.212, 280, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4541, d2bdfA_, 0.7040, 3.02, 0.242, 261, 240, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4542, d5tehA_, 0.7039, 2.84, 0.244, 261, 238, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4543, d5i9uA_, 0.7039, 3.13, 0.193, 281, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4544, d4f0fA1, 0.7039, 3.29, 0.230, 274, 244, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
4545, d4d58A_, 0.7039, 2.88, 0.251, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4546, d4d4sA_, 0.7039, 2.88, 0.247, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4547, d3svvB_, 0.7039, 2.65, 0.240, 257, 233, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4548, d3fpqB_, 0.7039, 3.25, 0.254, 263, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4549, d2pzpB_, 0.7039, 3.26, 0.226, 282, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
4550, d2pl0A_, 0.7039, 3.30, 0.215, 268, 246, LCK BOUND TO IMATINIB
4551, d5i8aA1, 0.7038, 2.74, 0.225, 265, 236, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
4552, d3efwA_, 0.7038, 2.40, 0.313, 240, 230, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4553, d2q0bB_, 0.7038, 3.34, 0.221, 282, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4554, d2bmcA_, 0.7038, 2.75, 0.291, 256, 234, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4555, d5h3qA_, 0.7037, 3.26, 0.224, 302, 246, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
4556, d5ar8A_, 0.7037, 2.57, 0.245, 255, 233, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4557, d2yhvA_, 0.7037, 3.39, 0.182, 291, 247, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
4558, d2bmcB_, 0.7037, 2.75, 0.291, 258, 234, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4559, d5valB_, 0.7036, 2.93, 0.197, 254, 238, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4560, d3b2tB_, 0.7036, 3.31, 0.234, 287, 244, STRUCTURE OF PHOSPHOTRANSFERASE
4561, d2nryB_, 0.7036, 3.25, 0.251, 286, 243, CRYSTAL STRUCTURE OF IRAK-4
4562, d6bp0C_, 0.7035, 3.63, 0.150, 315, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4563, d5owqB_, 0.7035, 2.52, 0.325, 254, 231, HUMAN STK10 BOUND TO DOVITINIB
4564, d5lpwA_, 0.7035, 3.18, 0.228, 280, 241, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4565, d5hnvA1, 0.7035, 2.93, 0.206, 278, 238, CRYSTAL STRUCTURE OF PPKA
4566, d4xg9A_, 0.7035, 2.81, 0.197, 259, 238, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4567, d4tyjA1, 0.7035, 3.11, 0.231, 275, 242, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4568, d3zfxF_, 0.7035, 2.66, 0.217, 254, 235, CRYSTAL STRUCTURE OF EPHB1
4569, d3byuA_, 0.7035, 3.07, 0.237, 256, 241, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
4570, d2pz5B_, 0.7035, 3.26, 0.222, 280, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4571, d2pz5A_, 0.7035, 3.32, 0.234, 280, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4572, d5i9wA_, 0.7034, 2.94, 0.196, 267, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
4573, d4k8aA_, 0.7034, 2.87, 0.243, 251, 239, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4574, d3f3uB_, 0.7034, 2.84, 0.245, 259, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4575, d6bruC_, 0.7033, 3.63, 0.150, 315, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4576, d4mxoB_, 0.7033, 3.00, 0.246, 264, 240, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4577, d4fnwA_, 0.7033, 3.42, 0.190, 304, 247, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4578, d3gqlC_, 0.7033, 3.28, 0.236, 275, 246, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4579, d6bu6C_, 0.7032, 3.63, 0.150, 315, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4580, d4kioA1, 0.7032, 2.45, 0.225, 238, 231, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4581, d4cmtA_, 0.7032, 3.29, 0.189, 284, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
4582, d3comB_, 0.7032, 3.46, 0.295, 279, 251, CRYSTAL STRUCTURE OF MST1 KINASE
4583, d2pvyC_, 0.7032, 3.27, 0.223, 285, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4584, d3en4A_, 0.7031, 2.85, 0.249, 257, 237, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4585, d1zxeE1, 0.7031, 2.82, 0.285, 254, 235, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4586, d1yomB_, 0.7031, 2.86, 0.249, 261, 237, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4587, d4yjuA_, 0.7030, 3.09, 0.194, 262, 242, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
4588, d4wovB_, 0.7030, 2.76, 0.229, 256, 236, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4589, d3uc3A_, 0.7030, 3.08, 0.267, 272, 243, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
4590, d3pxkA_, 0.7030, 2.95, 0.242, 256, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4591, d3dk6B_, 0.7030, 3.39, 0.235, 259, 243, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4592, d1r1wA_, 0.7030, 3.17, 0.236, 287, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
4593, d4mcvB_, 0.7029, 2.98, 0.246, 265, 240, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4594, d4f65B_, 0.7029, 3.61, 0.231, 279, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4595, d1zxeD1, 0.7029, 2.75, 0.282, 246, 234, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4596, d5e8vA_, 0.7028, 3.50, 0.236, 296, 246, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
4597, d4yc8A_, 0.7028, 3.21, 0.232, 259, 241, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
4598, d3idpB_, 0.7028, 3.07, 0.199, 256, 241, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4599, d3fzoA_, 0.7028, 3.13, 0.215, 262, 246, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
4600, d2ydjB_, 0.7028, 2.88, 0.270, 251, 237, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4601, d2pvyD_, 0.7027, 3.40, 0.218, 283, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4602, d3vw8A_, 0.7026, 3.44, 0.202, 303, 247, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
4603, d3ot8A_, 0.7026, 2.90, 0.288, 251, 236, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
4604, d5we8B_, 0.7025, 2.62, 0.260, 272, 231, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4605, d5fm3A_, 0.7025, 3.26, 0.243, 276, 243, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4606, d5c9cB_, 0.7025, 2.95, 0.197, 251, 238, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4607, d4ztlD_, 0.7025, 3.29, 0.213, 285, 244, IRAK4-INHIBITOR CO-STRUCTURE
4608, d4hokO_, 0.7025, 3.48, 0.168, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4609, d3zxtA_, 0.7025, 2.53, 0.271, 249, 229, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4610, d3zfxG_, 0.7025, 2.67, 0.221, 253, 235, CRYSTAL STRUCTURE OF EPHB1
4611, d3qlgA_, 0.7025, 2.90, 0.244, 259, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4612, d3ewhA1, 0.7025, 3.64, 0.206, 295, 252, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
4613, d2jc6A_, 0.7025, 2.78, 0.289, 278, 235, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4614, d6btwC_, 0.7024, 3.64, 0.150, 315, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4615, d5uorA_, 0.7023, 2.82, 0.295, 249, 234, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4616, d3zewB_, 0.7023, 2.80, 0.227, 252, 238, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4617, d3w18B_, 0.7023, 2.47, 0.312, 236, 231, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4618, d3tz8B_, 0.7023, 2.97, 0.246, 263, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4619, d3p86B_, 0.7023, 2.38, 0.240, 239, 229, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4620, d2zm3A2, 0.7023, 3.42, 0.205, 299, 249, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
4621, d5w86A_, 0.7022, 3.03, 0.256, 269, 238, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4622, d5sysA_, 0.7022, 2.86, 0.241, 258, 237, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4623, d2reiA1, 0.7022, 2.87, 0.201, 274, 239, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
4624, d2iwiB_, 0.7022, 2.27, 0.276, 249, 228, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4625, d5d11A_, 0.7021, 2.69, 0.248, 254, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4626, d3qriB_, 0.7021, 3.12, 0.239, 262, 243, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4627, d2bmcD_, 0.7021, 2.76, 0.291, 256, 234, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4628, d3g5dA_, 0.7020, 2.71, 0.248, 256, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4629, d5ia5A_, 0.7019, 3.35, 0.190, 273, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
4630, d2bmcE_, 0.7019, 2.67, 0.292, 256, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4631, d4oabA_, 0.7018, 3.25, 0.227, 279, 242,  
4632, d1i44A_, 0.7018, 3.10, 0.205, 282, 244, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4633, d5hezC_, 0.7017, 3.39, 0.254, 289, 244, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4634, d4hokE_, 0.7017, 3.56, 0.171, 291, 251, CRYSTAL STRUCTURE OF APO CK1E
4635, d4c4hA1, 0.7017, 2.56, 0.298, 245, 235, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4636, d3oezA_, 0.7017, 2.94, 0.243, 261, 239, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4637, d5ur1A_, 0.7016, 3.20, 0.239, 278, 243, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4638, d4h1jA_, 0.7016, 3.20, 0.220, 263, 246, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
4639, d4f4pA1, 0.7016, 3.16, 0.215, 260, 242, SYK IN COMPLEX WITH LIGAND LASW836
4640, d4cqeB_, 0.7016, 2.69, 0.197, 248, 234, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4641, d2xezA_, 0.7016, 2.99, 0.274, 249, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4642, d2x2mB1, 0.7016, 3.29, 0.252, 274, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4643, d5iugA_, 0.7015, 3.20, 0.182, 285, 242, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
4644, d3pa5A_, 0.7015, 3.09, 0.289, 255, 239, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4645, d5lpyA_, 0.7014, 3.29, 0.227, 282, 242, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4646, d3zfxC_, 0.7014, 2.68, 0.221, 248, 235, CRYSTAL STRUCTURE OF EPHB1
4647, d3of0A_, 0.7014, 2.91, 0.248, 260, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4648, d3h0zB_, 0.7014, 2.49, 0.304, 240, 230, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4649, d3eflA1, 0.7014, 2.88, 0.209, 279, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4650, d2xkdA1, 0.7014, 2.31, 0.281, 243, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4651, d6bruB_, 0.7013, 3.29, 0.142, 301, 246, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4652, d4i4fA_, 0.7013, 3.12, 0.241, 255, 241, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4653, d4ftnA_, 0.7013, 2.84, 0.272, 253, 235, CRYSTAL STRUCTURE OF THE CHK1
4654, d4brxA_, 0.7013, 3.10, 0.243, 259, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4655, d2pzrB_, 0.7013, 3.48, 0.204, 282, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4656, d5kbrB_, 0.7012, 2.78, 0.308, 260, 234, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4657, d5hezA_, 0.7012, 3.47, 0.234, 287, 244, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4658, d4ybjB_, 0.7012, 2.64, 0.245, 253, 233, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4659, d2jkqA_, 0.7012, 3.10, 0.239, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4660, d3g5dB_, 0.7011, 2.81, 0.246, 257, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4661, d2wmtA_, 0.7011, 2.92, 0.271, 248, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4662, d4xg7A1, 0.7010, 3.20, 0.198, 265, 243, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4663, d4wunA_, 0.7010, 3.25, 0.242, 282, 244, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4664, d4d2sA_, 0.7010, 2.49, 0.305, 249, 233, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4665, d3ujgA_, 0.7010, 3.59, 0.283, 290, 251, CRYSTAL STRUCTURE OF SNRK2.6 IN COMPLEX WITH HAB1
4666, d3kmuA_, 0.7010, 2.77, 0.178, 253, 236, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (APO)
4667, d5uabA_, 0.7009, 3.34, 0.224, 288, 241, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4668, d3aoxA_, 0.7009, 3.40, 0.187, 298, 246, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
4669, d5mjaA_, 0.7008, 2.97, 0.224, 271, 241, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
4670, d5ia1A_, 0.7008, 3.00, 0.199, 261, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
4671, d4fstA_, 0.7008, 2.92, 0.284, 253, 236, CRYSTAL STRUCTURE OF THE CHK1
4672, d3g6hB_, 0.7008, 2.86, 0.249, 259, 237, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4673, d3bysA_, 0.7008, 3.01, 0.238, 255, 239, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
4674, d1zxeA1, 0.7008, 3.06, 0.262, 259, 240, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4675, d4p2wA_, 0.7007, 2.88, 0.219, 250, 237,  
4676, d3fqhB_, 0.7007, 2.97, 0.188, 258, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4677, d3emgA_, 0.7007, 2.87, 0.197, 255, 238, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
4678, d4gk3A_, 0.7006, 3.11, 0.210, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
4679, d2pvyA_, 0.7006, 3.43, 0.218, 288, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4680, d2fh9A_, 0.7006, 2.96, 0.310, 255, 239, STRUCTURE AND DIMERIZATION OF THE KINASE DOMAIN FROM YEAST SNF1
4681, d5mjaB_, 0.7005, 3.41, 0.211, 274, 246, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
4682, d5iuhA_, 0.7005, 3.15, 0.178, 285, 241, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
4683, d2jkkA_, 0.7005, 3.06, 0.240, 258, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4684, d5swhA_, 0.7004, 2.85, 0.246, 258, 236, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4685, d5a6nA1, 0.7004, 2.53, 0.259, 270, 232, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4686, d4ztmD_, 0.7004, 3.34, 0.238, 282, 244, IRAK4-INHIBITOR CO-STRUCTURE
4687, d3dpkA_, 0.7004, 3.21, 0.210, 279, 243, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
4688, d4yjpA_, 0.7003, 3.19, 0.198, 263, 243, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
4689, d4rlpA_, 0.7003, 2.48, 0.301, 261, 229, HUMAN P70S6K1 WITH RUTHENIUM-BASED INHIBITOR FL772
4690, d4kioB1, 0.7003, 2.45, 0.226, 237, 230, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4691, d3qrkA1, 0.7003, 3.14, 0.225, 268, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
4692, d3cp9B_, 0.7003, 3.02, 0.199, 269, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4693, d2ym5A_, 0.7003, 2.94, 0.275, 248, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4694, d2pvyB_, 0.7003, 3.18, 0.221, 286, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4695, d1yomA_, 0.7003, 2.83, 0.242, 260, 236, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4696, d6btwB_, 0.7002, 3.43, 0.153, 301, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4697, d4kabA_, 0.7002, 2.95, 0.238, 255, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4698, d2iwiA_, 0.7002, 2.53, 0.278, 244, 230, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4699, d5tiuA1, 0.7001, 3.07, 0.196, 262, 240, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
4700, d5hx6B_, 0.7001, 3.42, 0.225, 264, 244, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4701, d3alnB_, 0.7001, 2.42, 0.258, 263, 229, CRYSTAL STRUCTURE OF HUMAN NON-PHOSPHORYLATED MKK4 KINASE DOMAIN COMPLEXED WITH AMP-PNP
4702, d4m67A_, 0.7000, 2.95, 0.183, 264, 241, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4703, d3piyA_, 0.7000, 3.41, 0.199, 262, 246, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4704, d5up3B_, 0.6999, 2.64, 0.303, 243, 231, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4705, d5ko1A_, 0.6999, 2.98, 0.182, 265, 242, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4706, d4yc8B_, 0.6998, 3.40, 0.230, 264, 244, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
4707, d4tyeA_, 0.6998, 3.60, 0.246, 292, 252, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4708, d4pmtA1, 0.6998, 3.11, 0.233, 269, 240, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
4709, d4kaoB_, 0.6998, 2.89, 0.238, 254, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4710, d2zm3C2, 0.6998, 3.47, 0.201, 295, 249, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
4711, d2wmxA_, 0.6998, 2.97, 0.280, 248, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4712, d5fdxA_, 0.6997, 3.60, 0.217, 280, 253, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4713, d5a6oA_, 0.6997, 2.54, 0.259, 265, 232, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4714, d3op5D_, 0.6997, 3.36, 0.142, 302, 247, HUMAN VACCINIA-RELATED KINASE 1
4715, d2ym4A_, 0.6997, 2.89, 0.294, 251, 235, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4716, d4gk4A_, 0.6996, 3.07, 0.202, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
4717, d3bz3A_, 0.6996, 3.10, 0.243, 259, 243, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
4718, d5lpbA_, 0.6995, 3.29, 0.227, 280, 242, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4719, d5jkgA_, 0.6995, 3.15, 0.244, 266, 242, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
4720, d4gt4A_, 0.6995, 3.25, 0.202, 274, 243, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4721, d4g2fA_, 0.6995, 3.17, 0.206, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
4722, d2e2bB1, 0.6994, 3.08, 0.225, 258, 240, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4723, d4yjtA_, 0.6993, 3.23, 0.193, 268, 243, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
4724, d4nksA_, 0.6993, 3.54, 0.230, 265, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
4725, d3uqgB_, 0.6993, 2.72, 0.245, 257, 233, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4726, d3lq8A_, 0.6993, 3.29, 0.209, 278, 244, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
4727, d2ym7A_, 0.6993, 2.99, 0.280, 248, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4728, d4ztnC_, 0.6992, 3.36, 0.230, 284, 244, IRAK4-INHIBITOR CO-STRUCTURE
4729, d4ztlA_, 0.6991, 3.29, 0.218, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
4730, d1yi6A_, 0.6991, 3.50, 0.233, 274, 245, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4731, d2qg5B1, 0.6990, 3.35, 0.261, 275, 245, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4732, d2bvaA_, 0.6990, 3.03, 0.255, 272, 239, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4733, d4x7qB_, 0.6989, 2.49, 0.261, 243, 230, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4734, d4gu9A_, 0.6989, 2.90, 0.239, 252, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4735, d4gu6B_, 0.6989, 3.12, 0.243, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4736, d4equA_, 0.6989, 2.92, 0.323, 274, 235, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4737, d3daeB_, 0.6989, 3.01, 0.301, 246, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4738, d4xg2A1, 0.6988, 2.89, 0.198, 258, 237, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
4739, d3f3vB_, 0.6988, 2.93, 0.244, 262, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4740, d5valA_, 0.6987, 3.06, 0.201, 254, 239, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4741, d3tt0B_, 0.6987, 3.17, 0.240, 272, 242, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4742, d3of0B_, 0.6987, 2.54, 0.248, 251, 230, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4743, d3krlA_, 0.6987, 3.30, 0.209, 281, 244, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
4744, d3dkgA_, 0.6987, 3.13, 0.225, 281, 240, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4745, d3dtwA1, 0.6986, 2.88, 0.210, 281, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4746, d4gfoA1, 0.6985, 3.04, 0.244, 270, 238, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
4747, d3b8rB_, 0.6985, 2.96, 0.226, 267, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4748, d4p2kA_, 0.6984, 3.07, 0.202, 259, 242, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4749, d1p14A_, 0.6984, 3.01, 0.203, 287, 241, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4750, d4hokS_, 0.6983, 3.51, 0.165, 286, 249, CRYSTAL STRUCTURE OF APO CK1E
4751, d3zuuA_, 0.6983, 3.14, 0.279, 281, 244, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4752, d2wqeA_, 0.6983, 2.63, 0.315, 241, 232, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4753, d5k7gC_, 0.6982, 3.34, 0.255, 283, 243, IRAK4 IN COMPLEX WITH AZ3862
4754, d5d11B_, 0.6982, 2.74, 0.253, 255, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4755, d3miyA1, 0.6982, 2.42, 0.231, 237, 229, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4756, d3cthA_, 0.6982, 3.52, 0.214, 295, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4757, d3f3uA_, 0.6981, 2.98, 0.243, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4758, d4aw5A_, 0.6979, 2.92, 0.209, 261, 239, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
4759, d3b8qB_, 0.6979, 3.04, 0.221, 271, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4760, d1k9aF3, 0.6979, 2.96, 0.226, 264, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4761, d5uvfD_, 0.6978, 3.38, 0.150, 296, 246, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4762, d5t1tA_, 0.6978, 3.31, 0.230, 283, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4763, d3is5D1, 0.6978, 1.79, 0.315, 230, 219, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4764, d4mcvA_, 0.6977, 3.04, 0.250, 267, 240, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4765, d5uq0A_, 0.6976, 3.03, 0.247, 266, 239, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4766, d5nkaA_, 0.6976, 3.15, 0.194, 271, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
4767, d3dj5A_, 0.6976, 2.60, 0.289, 252, 232, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4768, d3cs9D_, 0.6975, 3.23, 0.222, 263, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4769, d5t1tC_, 0.6973, 3.39, 0.238, 286, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4770, d5d12B_, 0.6973, 2.67, 0.250, 253, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4771, d4gk2A_, 0.6973, 2.92, 0.205, 265, 239, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
4772, d3uysB_, 0.6973, 3.27, 0.160, 279, 244, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4773, d2ym3A_, 0.6973, 2.94, 0.277, 247, 235, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4774, d2hk5A2, 0.6973, 3.23, 0.245, 268, 241, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
4775, d4ftoA_, 0.6972, 2.90, 0.285, 252, 235, CRYSTAL STRUCTURE OF THE CHK1
4776, d3zuuB_, 0.6972, 3.32, 0.279, 282, 247, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4777, d2hyyB1, 0.6972, 3.06, 0.220, 252, 241, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4778, d5tobA_, 0.6971, 2.61, 0.215, 245, 233, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4779, d4wunB_, 0.6971, 3.16, 0.247, 268, 243, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4780, d4p5qA_, 0.6971, 3.16, 0.206, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4781, d3zutA_, 0.6971, 3.17, 0.262, 281, 244, THE STRUCTURE OF OST1 (D160A) KINASE
4782, d3nw7A_, 0.6971, 3.46, 0.213, 297, 249, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
4783, d5m08B_, 0.6970, 2.93, 0.207, 253, 237, CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS PKNI KINASE DOMAIN C20A_R136A DOUBLE MUTANT
4784, d5k7gD_, 0.6970, 3.35, 0.255, 283, 243, IRAK4 IN COMPLEX WITH AZ3862
4785, d4yo6C_, 0.6970, 3.39, 0.230, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4786, d3dtwB_, 0.6969, 3.12, 0.212, 269, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4787, d2bmcC_, 0.6969, 3.02, 0.288, 257, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4788, d4ztmA_, 0.6968, 3.34, 0.239, 287, 243, IRAK4-INHIBITOR CO-STRUCTURE
4789, d4wrgA1, 0.6968, 3.07, 0.207, 287, 237, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
4790, d2y4pC_, 0.6968, 2.52, 0.262, 264, 229, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4791, d2og8A_, 0.6968, 2.93, 0.228, 246, 237, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4792, d5t1sC_, 0.6967, 3.40, 0.234, 284, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4793, d3lvpD_, 0.6967, 3.34, 0.222, 282, 243, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4794, d3eflB_, 0.6967, 3.02, 0.200, 263, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4795, d2j90A1, 0.6967, 2.61, 0.255, 259, 231, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4796, d1zxeB1, 0.6967, 2.82, 0.278, 242, 234, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4797, d5sysB_, 0.6966, 2.88, 0.246, 258, 236, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4798, d4ybjA_, 0.6966, 2.79, 0.248, 255, 234, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4799, d4wo5A1, 0.6966, 2.65, 0.198, 250, 232, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4800, d3q6uA1, 0.6966, 3.26, 0.218, 281, 243, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
4801, d3nw6A_, 0.6966, 3.45, 0.209, 301, 249, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
4802, d4x7oA_, 0.6965, 2.60, 0.253, 246, 229, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 1-[5-(4-AMINO-27-DIMETHYL-7H- PYRROLO[23-D]PYRIMIDIN-5-YL)-23-DIHYDRO-1H-INDOL-1-YL]-2-[3-FLUORO- 5-(TRIFLUOROMETHYL)PHENYL]ETHANONE INHIBITOR
4803, d4hokK_, 0.6965, 3.60, 0.172, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4804, d5t1tD_, 0.6964, 3.33, 0.230, 283, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4805, d5kx7B_, 0.6964, 3.40, 0.254, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4806, d4pdoB_, 0.6964, 2.82, 0.199, 261, 236, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4807, d2wmwA_, 0.6964, 2.78, 0.262, 247, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4808, d4ithA_, 0.6963, 2.81, 0.237, 247, 232, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4809, d4pdoA_, 0.6962, 2.82, 0.199, 261, 236, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4810, d3ekkA_, 0.6962, 3.10, 0.202, 285, 242, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4811, d3f3wA_, 0.6961, 3.02, 0.243, 261, 239, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4812, d4dceA_, 0.6960, 3.18, 0.187, 288, 241, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4813, d3f3tA_, 0.6960, 3.03, 0.243, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4814, d5ia0A_, 0.6959, 3.02, 0.196, 263, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4815, d3zutB_, 0.6959, 3.33, 0.279, 282, 247, THE STRUCTURE OF OST1 (D160A) KINASE
4816, d2wmqA_, 0.6959, 2.93, 0.291, 246, 234, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4817, d4wa9B1, 0.6958, 3.40, 0.238, 263, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
4818, d2yjsA_, 0.6958, 3.30, 0.185, 286, 243, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
4819, d2wmuA_, 0.6957, 2.93, 0.274, 246, 234, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4820, d2qi8B_, 0.6957, 2.53, 0.262, 249, 229, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4821, d2hyyD1, 0.6957, 3.07, 0.221, 251, 240, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4822, d5kx8C_, 0.6956, 3.42, 0.230, 287, 244, IRAK4-INHIBITOR CO-STRUCTURE
4823, d5ew3B_, 0.6956, 2.84, 0.208, 266, 236, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4824, d3ce3A_, 0.6956, 3.66, 0.222, 293, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
4825, d2hyyC1, 0.6956, 2.94, 0.241, 249, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4826, d4hokA_, 0.6955, 3.56, 0.168, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4827, d3miyB1, 0.6955, 2.66, 0.216, 238, 232, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4828, d3cs9B_, 0.6955, 3.01, 0.235, 247, 238, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4829, d5nk0A_, 0.6954, 3.11, 0.203, 273, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
4830, d4xs2A_, 0.6954, 3.34, 0.214, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
4831, d2ym8A_, 0.6954, 2.84, 0.275, 246, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4832, d4yffB_, 0.6953, 2.94, 0.215, 264, 233, TNNI3K COMPLEXED WITH INHIBITOR 2
4833, d4ztnA_, 0.6952, 3.35, 0.239, 286, 243, IRAK4-INHIBITOR CO-STRUCTURE
4834, d4dceB_, 0.6952, 3.17, 0.183, 284, 240, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4835, d3fztA_, 0.6952, 3.16, 0.218, 259, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
4836, d1mqbA_, 0.6952, 3.21, 0.202, 263, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4837, d2auhA1, 0.6950, 3.57, 0.206, 294, 248, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
4838, d3b8rA1, 0.6949, 2.95, 0.227, 282, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4839, d5tx5B_, 0.6948, 3.47, 0.227, 263, 242, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4840, d3c1xA_, 0.6948, 3.27, 0.215, 290, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
4841, d4yp8C_, 0.6947, 3.39, 0.239, 287, 243, IRAK4-INHIBITOR CO-STRUCTURE
4842, d4yfiA_, 0.6947, 2.90, 0.216, 268, 232, TNNI3K COMPLEXED WITH INHIBITOR 1
4843, d4ficA_, 0.6946, 2.50, 0.250, 251, 228, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
4844, d4ebvA1, 0.6946, 3.09, 0.243, 261, 239, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4845, d3d7tB_, 0.6946, 3.15, 0.242, 265, 240, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4846, d1zxeF1, 0.6946, 2.67, 0.270, 239, 230, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4847, d2dylA_, 0.6945, 3.13, 0.219, 272, 242, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
4848, d2xkfA1, 0.6944, 2.38, 0.283, 242, 230, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4849, d2qg5A1, 0.6944, 3.40, 0.261, 268, 245, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4850, d2jkoA_, 0.6944, 3.19, 0.248, 256, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4851, d4yffA_, 0.6943, 2.97, 0.227, 264, 233, TNNI3K COMPLEXED WITH INHIBITOR 2
4852, d2qi8A_, 0.6943, 2.79, 0.249, 255, 233, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4853, d2hz4B1, 0.6943, 2.96, 0.217, 248, 235, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4854, d4rzvB1, 0.6942, 2.75, 0.197, 254, 233, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4855, d3f3vA_, 0.6942, 3.04, 0.243, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4856, d2jc6C_, 0.6942, 2.77, 0.288, 277, 233, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4857, d1yolA_, 0.6942, 2.86, 0.249, 256, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4858, d4hokG_, 0.6941, 3.60, 0.168, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4859, d4fnzA_, 0.6941, 3.15, 0.187, 287, 241, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
4860, d6b8uB_, 0.6940, 2.96, 0.204, 248, 235, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4861, d2rioA_, 0.6940, 2.72, 0.306, 396, 232, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4862, d4knbD_, 0.6939, 2.74, 0.225, 247, 231, C-MET IN COMPLEX WITH OSI LIGAND
4863, d2nruA_, 0.6939, 3.33, 0.240, 293, 242, CRYSTAL STRUCTURE OF IRAK-4
4864, d5uitB_, 0.6938, 3.33, 0.240, 283, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4865, d5kx8D_, 0.6938, 3.36, 0.214, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
4866, d4ztnD_, 0.6938, 3.37, 0.239, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
4867, d3qlfA_, 0.6938, 2.58, 0.249, 249, 229, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4868, d2qo9A_, 0.6938, 3.24, 0.201, 277, 244, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
4869, d1jqhA_, 0.6938, 3.53, 0.208, 291, 250, IGF-1 RECEPTOR KINASE DOMAIN
4870, d4y73C_, 0.6937, 3.44, 0.234, 290, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4871, d4rloA_, 0.6937, 2.50, 0.313, 259, 227, HUMAN P70S6K1 WITH RUTHENIUM-BASED INHIBITOR EM5
4872, d4hokQ_, 0.6937, 3.61, 0.172, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4873, d2yn8B_, 0.6937, 2.87, 0.215, 260, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4874, d5t1sB_, 0.6936, 3.23, 0.234, 282, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4875, d5fdxB_, 0.6936, 3.60, 0.216, 274, 250, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4876, d4yo6A_, 0.6936, 3.38, 0.239, 286, 243, IRAK4-INHIBITOR CO-STRUCTURE
4877, d2qq7A_, 0.6936, 2.61, 0.258, 251, 229, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
4878, d2qocA_, 0.6936, 3.33, 0.208, 283, 245, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
4879, d4xs2B_, 0.6935, 3.23, 0.218, 278, 239, IRAK4-INHIBITOR CO-STRUCTURE
4880, d3tl8D_, 0.6935, 3.78, 0.201, 306, 249, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4881, d2nruB_, 0.6935, 3.42, 0.235, 294, 243, CRYSTAL STRUCTURE OF IRAK-4
4882, d5t1sA_, 0.6934, 3.37, 0.240, 280, 242, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4883, d4ztlC_, 0.6934, 3.34, 0.237, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4884, d2og8B2, 0.6934, 3.03, 0.223, 247, 238, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4885, d5w84A_, 0.6933, 3.34, 0.257, 279, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4886, d4xg8C_, 0.6933, 2.80, 0.205, 254, 234, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4887, d2rioB_, 0.6933, 2.60, 0.304, 395, 230, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4888, d1jqhC_, 0.6933, 3.53, 0.208, 291, 250, IGF-1 RECEPTOR KINASE DOMAIN
4889, d4rmzA_, 0.6932, 3.35, 0.240, 284, 242, CRYSTAL STRUCTURE OF IRAK-4
4890, d2hwoA_, 0.6932, 2.52, 0.250, 251, 228, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
4891, d1yolB_, 0.6932, 2.78, 0.249, 253, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4892, d5tkdB_, 0.6931, 2.86, 0.222, 247, 234, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4893, d3tz9B_, 0.6931, 2.98, 0.249, 259, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4894, d3dj6A_, 0.6931, 2.72, 0.291, 252, 230, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4895, d3daeA_, 0.6931, 3.02, 0.303, 248, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4896, d5k76B_, 0.6930, 3.36, 0.236, 281, 242, IRAK4 IN COMPLEX WITH COMPOUND 28
4897, d5ur1B_, 0.6929, 3.27, 0.240, 265, 242, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4898, d4yfiC_, 0.6929, 2.89, 0.228, 269, 232, TNNI3K COMPLEXED WITH INHIBITOR 1
4899, d3tz8A_, 0.6929, 3.06, 0.247, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4900, d2rl5A1, 0.6929, 3.33, 0.197, 290, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
4901, d5fdpA_, 0.6928, 3.77, 0.217, 285, 254, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
4902, d4rmzB_, 0.6927, 3.34, 0.231, 282, 242, CRYSTAL STRUCTURE OF IRAK-4
4903, d4ebwA_, 0.6927, 3.17, 0.242, 259, 240, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4904, d3zxtC_, 0.6927, 2.57, 0.259, 259, 228, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4905, d3f5pD1, 0.6927, 3.66, 0.208, 296, 250, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4906, d2henD1, 0.6927, 2.95, 0.197, 258, 238, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4907, d2bmcF_, 0.6927, 2.81, 0.292, 257, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4908, d3qquA_, 0.6926, 3.51, 0.206, 285, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4909, d3f5pT1, 0.6925, 3.54, 0.210, 294, 248, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4910, d2henB1, 0.6925, 2.96, 0.197, 258, 238, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4911, d5t1sD_, 0.6924, 3.33, 0.232, 281, 241, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4912, d4yp8A_, 0.6924, 3.41, 0.239, 284, 243, IRAK4-INHIBITOR CO-STRUCTURE
4913, d4xs2D_, 0.6924, 3.31, 0.212, 277, 241, IRAK4-INHIBITOR CO-STRUCTURE
4914, d4f0gA1, 0.6923, 3.00, 0.237, 260, 236, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4915, d3my0X_, 0.6923, 2.93, 0.240, 257, 233, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4916, d3f5pH1, 0.6923, 3.66, 0.208, 298, 250, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4917, d3f5pC1, 0.6923, 3.55, 0.209, 300, 249, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4918, d2hakA_, 0.6923, 3.40, 0.316, 309, 247, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4919, d1ywnA_, 0.6923, 3.54, 0.206, 279, 247, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4920, d5kx8A_, 0.6922, 3.39, 0.239, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
4921, d4yffD_, 0.6922, 2.83, 0.204, 257, 230, TNNI3K COMPLEXED WITH INHIBITOR 2
4922, d5uiqC_, 0.6921, 3.22, 0.233, 280, 240, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4923, d3tz9A_, 0.6920, 3.06, 0.243, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4924, d3nw5A_, 0.6920, 3.53, 0.188, 302, 250, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4925, d3f5pA1, 0.6920, 3.64, 0.208, 298, 250, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4926, d4cnhA_, 0.6919, 3.39, 0.182, 285, 242, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
4927, d2vwvA_, 0.6919, 2.96, 0.218, 255, 238, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4928, d2qu6B_, 0.6919, 2.95, 0.207, 260, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4929, d2oj9A_, 0.6919, 3.64, 0.212, 295, 250, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
4930, d1jqhB_, 0.6919, 3.52, 0.209, 287, 249, IGF-1 RECEPTOR KINASE DOMAIN
4931, d4hokC_, 0.6917, 3.57, 0.168, 289, 250, CRYSTAL STRUCTURE OF APO CK1E
4932, d3d7tA_, 0.6917, 3.10, 0.218, 249, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4933, d2oibC_, 0.6917, 3.30, 0.245, 278, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4934, d4yo6D_, 0.6916, 3.40, 0.230, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
4935, d4yffC_, 0.6916, 2.73, 0.205, 258, 229, TNNI3K COMPLEXED WITH INHIBITOR 2
4936, d3cpcB_, 0.6916, 3.00, 0.211, 262, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4937, d3f5pB1, 0.6915, 3.67, 0.208, 297, 250, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4938, d3cp9A1, 0.6915, 2.97, 0.215, 281, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4939, d4y73A_, 0.6914, 3.47, 0.262, 289, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4940, d4twoA_, 0.6914, 3.26, 0.202, 278, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
4941, d4qq5A1, 0.6914, 3.39, 0.234, 272, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4942, d4agwA_, 0.6914, 2.97, 0.250, 258, 236, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4943, d3f5pG1, 0.6914, 3.57, 0.213, 298, 249, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4944, d3cpcA1, 0.6914, 2.93, 0.216, 277, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4945, d5nkiA_, 0.6913, 3.08, 0.188, 268, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
4946, d4yfiB_, 0.6913, 2.97, 0.220, 262, 232, TNNI3K COMPLEXED WITH INHIBITOR 1
4947, d3i81A_, 0.6912, 3.61, 0.188, 296, 250, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4948, d2xyuA_, 0.6912, 2.95, 0.185, 260, 238, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
4949, d2p2iB_, 0.6912, 3.08, 0.197, 263, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4950, d2p2hA1, 0.6912, 3.33, 0.214, 289, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
4951, d5l6oA_, 0.6911, 3.19, 0.209, 267, 239, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
4952, d4k9yA_, 0.6911, 3.80, 0.242, 271, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
4953, d4i4eA_, 0.6911, 3.16, 0.242, 254, 240, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4954, d3f3wB_, 0.6911, 3.09, 0.243, 260, 239, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4955, d5w5jA_, 0.6910, 2.55, 0.224, 251, 228, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4956, d5mo4A3, 0.6910, 3.25, 0.225, 271, 240, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
4957, d3v8tA1, 0.6910, 2.75, 0.222, 236, 230, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4958, d2nruD_, 0.6910, 3.36, 0.227, 293, 242, CRYSTAL STRUCTURE OF IRAK-4
4959, d3ohtA_, 0.6909, 3.81, 0.320, 331, 253, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
4960, d2cl1A_, 0.6909, 3.13, 0.295, 250, 241,  
4961, d4yfiD_, 0.6908, 3.00, 0.224, 261, 232, TNNI3K COMPLEXED WITH INHIBITOR 1
4962, d3pyyA1, 0.6908, 3.20, 0.229, 251, 240, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4963, d2yzaA_, 0.6908, 3.24, 0.283, 258, 240, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
4964, d2y6oA_, 0.6908, 2.97, 0.185, 263, 238, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
4965, d2qu6A1, 0.6908, 2.99, 0.219, 276, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4966, d2qokA_, 0.6908, 3.23, 0.202, 281, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
4967, d4ztmC_, 0.6907, 3.38, 0.232, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4968, d3ohtB_, 0.6907, 3.80, 0.320, 331, 253, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
4969, d2nruC_, 0.6906, 3.46, 0.235, 293, 243, CRYSTAL STRUCTURE OF IRAK-4
4970, d3f5pM1, 0.6904, 3.69, 0.208, 294, 250, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4971, d2qg5D1, 0.6904, 3.41, 0.258, 267, 244, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4972, d2oibD_, 0.6904, 3.41, 0.236, 288, 242, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4973, d3c7qA_, 0.6903, 3.56, 0.202, 286, 248, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
4974, d5k72A_, 0.6902, 3.22, 0.231, 277, 238, IRAK4 IN COMPLEX WITH COMPOUND 21
4975, d5b2mA_, 0.6902, 2.79, 0.240, 255, 233, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4976, d4fnxA_, 0.6902, 3.57, 0.180, 292, 245, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4977, d1vr2A_, 0.6902, 3.31, 0.218, 275, 243, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4978, d3uc4A_, 0.6901, 3.37, 0.272, 295, 246, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4979, d2nryD_, 0.6901, 3.40, 0.237, 282, 241, CRYSTAL STRUCTURE OF IRAK-4
4980, d4rzvA1, 0.6899, 2.57, 0.214, 245, 229, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4981, d3wzdA_, 0.6899, 3.16, 0.221, 278, 240, KDR IN COMPLEX WITH LIGAND LENVATINIB
4982, d2oibA_, 0.6899, 3.25, 0.234, 280, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4983, d5k7gA_, 0.6898, 3.29, 0.255, 277, 239, IRAK4 IN COMPLEX WITH AZ3862
4984, d4y73B_, 0.6898, 3.44, 0.239, 289, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4985, d1a06A_, 0.6898, 3.10, 0.277, 279, 235, CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
4986, d5k75C_, 0.6896, 3.39, 0.240, 282, 242, IRAK4 IN COMPLEX WITH COMPOUND 1
4987, d3orlA_, 0.6896, 2.83, 0.270, 268, 233, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 3)
4988, d3cjgA_, 0.6896, 3.29, 0.212, 280, 241, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4989, d3f5pI1, 0.6895, 3.68, 0.209, 293, 249, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4990, d3f5pF1, 0.6893, 3.63, 0.205, 298, 249, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4991, d3el7A_, 0.6893, 2.83, 0.250, 254, 232, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
4992, d4eevA_, 0.6892, 3.26, 0.212, 283, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
4993, d3be2A1, 0.6892, 3.25, 0.215, 285, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
4994, d5k7gB_, 0.6891, 3.20, 0.239, 275, 238, IRAK4 IN COMPLEX WITH AZ3862
4995, d2oicD_, 0.6890, 3.41, 0.233, 284, 240, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4996, d3cpbA1, 0.6889, 2.84, 0.214, 278, 234, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4997, d5l6pA_, 0.6888, 3.34, 0.202, 274, 243, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
4998, d2yn8A_, 0.6888, 2.87, 0.213, 253, 235, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4999, d5uiuB_, 0.6887, 3.54, 0.266, 287, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
5000, d3tubA_, 0.6887, 3.11, 0.201, 253, 239, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
